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To boldly go where a lot of people have gone before

  
ABSTRACT 
Prostaglandin E2 (PGE2) is a lipid mediator produced by virtually every cell of the human body. 
Because common non-steroidal anti-inflammatory drugs (NSAIDs) inhibit its biosynthesis, 
PGE2 is usually considered to be a ‘pro-inflammatory’ mediator.  The role of PGE2 in the lung 
and airways has however always been unclear.  In particular, the airway responses caused by 
activation of its four different EP receptors have been debated.  Research on the mechanisms 
involved in the actions of PGE2 has previously been limited by the low potency and selectivity 
of available pharmacological tools.   
 
Recently, a number of potent receptor antagonists and enzyme inhibitors have become 
available.  The aim of this thesis was therefore to characterise airway responses to PGE2 in 
greater detail, focusing on the role of its receptors on baseline smooth muscle function and 
during antigen-induced contractions.  Alongside investigating PGE2 responses, the newly 
discovered relaxant effects of bitter tasting substances acting at their respective receptors 
(TAS2Rs) were examined.   
The project mainly involved analysis of isometric contractions and relaxations in isolated 
airways from guinea pigs and humans in organ baths. In addition, mRNA expression of 
receptors and enzymes was analysed by PCR and prostanoid release was measured by chemical 
or immunological methods.   
 
It was found that all four EP receptors, the two cyclooxygenases (COX-1 and COX-2) and three 
PGE synthases were expressed in the guinea pig trachea and lung.  Exogenous PGE2 induced a 
bell-shaped concentration-response curve, causing contraction at lower concentrations mediated 
by the EP1 receptor and relaxation mediated by the EP2 receptor at higher concentrations.  The 
spontaneous airway tone was maintained by biosynthesis of endogenous PGE2, mainly 
catalysed by COX-2 in the airway epithelium. The level of tone in the preparation was 
determined by the balance between activation of EP1 and EP2 receptors.  The EP1 receptor, but 
not the EP2 receptor, displayed homologous desensitisation to endogenous PGE2.  
 
When the antigen-induced contractions of the guinea pig trachea were studied, it was found that 
the primary effect of PGE2 was again to maintain the spontaneous airway tone.  When this 
effect was blocked by EP1 and EP2 receptor antagonists, it was revealed that a component of the 
antigen-response was mediated by prostaglandin D2 and thromboxane A2, acting at the 
thromboxane TP receptor. 
 
In human small airways, PGE2 induced relaxations mediated by EP4 receptors at low 
concentrations and contractions through TP receptors at higher concentrations.  In addition, it 
was discovered that the IgE-dependent contraction of human bronchi could be abolished by the 
action of exogenous PGE2 at the EP2 receptor, an effect presumably involving inhibition of 
mast cell mediator release. 
 
The bitter tasting substances chloroquine, denatonium, thiamine, and noscapine caused 
relaxations of human and guinea pig airways with a greater efficacy than beta-adrenergic 
bronchodilators.  TAS2R3, TAS2R4 and TAS2R10 were expressed in the guinea pig trachea. 
The EP receptor-mediated tone could be relaxed by chloroquine and noscapine, but not by 
denatonium and thiamine. Although the mechanisms underlying these powerful relaxations 
remain unknown, the data support the involvement of several different pathways. 
 
In summary, PGE2 causes contractions and relaxations of guinea pig and human airways, but 
the receptors involved differ between the two species.  Furthermore, the data gathered suggest 
that EP, TP and TAS2R receptors may be potential targets for the development of drugs to treat 
asthma and other forms of airway obstruction. 
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1 INTRODUCTION 
 
Despite modern therapies using corticosteroids and β2 adrenoceptor agonists to combat 
airway constriction, a substantial number of patients suffering from airway ailments 
still remain insufficiently controlled.  
 
The main focus of this thesis is on the function of the eicosanoid prostaglandin E2 
(PGE2), a central messenger molecule with diverse biological effects. In the airways, 
several clinical studies have described PGE2 as a potent smooth muscle relaxant that 
also displays anti-inflammatory properties. However, some studies have reported 
opposing responses after exposure to PGE2 with powerful bronchoconstriction and 
cough. Multiple effects may be explained by the activation of several different 
receptors. Although the first observations of the contractile and relaxant effects of PGE2 
were made over 30 years ago, research on the mechanisms involved in the actions of 
PGE2 has been limited by the low selectivity of the previously available 
pharmacological tools. During the last few years new subtype selective receptor 
antagonists and potent enzyme inhibitors have become available and thus the role of 
PGE2 can be elucidated with greater precision. 
 
The overall aim of this thesis was to characterise the role of PGE2 in the airways and to 
describe the receptors responsible for its action, both under normal conditions and 
during reactions triggered by antigen-challenge. This was primarily achieved by 
intervention with selective enzyme inhibitors as well as selective receptor antagonists in 
both guinea pig and human tissue, mainly using a classical pharmacological model; to 
record smooth muscle contractions isometrically in isolated segments of airways.  
Alongside the investigations into the mechanisms of action of PGE2, it was discovered 
that bitter tasting substances caused powerful relaxations of the airways. As initial 
experiments revealed marked interactions between bitter tastants and PGE2, this line of 
research was included in the thesis. 
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2 AIMS OF THE THESIS 
The overall aim of this thesis was to investigate the role of PGE2 on airway smooth 
muscle function under normal resting conditions and during antigen-induced responses. 
 
 
Specific aims 
 
• To define the response to PGE2 in isolated human and guinea pig airway 
smooth muscle studied in vitro. 
 
• To examine which receptors are responsible for the action(s) of PGE2 in human 
and guinea pig airway smooth muscle. 
 
• To investigate how PGE2 is produced in the airways. 
 
• To describe the role of endogenous and exogenous PGE2 during antigen-
induced responses in human and guinea pig airway smooth muscle. 
 
• To investigate the relaxant properties of bitter taste agonists and their possible 
interactions with PGE2, as suggested by preliminary experiments. 
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3 BACKGROUND 
 
3.1 ASTHMA 
Asthma, a multifactorial and heterogeneous disorder of the airways, is one of the most 
common chronic diseases in the world. It is estimated that over 300 million people 
worldwide suffer from asthma with a rising prevalence in societies adopting a western 
lifestyle or becoming urbanized (Eder et al., 2006; Masoli et al., 2004). The lifetime 
risk of developing chronic diseases such as cancer (Fay et al., 2003), diabetes (Narayan 
et al., 2003) and coronary heart disease (Lloyd-Jones et al., 1999) ranges from 30-35% 
with a low occurrence in early life and a substantial increase during middle age to old 
age. Asthma, although exhibiting the same lifetime risk as other chronic diseases, 
displays a completely different profile, initiating during early childhood and increasing 
throughout life (To et al., 2010). Also, during childhood, asthma is more common 
among boys than among girls, a ratio that is shifted to the opposite in adult individuals 
(Almqvist et al., 2008; To et al., 2010). 
 
Although the origin of asthma is still unknown, several factors have been proposed to 
explain the increasing prevalence. Genetic susceptibility accounts for one part (Moffatt 
et al., 2010), but it is also recognised that genetic changes in populations would be too 
slow considering such a rapid increase. Another factor is that of environmental 
exposures where allergens were considered to be the main driving force (Lemanske et 
al., 2010), but it is now clear that while most children with asthma are allergic, only a 
minority of allergic patients actually develop asthma and most adults with asthma are 
actually non-allergic. A recently identified factor is the microbiome, where loss of 
certain microorganisms has been shown to negatively influence the immune system 
exerting deleterious effects in asthma (Heederik et al., 2012). It is most likely that 
several known and unknown factors co-contribute. 
 
Common triggers that can incite an exacerbation include an antigen-induced response, 
exercise, temperature change, smoke, strong odours, dust and other airborne irritants 
(Jackson et al., 2011; Wenzel, 2012). However, respiratory tract viruses have emerged 
as the most frequent cause of exacerbations in both children and adults (Busse et al., 
2010). 
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The cardinal symptoms of asthma typically feature recurrent episodes of breathlessness, 
chest tightness, airway hyperresponsiveness, wheezing and cough (Fireman, 2003). The 
airflow obstruction is caused by bronchial wall oedema, mucus plugging and 
bronchoconstriction of the airway smooth muscle (ASM) in the bronchi and 
bronchioles, causing a partially or complete closure of the small airways (Tashkin, 
2002; Tulic et al., 2006). This impairs O2/CO2 exchange resulting in reduction of blood 
oxygenation with a potential to cause hypoxia and death by respiratory failure (Fuller, 
1996; Wasserfallen et al., 1990).  
 
The structural changes observed in an asthmatic airway, often referred to as 
remodelling, include denudation or disruption of airway epithelium, collagen 
deposition within the sub-basement membrane, hyperplasia of goblet cells and both 
hyperplasia and hypertrophy of bronchial smooth muscle fibres (Bara et al., 2010; Folli 
et al., 2008). The fact that a significant proportion of asthma is associated with atopy 
has led the disease to be regarded largely as an inflammatory disorder of the airways 
associated with T helper type 2 cell-dependent promotion of IgE production and 
recruitment of mast cells and eosinophils in concert with increased cytokine production 
(Galli et al., 2012; Holgate, 2012; Wenzel, 2012). However, although asthma was once 
considered to be a single disease entity, different phenotypes are now recognized with 
distinct pathophysiology, clinical expression and response to treatment (Wenzel, 2012). 
It is now clear that the presence of eosinophils in the airways is neither sufficient nor 
necessary to cause symptoms of asthma.  
 
Guidelines for asthma diagnosis and management are recommended by an international 
consortium titled the Global Initiative for Asthma. The goals are not only to achieve 
day-to-day asthma control, but also to minimize future risk of exacerbations and 
prevent decline in lung function. The current paradigm is based on a stepwise increase 
in medication over five treatment steps with a preferred option for each step. 
Initially (step 1) only short-acting β2 adrenoceptor agonists is advised, however if the 
asthma is uncontrolled, treatment needs to be increased to the next step. For treatment 
of mild asthma (step 2) low-doses of inhaled corticosteroids or leukotriene modifiers 
(either receptor antagonists or synthesis inhibitors) is recommended. For moderate 
asthma (step 3 and 4) increasing concentrations of inhaled corticosteroids, long-acting 
β2 adrenoceptor agonists and leukotriene modifiers are advised. Severe asthma (step 5) 
includes all the previous treatments plus oral glucocorticosteroids and in some cases 
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anti-IgE treatment (GINA, 2011). Although current therapies for asthma are relatively 
safe and effective at controlling symptoms, it is debatable whether they change the 
chronic course of the disease. One major therapeutic approach for a long-term disease-
modifying effect involves allergen-specific immunotherapy to induce specific immune 
tolerance (Akdis, 2012). 
 
3.2 AIRWAY PHYSIOLOGY 
The respiratory system includes the upper airways consisting of the nose, nasal cavity, 
pharynx and larynx connected to the lower airways consisting of the trachea, bronchi 
and alveoli. The lower airways can be further divided into a proximal portion referring 
to the trachea and the main bronchi and a distal portion referring to the bronchioles and 
alveoli. The conducting airways form a complex series of branching tubes that 
culminate in the gas exchange area. At each generation, the branching is essentially 
dichotomous, each airway being divided into two smaller daughter airways. Overall 
there are about 23-27 divisions of the bronchial tree from the trachea to the terminal 
bronchioles and the border between proximal and distal airway is positioned at the 
eighth division where the airway diameter is < 2 mm, also commonly recognized as the 
border to the “small airways” (Hogg et al., 2004; Marieb, 2004).  
 
3.2.1 Trachea 
The trachea descends from the larynx into the mediastinum dividing into two primary 
bronchi at mid-thorax. It is a flexible and mobile tubular structure consisting of several 
cell-layers; the mucosa, submucosa and adventia. The mucosa is built up by an 
innervated pseudostratified ciliated epithelium with inclusions of goblet cells resting on 
the lamina propria, whereas the submuscosa is a connective tissue layer containing 
seromucous glands. The adventia is also a connective tissue layer structurally 
reinforced by integrated hyaline cartilage, preventing the trachea from collapsing and 
maintaining a normal structure during breathing (Marieb, 2004).  
 
3.2.2 Small airways 
The distal airways, often referred to as “small airways”, comprise the 8th–19th 
generation of airways with a diameter ranging between 2– 0.5 mm (Holz et al., 2000; 
Tashkin, 2002). Anatomically, the small airways differ from the larger airways because 
they contain fewer ciliated epithelial cells and rely on pulmonary surfactant to protect 
against excessive volume-related changes in diameter as compared to a structural 
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protection in the larger airways (Kraft, 1999). As the airways become smaller and more 
distal, cartilage support becomes scarce, and in the terminal bronchioles (< 0.5 mm in 
diameter) no cartilage is found. Distal to the terminal bronchioles are the respiratory 
bronchioles and alveoli where gas exchange takes place. (Macklem, 1998; Marieb, 
2004).  
 
3.2.3 Airway smooth muscle 
Smooth muscles are found in several places in the body, often located within the walls 
of organs and structures such as the stomach, intestines, airways, uterus, bladder, blood 
vessels, and erector pili in the skin. Smooth muscle is different from skeletal muscle in 
several respects, e.g. it is non-striated, the control is involuntary and each muscle fibre 
contains a single nucleus (Stephens, 2001).  
 
The ASM plays an important role both in healthy and asthmatic individuals (An et al., 
2007). Traditionally, the ASM was considered to primarily respond with a contraction 
or relaxation to mediators or drugs, however, that view is now antiquated. It is now 
clear that ASM is a very active tissue responsible for a profound synthesis of several 
mediators, cytokines, chemokines and growth factors (Black et al., 2002; Knox et al., 
2000).  
 
Increased ASM mass, one hallmark of asthma, may be caused by hypertrophy or 
hyperplasia. A recent study has found that hypertrophy occurs in the large airways in 
both nonfatal and fatal cases of asthma whereas hyperplasia was only present in the 
large and small airways in fatal asthma cases (James et al., 2012b).  
 
Humans and several other species exert an inherent ASM tone with a suggested 
purpose to maintain homeostasis within the airway as it is exposed to both constrictive 
and relaxant stimuli. In the guinea pig trachea (GPT), prostanoids and especially 
prostaglandin E2 have been associated with maintenance whereas in the human 
airways, cysteinyl-leukotrienes are proposed as the responsible mediator (Orehek et al., 
1973; Schmidt et al., 2000). 
 
In the present thesis, the ASM was mainly investigated in the context of its contractile 
and relaxant properties.  
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3.2.4 Airway epithelium 
The airway epithelium has many important functions. Firstly, it is a physiological 
barrier that prevents allergens, irritants, agonists and gases from stimulating the 
underlying ASM and intra-epithelial nerves (Sparrow et al., 1995). Secondly, the 
epithelial cells have a metabolic function for several relevant endogenous mediators, 
such as acetylcholine by acetylcholinesterase and histamine by diamine oxidase (Koga 
et al., 1992; Lindstrom et al., 1991). Thirdly, the epithelial layer liberates a variety of 
bronchoactive mediators, e.g. lipoxygenase, cyclooxygenase products and ‘epithelium-
derived relaxing factors’ such as nitric oxide and prostaglandin E2 (Munakata et al., 
1990; Ruan et al., 2011). Furthermore, the epithelium is a major source of 
inflammatory cytokines and chemokines, such as IL-25, IL-33, TSLP and eotaxin 
involved in local inflammatory responses and tissue repair mechanisms (Holgate, 
2011). 
 
3.3 THE MAST CELL AND ITS MEDIATORS 
Mast cells are tissue resident immune cells often located close to blood vessels and in 
proximity to surfaces that border the external environment, such as the skin and 
respiratory tract. The mast cell displays a multitude of functions, including important 
roles in tissue homeostasis, wound healing and host defence against pathogens and 
parasites (Metcalfe et al., 1997). Generally, the mast cell is classified according to the 
different serine proteases contained in its secretory granules, either tryptase (MCT) 
alone or both tryptase and chymase (MCTC). Mast cells residing in the bronchi, 
bronchioles and the alveolar parenchyma primarily belong to the MCT classification 
and are often referred to as “mucosal” mast cells, in contrast to MCTC which are largely 
found in the pulmonary vessels and the pleura, as well as in the skin, and are commonly 
described as “connective tissue” types (Andersson et al., 2009; Irani et al., 1986).  
 
In the pathophysiology of asthma, mast cells have been implicated as one of the key 
cells responsible for the early phase reaction, both for allergic and non-allergic 
exacerbations, as well as the late phase reaction and chronic induction of 
hyperresponsiveness (Bradding et al., 2006; Brightling et al., 2002; Wenzel, 2012). 
Mast cells also display a different pattern of localisation within the airway of subjects 
with asthma compared to healthy controls; with increased numbers in airway smooth 
muscle and epithelial layers and decreased numbers in the submucosa (Balzar et al., 
2011; Brightling et al., 2002; James et al., 2012a).  
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3.3.1 Mast cell activation 
Mast cell activation is primarily initiated via cross-linking of immunoglobulin E (IgE) 
antibodies attached to the high affinity receptor (Fc�RI) on the cell surface. When 
crosslinking of adjacent Fc�RI bound IgE antibodies by allergen or anti-IgE antibodies 
occurs, aggregation of FcεRI triggers a complex intracellular signalling process that 
results in degranulation and secretion of biologically active products. Three separate 
classes of mediators are released, including pre-formed mediators stored in cytoplasmic 
granules (e.g. histamine, proteases and heparin), de novo synthesised lipid mediators 
(e.g. prostanoids, leukotrienes and other oxylipins) and both preformed and newly 
synthesised cytokines and chemokines (e.g. TNF-α, IL-4 and IL-13) (Galli et al., 2008). 
Importantly however, mast cell activation also occurs through non-IgE mediated 
pathways, such as osmotic stimulation, cytokines, neuropeptides or adenosine 
(Forsythe et al., 2000; Gulliksson et al., 2006; Metcalfe et al., 1997). Such IgE-
independent pathways may explain e.g. exercise-induced bronchoconstriction in 
asthma.  
 
3.3.2 Early phase reactions 
Early-phase reactions, also known as “type I immediate hypersensitivity reactions” 
occur within minutes of mast cell activation and mainly reflect the secretion of 
mediators at the affected location. They begin with the fusing of cytoplasmic granules 
to the mast cell membrane causing an exocytosis of preformed substances to the 
external environment. The mediators released include biogenic amines (mainly 
histamine in humans and guinea pig, but serotonin in rats and mice) together with 
serglycin proteoglycans and serine proteases acting in an autocoid manner (Galli et al., 
2012).  
 
Histamine has the possibility to activate at least four different receptors (H1-4). In the 
airways, the H1 receptor has been implicated in bronchoconstriction whereas the H2 
receptor is more associated with mucus secretion (Barnes, 1991; White, 1990). H3 
receptors are often found on sensory nerves where they are shown to modulate 
cholinergic neurotransmission and H4 receptors are considered to play an 
immunomodulatory role (Barnes, 1991; Dunford et al., 2010). Today, the use of H1 
receptor antagonists, so called “antihistamines” has proven beneficial for the treatment 
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of allergic symptoms, especially in patients with rhinitis and allergic conjunctivitis 
(Simons, 2004). 
 
Upon mast cell activation, the production of lipid mediators is promptly initiated and 
these mediators also contribute to the immediate reaction. These diverse lipid mediators 
are generated primarily from arachidonic acid and have the capability to either amplify 
or dampen the tissue response. Several different pathways are activated, such as the 
cyclooxygenase (COX) pathway generating prostanoids or the 5-lipoxygenase (5-LOX) 
producing leukotrienes (Boyce, 2007). These mediators and pathways will be covered 
in more depth in the eicosanoid-section of the thesis. 
 
Taken together, the acute effects of the mast cell mediators include contraction of the 
airway smooth muscle, increased vascular permeability and enhanced secretion of 
mucus resulting in acutely reduced airflow. This response is usually resolved within a 
few hours. However, in some individuals a second phase of obstruction, often referred 
to as “the late phase reaction”, develops a few hours after antigen exposure (Galli et al., 
2012). 
 
3.3.3 Late phase reactions 
The late phase reaction has a prevalence of up to 50% in adults who previously 
developed an early phase response. Usually it commences within 2-6 hours after 
antigen exposure and is fully developed after 12 hours. It presents as a slowly 
progressing smooth muscle constriction causing a decrease in lung capacity of a similar 
extent to that caused during the early phase response (O'Byrne et al., 1987). The degree 
of the reaction has been linked with increased numbers and activation of inflammatory 
cells, such as eosinophils and neutrophils (Aalbers et al., 1993; Smith et al., 1992) as 
well as an increase in airway hyperresponsiveness which may occasionally last for 
months (Cartier et al., 1982). Although the late response can be partially reversed by 
different bronchodilators, it does not appear to be truly preventable. It is, however, 
blocked by prophylactic treatment with inhaled sodium cromoglycate, nedocromil, anti-
IgE antibodies, anti-leukotrienes and corticosteroids (Cockcroft, 1988; Fahy et al., 
1997; Krawiec et al., 1999; Roquet et al., 1997), supporting mast cell involvement. 
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3.4 EICOSANOIDS 
One of the most important classes of lipid derived mediators in mammalian cells are the 
eicosanoids. The word itself is derived from the Greek word for twenty; eicosa (είκοσι), 
referring to the 20 carbon polyunsaturated fatty acid derivatives synthesized de novo 
from liberated phospholipids. Its existence and significance was hinted at in a few, 
seemingly unrelated, observations published around 1930 (Burr et al., 1929; Kurzrok et 
al., 1930; von Euler, 1934). More than 30 years later, Bergström and Samuelsson 
revealed the structures of the primary prostaglandins and described a link to its major 
precursor, arachidonic acid (Bergstroem et al., 1964). In 1971, Vane discovered that 
aspirin-like drugs, used to treat fever and inflammation, inhibited prostaglandin 
biosynthesis (Vane, 1971). Bergström, Samuelsson and Vane jointly received the Nobel 
Prize in Physiology or Medicine in 1982 “for their discoveries concerning 
prostaglandins and related biologically active substances”. 
 
Arachidonic acid (20:4ω6; four double bonds with the first located at the 6th carbon 
position) is the main precursor for synthesis of eicosanoids in mammalian cells. It is 
stored as an ester in the phospholipid cell membrane until liberated by Ca2+-dependent 
phospholipase A2 (PLA2). PLA2 hydrolyses the polyunsaturated fatty acid from the sn-2 
position (the 2nd carbon of the glycerol molecule), and when released, these can be 
metabolized to form various bioactive lipid mediators. Although there are several 
different types and forms of PLA2, the cytosolic version of type IV is considered 
responsible for eicosanoid production since cells lacking this particular enzyme 
generally have no synthesis (Six et al., 2000).  Hormones, autocoids, antigens, bacterial 
peptides, immune complexes and mechanical stress are among the many stimuli that 
can induce PLA2 activation, causing a translocation of the enzyme to the nuclear 
envelope and endoplasmic reticulum and a release of arachidonic acid (Smith, 1989).  
 
3.4.1 Essential fatty acids 
Essential fatty acids (EFAs) are important elements of all cell membranes with the 
capacity to alter membrane fluidity and thus, determine and influence the behaviour of 
membrane-bound enzymes and receptors. They are essential for human survival and 
cannot be synthesised by the body, so therefore have to be obtained through our diet. In 
the human body two types occur; the omega (ω) -6 series derived from cis-linoleic acid 
(LA, 18:2) and the ω -3 series derived from α -linolenic acid (ALA, 18:3). There are 
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also fatty acids derived from oleic acid (OA, 18:1ω9), however they are not an EFA 
(Das, 2006a). 
 
LA is converted to γ-linoleic acid (GLA, 18:3ω6) by the enzyme Δ6-desaturase and 
GLA is elongated to form dihomo-GLA (DGLA, 20:3ω6), the precursor of the 1 series 
of prostaglandins. DGLA can also be converted to arachidonic acid by Δ5-desaturase 
forming the precursor of 2 series of prostanoids and the 4 series of leukotrienes. Also, 
ALA is converted to eicosapentaenoic acid (EPA, 20:5ω3), via Δ5-6-desaturase, forming 
the precursor for the 3 series of prostanoids and the 5 series of leukotrienes (Das, 
2006b). 
 
As there are many enzymes, the possibilities for lipid metabolite formation from a 
single pre-cursor are numerous (Figure 1).  
 
 
Figure 1. Schematic overview of eicosanoid metabolism. Enzyme catalysed pathways are 
indicated by filled arrows: COX=Cyclooxygenase; 5-LOX=5-lipoxygenase; 12/15-
LOX=12/15-lipoxygenases; CYP=Cytochrome P450 monooxygenases.  Non-enzymatic 
formation of isoprostanes indicated by dashed arrow. 
 
3.4.2 Biosynthesis and catabolism in the cyclooxygenase pathway 
Prostanoids are generated from free arachidonic acid in a two-step reaction catalysed by 
prostaglandin endoperoxide H synthases, commonly known as cyclooxygenases 
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The precise roles of prostaglandin receptors are determined by an intricate set of ligand-
receptor interactions such as ligand affinity, receptor expression profile and different 
coupling to signal transduction pathways. It is not surprising, given their structural 
similarities, that prostaglandins activate more than one subtype of prostaglandin 
receptor (Abramovitz et al., 2000; Coleman et al., 1994). 
 
Table 1. Pharmacological properties of the prostanoids. 
Agonist Primary receptor Primary signalling pathway 
PGD2 DP1 
DP2 
Gs 
Gi 
↑ cAMP 
↓ cAMP, ↑ Ca2+ 
PGE2 EP1 
EP2 
EP3 
EP4 
Gq 
Gs 
Gi 
Gs 
↑ Ca2+ 
↑ cAMP 
↓ cAMP, ↑ Ca2+ 
↑ cAMP 
PGF2α FP Gq ↑ Ca2+ 
PGI2 IP Gs ↑ cAMP 
TXA2 TP Gq ↑ Ca2+ 
cAMP=Cyclic adenosine monophosphate 
 
Gq signalling pathway 
Signalling through Gq-coupled receptors is of particular interest in the airways since it 
promotes ASM contraction (Billington et al., 2003). Upon agonist binding, the receptor 
undergoes a conformational change exposing a high-affinity binding site for a G-
protein complex (Gαqβγ) in its GDP state (inactive). Once the G-protein is bound to the 
receptor, the GDP is released into the cytosol and replaced by a GTP which induces a 
conformational change dissociating the Gαq from the Gβγ-dimer. The Gβγ unit remains 
in the lipid bilayer whereas the Gαq activates the phospholipid-cleaving enzyme 
phospholipase C (PLC) promoting hydrolysis of phosphoinositol 4,5-bisphospate 
(PIP2) to form 1,2-diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). DAG 
remains in the membrane where it induces a translocation and activation of protein 
kinase C (PKC). IP3 translocate and binds to IP3 receptors located on the sarcoplasmic 
reticulum (SR) which in turn opens Ca2+ channels resulting in further influx of 
extracellular Ca2+. Elevated Ca2+ promotes binding to calmodulin forming a Ca2+-
calmodulin complex that, in turn, activates the myosin light chain kinase which 
phosphorylates myosin light chains (MLC) and enables actin to activate myosin 
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ATPase activity; resulting in cross-bridge cycling and contraction (Billington et al., 
2003). 
 
Gs signalling pathway 
The Gs pathway is also of great importance in the airways since it induces smooth 
muscle relaxation. Agonist binding to the receptor induces a reaction similar to Gαq 
with the exception that the Gαs subunit does not activate PLC, but membrane bound 
adenylyl cyclase (AC). AC activation catalyses the formation of cyclic AMP (cAMP) 
from free cytoplasmic ATP. Binding of cAMP to the regulatory subunits of protein 
kinase A (PKA) will induce a conformational change releasing the PKAs catalytic 
subunits. These catalytic subunits have tremendous effects in the cell with the capacity 
to inactivate PLC, IP3 receptors and cross-bridge cycling through MLC 
phosphorylation. The net outcome in airway smooth muscle cells is a decrease in 
intracellular calcium with a subsequent inhibition of contraction (Billington et al., 
2003). 
 
Gi signalling pathway 
Activation of Gαi associated receptors has the possibility to initiate and modulate 
intracellular signalling through both the α- and βγ-subunit. Primarily, Gαi binds to AC 
making it difficult for Gαs to activate it. At the same time, Gβγ has the possibility to 
activate PLC generating IP3 and DAG, resulting in calcium mobilization (Billington et 
al., 2003). Furthermore, Gαi-coupled receptors have been linked to ASM growth 
(Ediger et al., 2002) and Rho-dependent changes in actin polymerisation (Hirshman et 
al., 1999). The Gi pathway has less known effects in the airway smooth muscle. 
 
A summary with interaction of all three signalling pathways is described in Figure 4. 
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DP receptors 
DP1 receptors are connected to AC via a Gαs protein, thus promoting cAMP generation 
(Boie et al., 1995). Activation of DP1 receptors leads to vasodilatation as well as 
inhibition of platelet activation (Giles et al., 1989). The primary agonist is PGD2, 
however in the airways, PGD2 signals mainly through the TP receptor to induce 
contraction via Gαq (Hamid-Bloomfield et al., 1990). The DP2 receptor formerly 
known as CRHT2 (chemoattractant receptor homologous molecule expressed on T-
Helper type 2 cells) is not yet well characterized, but has been shown to modulate 
eosinophil morphology and degranulation as well as increase eosinophil and T-Helper 
type 2 cell motility (Bos et al., 2004). 
 
EP receptors 
As a broad generalization, EP1 and EP3 receptors mediate excitatory effects, while EP2 
and EP4 receptors mediate inhibitory effects. Although EP receptor distribution among 
cells within the lung is not well established, it is clear that various airway cells can 
express multiple EP receptors increasing the complexity of subsequent activation 
(Tilley et al., 2003).  The EP1 receptor has been shown to increase intracellular Ca2+ 
which is associated with bronchoconstriction in experimental models (Coleman et al., 
1985), a response that has not yet been translated into humans. Recently, the EP1 
receptor has been described to modulate the β2-adrenergic receptor (β2AR) response, 
causing an EP1:β2AR heterodimeric complex to form which reduces cAMP formation 
and thus decreases bronchorelaxation (McGraw et al., 2006). The EP2 receptor is 
coupled to a Gαs protein stimulating AC and cAMP formation. It has been shown to 
mediate bronchorelaxation in several models (Birrell et al., 2013; Fortner et al., 2001) 
and also mediate ASM migration inhibition (Aso et al., 2013). Furthermore, due to a 
short intracellular domain it is resistant to arrestin-induced internalisation (Penn et al., 
2001) as compared to other EP receptors. In order to turn off an activated GPCR 
response, phosphorylation by G protein coupled receptor kinases (GRKs) occurs on the 
cytoplasmic part when the G proteins are disassociated from the receptor. GRK acts as 
a binding site for arrestin, which in turn blocks further G protein-mediated signalling 
and targets receptors for internalization (Magalhaes et al., 2012) The EP3 receptor, 
generally inhibits AC via Gαi, and is one of the most complex EP receptors with at least 
ten isoforms, defined by unique C-terminal cytoplasmic tails, identified across species, 
six of these being expressed in man (An et al., 1994). The isoforms differ in their G-
protein coupling resulting in a wide spectrum of EP3 actions, such as smooth muscle 
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contraction, enhancement of platelet aggregation and inhibition of autonomic 
neurotransmitter release (Bos et al., 2004). Recently, the EP3 receptor has been 
implicated as the possible culprit promoting PGE2-induced cough (Maher et al., 2009).  
The EP4 receptor couples, like the EP2 receptor, to AC via a Gαs protein. The receptors 
structural design is however very dissimilar with a substantially longer cytoplasmic tail 
including multiple phosphorylation sites which enables a rapid desensitization 
(Nishigaki et al., 1996). Recently, the EP4 receptor has been implicated in PGE2-
induced HB relaxation, showing similarities with the rat trachea (Buckley et al., 2011; 
Lydford et al., 1994).  
 
FP receptors 
Not much is known regarding FP receptors in the airways. They are indicated to be 
coupled via the Gαq pathway and induce strong contractions in blood vessels. In 
airways,  the agonist with the highest affinity, PGF2α, induces contraction (Mathe et al., 
1975) mainly through the TP receptor (Devillier et al., 1997).  
 
IP receptors 
IP receptors are coupled via a Gαs protein, stimulating AC induced cAMP production. 
Its role in the airways is still at large, but it is known to relax vascular smooth muscle 
and inhibit platelet aggregation (Mitchell et al., 2006). In experimental knock-out mice 
models, loss of IP receptors has been linked to increased goblet cell hyperplasia and 
fibrosis (Nagao et al., 2003). Unfortunately, many of the agonists used to investigate 
the IP receptor have a high affinity for the EP1 and/or EP3 receptors, making it difficult 
to draw conclusions (Abramovitz et al., 2000).  
 
TP receptors 
TP receptors have been found in nearly all mammalian blood vessels, in the airways 
and on blood platelets, where their primary task is to mediate smooth muscle 
contraction and platelet aggregation (Nakahata, 2008). There are claims for two splice 
variants, TPα and TPβ, with a small variance in the carboxyl-terminal resulting in a 
more rapid internalization of the β–version (Raychowdhury et al., 1994). The TP 
receptor is functionally coupled to the Gαq protein increasing Ca2+.  
 
The TP receptor has the highest affinity for TXA2, but other prostanoids such as PGD2, 
PGE2 or PGF2α can activate it (Abramovitz et al., 2000; Coleman et al., 1989; 
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Featherstone et al., 1990), making it an attractive target for prevention of allergy-
associated mast cell induced bronchoconstriction (Beasley et al., 1989). With a half-life 
of 30 seconds in the presence of water, TXA2 is rapidly metabolised to the inactive 
metabolite TXB2 (Hamberg et al., 1975). Therefore, U-46619, a stable synthetic PGH2 
analogue acting as a TXA2 mimetic is often used during pharmacological experiments. 
 
3.4.4 Prostaglandin E2 
PGE2 was first isolated from the vesicular gland of sheep in 1962 (Bergström et al., 
1962). Since then, numerous physiological effects have been described to be caused by 
this particular prostaglandin, which is considered the most abundant in the body (Legler 
et al., 2010). It is formed by PGE synthases (PGES) and to date three enzymes have 
been cloned; cytosolic PGES (cPGES), microsomal PGES-1 (mPGES-1) and 
microsomal PGES-2 (mPGES-2) (Murakami et al., 2002). mPGES-1 is a membrane 
bound member of the MAPEG (membrane-associated proteins involved in eicosanoid 
and glutathione metabolism) superfamily (Jakobsson et al., 1999) and co-localized with 
COX-2 at the perinuclear membrane. Both mPGES-1 and COX-2 are often found to be 
upregulated in concerted action during pro-inflammatory conditions (Samuelsson et al., 
2007). mPGES-2 and cPGES are constitutively expressed in various tissues and cell 
types, and both are believed to serve a homeostatic function. mPGES-2 is often 
localized either in the cytosol or on the Golgi whereas cPGES is located only in the 
cytosol. Both enzymes favour COX-1, but mPGES-2 is known to also couple with 
COX-2 (Kudo et al., 2005).  
 
Both COX-1 and COX-2 are localized to the ER where the prostaglandins primarily are 
synthesized (Morita et al., 1995). In order for the prostanoids to exert their effects they 
need to exit the cell in which they were produced. This was originally thought to be a 
simple passive diffusion, due to the fact that PGs are anions in contrast with the cells 
electronegative interior (Bito et al., 1975). However, the kinetics of PG synthesis could 
not be explained by slow diffusion (Baroody et al., 1981) and in 1995, Kanai et al. 
identified a prostaglandin transporter (PGT) that was associated with the rapid transport 
of PGE1, PGE2, and PGF2α mainly into the cell (Kanai et al., 1995). This was followed 
by Reid et al. who found that MRP (multidrug resistance protein)-4 was used 
specifically for the transport of PGE1 and PGE2 out of cells in the presence of ATP and 
glutathione. Interestingly, MRP4-dependent PGE efflux is reduced by both non-E 
prostaglandins and NSAIDs (non-steroidal anti-inflammatory drugs), suggesting that 
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other PGs could be substrates for the same protein and that NSAIDs could exert their 
pharmacologically beneficial actions by both inhibiting PG synthesis and by inhibiting 
the secretion of PGE2 (Reid et al., 2003). 
 
The biological effects of PGE2 are diverse and of a high complexity since they can be 
produced by virtually any cell of the human body and signal through different 
receptors. PGE2 also regulates numerous physiological functions e.g. reproduction, 
neuronal, metabolic and immune functions. In the central nervous system, PGE2 
controls body temperature, sleep–wake activity and an increased sensitivity to pain. It 
has been described as a regulating factor for bone formation and bone healing (Fortier 
et al., 2008). In addition to the respiratory system, its powerful effects on smooth 
muscle cells are also evident in processes such as childbirth, blood pressure control and 
in gastrointestinal motility (Dey et al., 2006). PGE2 is involved in all the classic signs 
of inflammation: redness, swelling and pain. Because of this, it is often referred to as a 
‘pro-inflammatory’ mediator, however it can exert ‘anti-inflammatory’ actions on 
innate immune cells like macrophages, neutrophils, monocytes and NK cells (Funk, 
2001; Harris et al., 2002). 
 
Besides the clinical use of PGE2 in inducing childbirth or abortion (Brunnberg, 1978), 
and in severe ischemia (McCullough et al., 2004), the current pharmaceutical focus lies 
in the inhibition of responses trough synthase inhibition and receptor antagonism.  
 
3.4.5 Inhibitors of the cyclooxygenase pathway 
Blocking the formation of prostanoids has been shown to reduce pain sensation, fever 
and inflammatory effects. Aspirin (acetylsalicylic acid) was the first NSAID introduced 
in 1889, which was followed, 70 years later, by other NSAIDs such as indomethacin 
and ibuprofen (Adams et al., 1969; Winter et al., 1963). Although they exert the same 
main effect, their COX-1/COX-2 inhibitory ratio and pharmacological properties are 
very different, with both aspirin and indomethacin causing an irreversible inhibition 
(aspirin covalently and indomethacin non-covalently) whereas ibuprofen is competitive 
(Rome et al., 1975). Today, many different NSAIDs exist, all of them exerting their 
main effect through COX inhibition, however, some of them have other mechanisms of 
action as well, such as MRP-4 inhibition (Reid et al., 2003), TP receptor antagonism 
(Selg et al., 2007) or DP2 receptor agonism (Hirai et al., 2002). 
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In the beginning of the 1990s a second COX-isoform was discovered that was induced 
by inflammatory responses (Xie et al., 1991). One structural difference between the 
isoenzymes, which also happens to be a major drug target, is the slightly larger active 
cyclooxygenase site for COX-2 (Smith et al., 2000). With this knowledge, selective 
COX-2 enzyme inhibitors (coxibs) were developed with the assumption that they 
would dampen known secondary effects caused by the unselective inhibitors, such as 
removal of the protective function for the mucosa of the gastrointestinal tract (Drews, 
2006). Unfortunately, COX-2 is not only an induced pro-inflammatory enzyme, but 
also involved in important vascular homeostasis. Consequently, long-term use of COX-
2 inhibitors was found to result in an increased rate of serious cardiovascular events 
possibly due to a change in the PGI2/TXA2 ratio. Normally PGI2 is formed by both 
COX-1 and COX-2 in vascular endothelial cells and dilates blood vessels reducing 
aggregation and adhesion of platelets whereas TXA2, formed primarily by COX-1 in 
platelets promotes aggregation. A change in this ratio to a more pro-thrombotic 
environment makes the formation of pathological blood clots more likely (FitzGerald, 
2003). In contrast, the cardio-protective effect of aspirin (Theroux et al., 1988) is due to 
the irreversible long-term inhibition of platelet COX-1 and hence of TXA2 biosynthesis 
by platelets in the circulation (aspirin has little effect on PGI synthesis). 
 
In this thesis several COX-enzyme inhibitors with different COX-1/COX-2 preferences 
have been used (Table 2). 
 
Table 2. IC50 values of COX-inhibitors towards COX-1 and COX-2 
 COX-1 (µM) COX-2 (µM) COX-1/COX-2 
Indomethacin 0.03 A 1.7 A 0.02 
Diclofenac 1.6 A 1.1 A 1.5 
Ibuprofen 12 B 80 B 0.15 
FR-122047 0.028 C 65 C 0.0004 
SC-560 0.0048 B 1.4 B 0.003 
Lumiracoxib 67 D 0.13 D 515 
Etoricoxib 116 E 1.1 E 105 
A (Laneuville et al., 1994), B (Kato et al., 2001), C (Ochi et al., 2000), D (Esser et al., 2005) 
and E (Riendeau et al., 2001). IC50 was measured in murine macrophages, in human 
recombinant blood assay or human whole blood assay. 
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In cells containing LTA4 hydrolase, LTA4 can be converted to LTB4 by a net addition 
of water (Haeggstrom et al., 2007). LTA4 can also be conjugated with glutathione 
(GSH) in cells which contains LTC4 synthase (an enzyme belonging the MAPEG 
family) to form the first of the cysteinyl-leukotrienes (CysLTs); LTC4 (Welsch et al., 
1994). In human mast cells a secondary pathway exists where microsomal GSH-s-
transferase type 2 (MGST2) can conjugate LTA4 with GSH to produce LTC4 (Sjostrom 
et al., 2002).  
 
LTB4 is transported out of the cell by the LTB4-transporter (Yokomizo et al., 2001) 
whereas LTC4 uses a conjugation with MRP-1 (Pulaski et al., 1996). Outside the cell, 
the glutamic acid on LTC4 is cleaved off by γ-glutamyl transpeptidase to form LTD4 
which is further metabolised via cleavage of a glycine by dipeptidase to form LTE4 
(Peters-Golden et al., 2007). Before the structure of the CysLTs was known they were 
collectively known as Slow Reacting Substance of Anaphylaxis (SRS-A). LTE4 is the 
final metabolic product of the CysLTs and can be measured in urine as a marker for 
CysLT produktion (Kumlin et al., 1992). 
 
3.4.7 Leukotriene receptors, signalling pathways and biological effects 
BLT receptors 
The major activities of LTB4 include the recruitment and activation of leukocytes 
(Dahlen et al., 1981). LTB4 is known to be a particularly potent neutrophil 
chemoattractant (Ford-Hutchinson et al., 1980). Two GPCRs for LTB4 have been 
identified, BLT1 and BLT2 (Peters-Golden et al., 2007). BLT1 is the high-affinity 
receptor and mediates most of the chemoattractant and pro-inflammatory actions of 
LTB4. The BLT2 receptor is a low-affinity receptor for LTB4 that can also be activated 
by other lipoxygenase products. Little is known about its physiological function, 
however, it is highly conserved across species suggesting a possible, yet undetermined, 
important biological role (Tager et al., 2003). 
 
CysLT receptors 
CysLTs are a group of compounds with a diverse range of effects in the airways. They 
are known to induce bronchoconstriction, mucus secretion, vascular permeability, 
oedema, ASM hyperplasia and hypertrophy and airway remodelling (Bäck et al., 
2011). Their effects are mediated through activation of two different receptors, CysLT1 
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and CysLT2, both GPCRs inducing calcium mobilization through the Gαq pathway 
(Heise et al., 2000; Lynch et al., 1999; Sarau et al., 1999). Certain reported effects of 
CysLTs are not fully explained by either CysLT1 or CysLT2 receptor responses, raising 
the possibility that other, as yet unknown, CysLT receptors may exist (Yoshisue et al., 
2007). One candidate receptor is GPR17 (Ciana et al., 2006) whereas another is GPR99 
(Kanaoka et al., 2013), both with the capacity to bind CysLTs. In HB, all three CysLTs 
are equipotent at inducing contraction through CysLT1, whereas in the guinea pig 
airway LTC4 primarily mediates its effects through the CysLT2 receptor and LTD4 and 
LTE4 via CysLT1 receptor (Bäck, 2002). 
 
3.4.8 Inhibitors of the 5-lipoxygenase pathway 
Anti-inflammatory glucocorticosteroids do not reduce LT responses (Gyllfors et al., 
2006) and classical NSAIDs have actually been shown to increase the production of 
LTs (Laekeman et al., 1979; Walker, 1980). There are several approaches that may be 
taken to inhibit 5-LOX metabolite responses, such as inhibition of the 5-LOX enzyme, 
or FLAP, and thus removal of LT production. One synthase inhibitor that has been 
approved for the treatment of asthma is the 5-LOX inhibitor zileuton (Dube et al., 
1999). There are currently no FLAP inhibitors on the market, however there are several 
undergoing clinical trials (Sampson, 2009). One potent and selective FLAP inhibitor 
used frequently within this thesis is MK-886 (Gillard et al., 1989). Another approach is 
to block the receptors mediating the response. CysLT1 receptor antagonists, such as 
montelukast (Singulair) or zafirlukast (Accolate), have been evaluated in several 
clinical studies where they improve pulmonary function, reduce inflammation and 
exacerbations, increase quality of life and are now considered standard treatment in 
asthma (Bäck et al., 2011; Dahlen, 2006). 
 
3.5 BITTER TASTE RESPONSES IN THE AIRWAYS 
The gustatory taste perceptions that can be sensed on the tongue upon exposure to bitter 
compounds are mediated by bitter taste-sensing type 2 receptors (TAS2Rs) (Meyerhof 
et al., 2010). TAS2Rs have recently been suggested to have important extra oral 
functions in the respiratory and gastrointestinal tracts (Behrens et al., 2011; Deshpande 
et al., 2010) proposing a possible defence mechanism against noxious compounds. 
Furthermore, correlations between the expression of the TAS2Rs and clinical markers 
of asthma severity have been found in both adults and children (Pietras et al., 2012). As 
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initial experiments performed also found an interaction between PGE2 and several, but 
not all TAS2R agonists, this connection was investigated further. 
 
3.5.1 Bitter taste receptors, signalling pathways and biological effects 
TAS2Rs are different from many other GPCRs (currently 25 known expressed in 
human and 10 in guinea pig), as the receptors are capable of binding a wide range of 
compounds with a relatively low specificity and affinity (Meyerhof et al., 2010). 
Initially it was discovered that activation of these receptors increased intracellular Ca2+, 
suggesting that they could play a role in bronchospasm. However, several in vitro and 
in vivo studies in mice, guinea pigs and humans, now confirm that despite increasing 
internal Ca2+, TAS2R agonists have a potent bronchorelaxant effect, not mediated via 
cAMP (Deshpande et al., 2010). The mechanism for this relaxation is still unknown. 
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4 MATERIAL AND METHODS 
A more detailed description regarding the material and methods used in the separate 
studies can be found in the different publications and manuscripts within this thesis. 
The section below provides a simplified overview regarding some of the key methods 
used. 
 
4.1 GENERAL 
To study the action of PGE2 and other agonists on smooth muscle tissue experiments 
were performed on airway preparations (trachea and bronchi) and vessels (aorta) using 
the classical organ bath setup (papers I-IV). To further investigate the response 
subsequent activation of mast cells two different methods was employed; either an 
active sensitization towards chicken egg albumin (OVA; paper III) or exposure to 
monoclonal anti-IgE antibodies (paper IV). The release of PGE2 was analysed using 
enzyme immune assay (EIA; paper I). The experiments (guinea pig, rat and human) 
were approved by the local ethics committee in Stockholm, Sweden. All animals were 
housed in cages (5 animals together) under 12-hour light/dark cycle with food and 
water ad lib. 
 
4.2 TISSUE COLLECTION 
Animals, rat and guinea pig, used in the functional studies were sacrificed either by 
inhalation of CO2 or overdose of sodium pentobarbital followed by rapid removal of 
the heart-lung-package which was placed in ice-cold Tyrode’s or Krebs-Ringer PSS 
buffer. For functional studies, tracheal segments were cut along the cartilage into eight 
intact rings of equal length whereas the thoracic aorta or rat trachea was cut into four 
intact ring-segments. The tissue was placed in a 5 mL tissue organ bath containing 
Krebs-Ringer PSS and kept at 37 °C, constantly bubbled with carbogen (5% CO2 in O2) 
to maintain pH at 7.4. 
 
Macroscopically healthy human lung tissue was obtained from patients undergoing 
lobectomy (after confirmed structural changes within the lobe) and placed immediately 
in ice-cold Krebs-Ringer PSS buffer. Within 3 hours, bronchial tissue was, using light 
microscopy, gently dissected clear from lung parenchyma under ice-cold Krebs-Ringer 
PSS buffer condition, cut into intact rings (approximately 0.5-1 mm inner airway 
diameter and 3-5 mm in length) and placed in separate wells containing Dulbecco’s 
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modified Eagle medium (DMEM) supplemented with 1% penicillin (100 IU·mL-1) and 
streptomycin (100 μg·mL-1) under sterile conditions. The culture plates were placed in a 
humidified incubator (37 °C at 95% O2 and 5% CO2) for 17-24 hours.  
 
4.3 ORGAN BATH EXPERIMENTS 
Changes in smooth muscle force upon administration of substances were detected using 
an isometric force-displacement transducer linked to a Grass polygraph or a myograph. 
During an equilibration period with washes every 15 min, the resting force was 
mechanically adjusted (30 mN for guinea pig trachea, 10 mN for rat trachea, 8 mN for 
guinea pig aorta and 1.5 mN for HB). As a control of reactivity and viability, either 
histamine or KCl were added which was followed by a second wash period and a new 
equilibration period. All experiments were finished by adding histamine (1 mM), 
acetylcholine (1 mM) and KCl (60 mM) as a reference for the maximal contraction 
followed by theophylline (1 mM) or a combination of papaverin (0.1 mM) and sodium 
nitroprusside (0.1 mM) as a reference for the maximal relaxation. In aorta, the presence 
of an intact endothelium was assessed at the end of the experiment by relaxation to 
acetylcholine after pre-contraction with phenylephrine prior to obtaining the maximal 
contractibility.  
 
Pharmacological tools, such as receptor antagonists or enzyme inhibitors, were given a 
minimum of 45 min to equilibrate.  
 
To study the response after mast cell activation, either OVA (0.1 ng/mL to 0.1 mg/mL 
in sensitized animals) or monoclonal anti-IgE (1/1000 dilution in HB), generating a 
contraction was elicited in the absence and presence of pharmacological tools which 
were given 45 min prior. Only one antigen response was investigated in each 
preparation. 
 
4.4 ORGAN CULTURE EXPERIMENTS 
During organ culture, intact individual guinea pig tracheal rings were placed in separate 
wells containing DMEM-F12 supplemented with 1% penicillin (100 IU·mL-1) and 
streptomycin (100 μg·mL-1) under sterile conditions. The culture plates were placed in a 
humidified incubator at 38 °C at 95% O2 and 5% CO2. Segments were incubated for 96 
hours in total and transferred into new wells containing fresh media every 24 hours 
(Adner et al., 2002).  
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4.5 ANTIGEN SENSITISATION 
Male albino guinea pigs (Dunkin-Hartley; 400-450 g) were sensitized by a single 
peritoneal injection containing 100 µg OVA grade V and 0.1 g aluminium hydroxide 
dissolved in 0.8 mL sterile PBS. This induced an active sensitisation producing both 
IgE and IgG1 antibodies towards OVA (Andersson, 1980). Animals were sacrificed 14 
to 28 days later by an overdose of sodium pentobarbital. 
 
4.6 ENZYME IMMUNOASSAY 
Two separate investigations were carried out using EIA; PGE2 and cAMP 
measurement. 
 
The determination is based on competition of the investigated free substrate (PGE2 or 
cAMP) and a substrate-acetylcholinesterase (AChE) conjugate, also known as a tracer. 
These substances compete for binding to a specific antibody that is mounted on the 
bottom of a 96-well plate. A fixed amount of tracer and substrate is added and while the 
concentration of the investigated substrate may differ between samples, the 
concentration of the tracer is known. Since this is a competition, the more tracer that 
will bind to the antibodies, the less substrate and vice versa. To detect the amount 
bound to the coated antibodies, a method to convert the concentration to a 
spectophotometrically visible signal is carried out using Ellman’s reagent 
(acetyltiocholine) which absorbs at 412 nm. The more tracers bound to antibodies the 
brighter the signal, thus, there is an inverse relationship with the investigated substrate. 
 
PGE2 levels were investigated in paper I and II. The detection limit was 15 pg·mL-1and 
the PGE2 monoclonal antibody displayed cross-reactivity towards PGE3 (43%), 8-iso 
PGE2 (37.4 %), PGE1 (18.7%), 6-keto PGF1α (1%), 8-iso PGF2α (0.25%), 13,14-
dihydro-15-keto prostaglandin E2 (0.02%) and <0.01% to PGD2, PGF2α and TXB2 
 
cAMP levels were investigated in paper II. The detection limit was 3 pmol·ml-1 and the 
antibody displayed cross-reactivity towards cGMP (1.5%) and other compounds 
(<0.01%). 
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4.7 MASS SPECTROMETRY 
Oxylipins were isolated by solid phase extraction in HLB Oasis cartridges. The 
quantification was done by tandem liquid chromatography coupled to triple quadrupole 
mass spectrometry (LC-MS/MS). Liquid chromatography was performed in an Acquity 
instrument with a UPLC BEH C18 column. The mass spectrometer was a Xevo TQ 
system.  
 
4.8 RNA PREPARATION AND REAL TIME-PCR 
Animals from which mRNA was extracted were all sacrificed by an overdose of 
sodium pentobarbital and tissue preparations were removed and stored in RNAlater® at 
room temperature until use (0-4 days later). Trachea, lung parenchyma and thoracic 
aorta were gently dissected from the surrounding connective tissue and tracheal 
epithelium was denuded using a scalpel after which the airway smooth muscle layer 
was cut out 
 
Guinea pig RNA was isolated using the RNeasy Mini Kit followed by concentration 
and purity measurement using a Nanodrop 3300. Aliquots of RNA were reverse-
transcribed into cDNA using a QuantiTect® Reverse Transcription Kit.  
All PCR primers were designed towards available guinea pig sequences from the 
Ensembl database (www.ensembl.org) and the NCBI Genebank Sequences 
(www.ncbi.nih.gov) from the 2nd scaffold of the guinea pig (Cavia porcellus) genome 
comprised by the Feb. 2008 Cavia porcellus draft assembly (Broad Institute cavPor3). 
Primers for the housekeeping genes glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) and β-actin were adapted from previous studies (Bourne et al., 2005; West et 
al., 2005). All primers were titrated using increasing concentrations of cDNA to get a 
shift of the CT values, expressed as a regression slope of 3.32 (23.32=10) with less than 
10% deviation. Furthermore, a melt curve analysis was performed to ensure the quality 
of the amplification product. 
 
Real-time PCR was performed using Power SYBR® Green PCR Master Mix. Each 
sample was analysed in duplicate in MicroAmp® Fast optical 96-well Reaction Plates 
using an Applied Biosystems 7500 Real-Time PCR system. The program was set to 
50 °C 2 min followed by a hot start at 95 °C for 15 min, followed by 6 cycles; 94 °C 30 
sec, 66 °C 1 min, followed by 40 cycles; 94 °C 30 sec, 55 °C 1 min and followed by a 
melt curve analysis. mRNA levels were calculated using the comparative CT method 
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and normalized to the housekeeping gene β-actin and expressed as 105 mol·mol-1 β-
actin. 
 
4.9 CALCULATIONS AND STATISTICS 
All data are presented as mean ± SEM. Data accumulated from the organ bath were 
expressed as a relation to the maximum contractions relative to maximal relaxation. For 
agonists, a non-linear regression with a variable slope fit was used to calculate Emax, 
pEC50 and Hill slope (Table 3). For the antagonist assay, agonist concentration-
response curves were globally fitted to the modified Gaddum/Schild model using 
GraphPad Prism®. 
 
Table 3. Basic pharmacological terms used within this thesis  
Term Definition 
Emax Maximal response elicited of an agonist  
pEC50 The –log10 concentration of an agonist that produces 50% of the 
maximal possible effect of that agonist  
pKB The dissociation constant expressed as –log10 concentration 
where occupancy is 0.5, reflecting the affinity of the antagonist to 
its receptor 
Hill slope Cooperativity of the agonist mediated reactions, reflected by the 
steepness of the concentration-response curve 
pA2 The value that is generated by a Schild plot analysis at Y = 0; 
(X-intercept) 
Schild Plot A pharmacological method of antagonist characterisation. A plot 
of log (concentration ratio − 1) versus log concentration of 
antagonist. If the slope of the regression is not different from 
unity then by definition the antagonist is a competitive antagonist 
(provided parallel shifts with maintained maximal effect) 
Affinity How the agonist binds to the receptor 
Efficacy How effective the drug is at activating the receptor  
 
Normally distributed unpaired data comparison between two groups was assessed by 
unpaired t-test with Mann Whitney U-test as the post hoc test. For more than two 
groups, the parametric test One-Way Analysis of Variance followed by the post hoc 
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Bonferroni’s Multiple Comparisons Test was used. A p-value of less than 0.05 was 
considered significant. All statistical analysis was performed using GraphPad Prism®. 
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5 RESULTS AND DISCUSSION 
 
5.1 CHARACTERISATION OF EP RECEPTORS IN AIRWAYS (PAPERS I 
AND IV) 
5.1.1 Guinea pig trachea 
To characterize the receptors involved in the PGE2 response, experiments were initiated 
by obtaining the profile and activity within our model. PGE2 produced a bell-shaped 
concentration-response curve with a pEC50-value for the contraction of 8.2±0.2 and 
6.7±0.1 for the relaxation (Figure 6A), closely similar to the one described by Coleman 
over 30 years ago (Coleman et al., 1980). This bell-shaped pattern, with an initial 
contraction displayed at low concentration, and relaxation at high concentrations 
indicated activation of multiple signalling pathways. Although experiments using the 
previous generation of drugs support a general concept where bronchoconstriction is 
mediated by EP1 and EP3 receptors, and airway relaxation by EP2 and EP4 receptors, 
(Buckley et al., 2011; Jones et al., 2009), it had not previously been possible to 
simultaneously assess the role of each EP receptor in any airway preparation.  
 
The role of PGE2 was investigated by identification of mRNA expression for both 
COX enzymes, all three PGE synthases and all four receptors in the airway of the 
guinea pig in our study in combination with a new class of available subtype selective 
pharmacological tools (Table 2 and 4). 
 
Table 4. Subtype selective pharmacological tools used within this thesis 
Name of receptor antagonist Primary target 
ONO-8130 EP1 
PF-04418948 EP2 
ONO-AE5-599 EP3 
ONO-AE3-208 EP4 
SQ-29,548 TP 
 
Using guinea pig specific primers, we found mRNA expression of all four EP receptors 
in GPT. To further characterize the EP receptors involved in the PGE2 response, initial 
experiments were performed using the novel and selective EP1 antagonist ONO-8130. 
ONO-8130 shifted the contractile part of the bell-shaped concentration-response curve 
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for exogenous PGE2 to the right and also, simultaneously depressed the peak 
contractions at higher concentrations (Figure 6B). This suggests that EP1 receptors are 
involved in the contraction. The responses to ONO-8130 did not demonstrate a 
classical competitive antagonism, possible due to interference by other receptors 
activated by PGE2. Therefore, the selective EP1/EP3 receptor agonist 17-phenyl trinor 
PGE2 was used in the characterisation of the contractile component. In these 
experiments no bell-shaped profile was observed and ONO-8130 caused a classic, 
competitive, parallel shift to the right of concentration-response curve with maintained 
maximal response, clearly depicting the EP1 receptor as a major contractile receptor in 
the GPT (Figure 6C). From these results, a pA2 value of 8.93 for ONO-8130 acting on 
the EP1 receptor could be calculated (Figure 6D). Thus, ONO-8130 is a far more 
potent EP1 receptor antagonist than the commonly used AH6809 with previously 
estimated pA2 values of 6.4 - 7.0 for the EP1 receptor and also with similar affinities for 
EP2, EP3 , DP1 and TP receptors (Abramovitz et al., 2000). 
 
With EP1 receptors identified as a contractile receptor in the GPT, the presence of 
mRNA expression for the EP3 receptor suggested the possibility of another contractile 
EP receptor within the ASM. The EP3 receptor have previously been implicated in the 
modulation of neural responses (Maher et al., 2009) and activation has been linked to 
inhibitory responses on parasympathetic nerves innervating the GPT (Clarke et al., 
2004). However, the selective EP3 receptor antagonist ONO-AE5-599 displayed no 
effect on the concentration-response curves to either PGE2 or 17-phenyl trinor PGE2. 
Furthermore, the EP1/EP3 receptor agonist sulprostone did not induce a contraction of 
the guinea pig trachea in the presence of ONO-8130. This suggests that EP3 is not 
directly involved in induction of ASM contraction and that EP1 is the sole contractile 
EP receptor in the GPT. 
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Figure 6. (A) Representative trace of PGE2 in a segment treated with indomethacin. (B) 
Concentration-response curves of PGE2 in guinea pig trachea in the presence of the selective 
EP1 receptor antagonist ONO-8130 at different concentrations. (C) Contraction induced by 
cumulative concentrations of 17-phenyl trinor PGE2 in guinea pig tracheal segments in the 
presence of ONO-8130 at different concentrations (1 nM to 30 nM). (D) Schild plot calculated 
from the concentration-response curves in figure 6C. Constraining the Schild slope to unity 
resulted in a pKB value of 8.9. 
 
Since the PGE2 profile in GPT was bell-shaped, it suggested activation of receptors 
mediating a relaxation that counteracts the induced contraction. To characterise the role 
of the EP2 receptor, the new and selective EP2 receptor antagonist PF-04418948 
(Forselles et al., 2011) was used. PF-04418948 caused a concentration-dependent 
increase of peak contraction by PGE2, in contrast to ONO-8130 that caused a decrease. 
PF-04418948 also induced a rightward shift of only the relaxation part of the 
concentration-response curve (Figure 7A). Thus, the relaxation could not be analysed 
properly at baseline due to opposite actions of PGE2. To isolate the relaxation, the ASM 
tone was pre-contracted with the cholinergic agonist carbachol in the presence of ONO-
8130. Increasing concentrations of PF-04418948 caused a parallel rightward shift of the 
concentration-response curve with maintained maximal response for PGE2-induced 
relaxation (Figure 7B) that was used to calculate a pKB value of 7.48 (Figure 7C). 
This value is almost 50 to 100-fold lower compared to the pKB value of 8.3 and 8.9 
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found in human myometrium and mouse trachea, respectively (Forselles et al., 2011), 
suggesting marked species differences. The relaxations also occurred at lower PGE2 
concentrations than observed for the relaxant part of the bell-shaped concentration-
response curve, suggesting an overlap in concentrations for the contractile and relaxant 
effects mediated by activation of EP1 and EP2 receptors. 
 
The EP4 receptor, known to induce relaxation in rat trachea (Lydford et al., 1994), was 
highly expressed at mRNA-level in GPT and was thus investigated using the selective 
EP4 receptor antagonist ONO-AE3-208. However, neither the potency nor the maximal 
relaxation to PGE2 was changed suggesting that EP4 receptors are not involved in PGE2 
mediated relaxation in GPT. 
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Figure 7. Concentration-response curves of PGE2 in guinea pig trachea. (A) In the presence of 
the selective EP2 receptor antagonist PF-04418948 at different concentrations. (B) In segments 
pre-contracted with 0.3 μM carbachol after treatment with PF-04418948 at different 
concentrations. (C) Schild plot calculated from the concentration-response curves in figure 7B. 
Constraining the Schild slope to unity resulted in a pKB value of 7.48. 
 
5.1.2 Human bronchi 
To characterise the contractile EP receptors involved in the PGE2 response in HB 
experiments were performed in presence of antagonists for the presumed relaxant 
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receptors. Both PGE2 and 17-phenyl trinor PGE2 induced a powerful contraction at 
high agonist concentrations. The contractions were not reduced when the EP1 receptor 
was antagonised with ONO-8130, but a substantial reduction was observed by the TP 
receptor antagonist SQ-29,548. This indicates that human small bronchi do not contract 
to PGE2 via EP1 or EP3 receptors, but instead via the TP receptor.  
 
Since PGE2 is known to induce bronchorelaxation in humans (Kawakami et al., 1973; 
Melillo et al., 1994; Pavord et al., 1993; Walters et al., 1982), the two cAMP –inducing 
EP2 and EP4 receptors were investigated. To observe a relaxation, the contraction of the 
TP receptor was blocked and the HB segments were pre-contracted with histamine. In 
these experiments it was shown that PGE2 caused a concentration-dependent relaxation 
which was inhibited by ONO-AE3-208, but not by PF-04418948. 
 
Initially it was proposed that EP2 was the relaxant PGE2 receptor, based on a study 
using AH6809 and the receptor agonist misoprostol (Norel et al., 1999) whereas recent 
studies, using more selective receptor antagonists, implicates the EP4 receptor 
(Benyahia et al., 2012; Buckley et al., 2011) as the responsible relaxant receptor. Thus, 
our study can confirm that PGE2 relax human small airways through the EP4 receptor 
and that the EP2 receptor is not involved in bronchorelaxation directly. 
 
5.1.3 Summary 
Expression of all four EP receptors was found at mRNA-level in GPT. However, using 
new and selective pharmacological antagonists and agonists, we could functionally 
identify the EP1 receptor mediating contraction and EP2 receptors mediating relaxation. 
Thus, the mRNA levels do not completely reflect the functional outcome, possible due 
to regulation at post-transcriptional levels. In human small airways no EP receptor is 
involved in contraction whereas the EP4 receptor is responsible for relaxation. Thus, in 
both GPT and human small airways, PGE2 have the possibility to contract and relax 
airway smooth muscle, however the receptors involved differ completely. 
 
 
5.2 SPONTANEOUS AIRWAY TONE (PAPERS I, III AND IV) 
5.2.1 Guinea pig trachea 
The observation that the spontaneous airway tone could be completely reduced by 
NSAIDs and ONO-8130 as well as increased by PF-04418948 was made during the 
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characterisation of the EP receptors. This suggested that PGE2 acting on the EP1 and 
EP2 receptors are involved and thus warranted closer investigations. 
 
After the wash and resting period, following the initial standard assessment of 
histamine responsiveness, GPT segments develop a spontaneous contractile tone that 
was reduced by administration of NSAIDs, such as indomethacin, ibuprofen and 
diclofenac, reaching the same level acquired by high concentration of papaverine or 
theophylline, i.e. maximally obtainable relaxation of the smooth muscle. This reduction 
was also observed upon administration of ONO-8130 whereas the PF-04418948 caused 
a substantial increase of the tone instead (Figure 8). It was also shown that the tone was 
more rapidly decreased by ONO-8130 than that caused by the enzyme inhibitors, 
suggesting a mechanism involving the immediate blockade of receptors rather than a 
gradually diminished biosynthesis. Since ONO-8130 and PF-04418948 were the only 
receptor antagonists that modulated the tone became apparent when other prostanoid 
receptor antagonists against DP1, EP3, EP4, FP, IP or TP failed to elicit a change, 
suggesting that PGE2 is the likely compound to mediate the effect. This conclusion 
obtained strong support when it was found that a high affinity neutralizing monoclonal 
antibody against PGE2 relaxed the preparations concentration-dependently. 
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Figure 8. Development of spontaneous tone after addition of EP1 receptor antagonist (ONO-
8130), EP2 receptor antagonist (PF-04418948) and COX inhibitor (indomethacin). 
 
To investigate which of the two COX isoenzymes that mediated and maintained the 
spontaneous tone, four selective COX inhibitors with different COX-1/COX-2 ratio 
were used. The more COX-1 selective inhibitors FR-122047 and SC-560 had a smaller 
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effect on spontaneous tone compared to the more COX-2 selective inhibitors etoricoxib 
and lumiracoxib, confirming that COX-2 is the major enzyme catalysing formation of 
PGE2. 
 
Evidence was obtained to support that a significant part of the biosynthesis of PGE2 
originate from the tracheal epithelium since the active tension was lower in epithelium 
denuded segments than in epithelium intact. The epithelium has previously been 
suggested to be an important source of PGE2 (Hay et al., 1988). The tone was however 
not completely reduced with epithelium denudation suggesting that the ASM also 
contributes in the synthesis of PGE2. This is in line with the high expression of COX-2 
in both smooth muscle and epithelial cells. 
 
The involvement of LTs in mediating the tone was investigated when the 5-LOX 
inhibitor zileuton reduced the spontaneous tone. However, neither the FLAP inhibitor 
MK-886 nor CysLT1-2 receptor antagonist Bay-u9773 had any effect. The reason why 
zileuton reduced the spontaneous tone is due to that it, together with its potent 5-LOX 
inhibitory action, also inhibits prostanoid production at higher concentration (Rossi et 
al., 2010). 
 
Since the spontaneous tone play a central and always present role for GPT ASM 
function, there is an importance of incorporating it when interpreting the response of 
other agonists. As is shown in absolute force, histamine causes a contraction and 
indomethacin reduces the spontaneous tone (Figure 9A). If the reduction of tone is not 
incorporated in the calculation, the starting point will be the same. If one also neglects 
to integrate the full contractile span, the increase in regard of maximum will not be 
related to the maximal relaxation, but to a false zero (Figure 9B). If the full contractile 
span is included, but not the level of spontaneous tone, there is an even greater 
discrepancy that could be misinterpreted as indomethacin treated segments contract 
more than untreated (Figure 9C). To be able to more accurately define the agonist 
response,  it is more correct to define the level of the spontaneous tone and combine it 
with the full contractile span of the segment, thus Specific Force =  
(Measurement – Minimum) / (Maximum – Minimum) (Figure 9D). 
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Figure 9. Concentration-response curve to histamine in the presence or absence of 
indomethacin. The same data are displayed in four different ways: (A) Absolute force, (B) 
related to maximum, (C) related to the full contractile span (D) incorporating both spontaneous 
tone and full contractile span. 
 
5.2.2 Human bronchi 
Airway preparations of different species possess varying degrees of spontaneous tone 
mediated by different agonists (Linden et al., 1991; Okazawa et al., 1990; Schmidt et 
al., 2000). In this study, NSAID treatment of HB did not cause the same complete 
abolishment of the tone as observed in the GPT. Instead an over-time gradual increase 
of tone was obtained reaching around 20%. This increased contraction could possibly 
be as a result of removal of relaxant responses by prostanoids, but antagonising 
possible relaxant EP2, EP4 and IP receptors as well as possible contractile EP1, EP3 or 
TP receptors did not induce a change. Another possibility for the observed increase is 
removal of inhibition of leukotriene synthesis (Kuehl et al., 1984), resulting in higher 
concentration of endogenously produced leukotrienes. The decreased tone by FLAP 
inhibitor MK-886 supports this theory also suggesting that in HB, leukotrienes are 
maintaining the tone. The phenomenon with change of tone after NSAID 
administration have previously been described, displaying both increased (Bjorck et al., 
1993; Coleman et al., 1996; Hutas et al., 1981), decreased (Ito et al., 1989) or no effect 
on the tone (Brink et al., 1980). This may be due to limited amount of investigated 
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tissue, different treatments of patients prior to surgery or possibly varying responses in 
different compartments of the lung. 
 
5.2.3 Organ culture 
Having identified the EP1 and EP2 receptors to mediate the response to exogenous 
PGE2 in GPT another aim of the current study was to examine how the endogenous 
production of PGE2 affects the responses of these receptors. A homologous 
desensitisation of the EP1 receptor and not EP2 receptor has previously been described 
in cell models (Illes et al., 1975; Penn et al., 2001; Vermue et al., 1987). In our in vitro 
study, we found that during four days culture, tracheal segments released a substantial 
amount of PGE2. This resulted in a completely abolished contraction, yet a maintained 
relaxation towards exogenously added PGE2 was shown. When different NSAIDs were 
introduced to the culture, the released PGE2 was abolished and a complete PGE2 
concentration-response curve could be obtained.  
 
HB was incubated using the same culture method over 8 days, however during that 
time no EP desensitisation was observed (not shown) suggesting that the release of 
PGE2 is not as extensive as in GPT. It could be argued that our lack of function for the 
EP1 receptor was due to a desensitisation, but there was no EP1 response in tissue used 
immediately after surgery (not shown). Furthermore, the culture of human segments 
showed to be an optimal method because the spontaneous fluctuations of tone observed 
in the tissue studied acutely was removed. Also, re-culture of used segments with 
maintained contractile capacity was possible up to at least three times over eight days, 
which opens up for a methodology where ex vivo “cross-over”-studies are possible. 
 
5.2.4 Summary 
In the GPT, the spontaneous tone is maintained by PGE2 primarily synthesised via 
COX-2 within the airway epithelium, mediating a simultaneous activation of both 
contractile EP1 and relaxant EP2 receptors. In human small airways, by use of selective 
receptor antagonists, we conclude that PGE2 does not play a role maintaining the tone, 
an action mediated by leukotrienes since a FLAP inhibitor have the capacity to reduce 
it. However, HB tone is modulated by NSAIDs through an unknown mechanism. Both 
HB and GPT utilize arachidonic acid metabolites as mediators for spontaneous tone, 
however, by completely different agonists as a result by different enzymatic pathways. 
Moreover, the organ culture experiments indicated that when culturing GPT, specific 
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caution should be taken since the EP receptors are constantly activated. Addition of 
NSAIDs will prevent this phenomenon.  
 
 
5.3 RELAXATION OF AIRWAYS MEDIATED BY BITTER TASTE 
RECEPTORS (PAPER II) 
5.3.1 Guinea pig trachea 
As initial experiments performed also showed an interaction between PGE2 and 
several, but not all TAS2R agonists, this connection was investigated further. 
 
Using in-house developed primers based on relevant TAS2Rs from agonists by 
Deshpande et al., expression of mRNA for TAS2R3, TAS2R4 and TAS2R10 were 
detected in both epithelial and smooth muscle cells. Denatonium, chloroquine, thiamine 
and noscapine induced strong relaxation of GPT pre-contracted with carbachol 
(Figure 10A-D). For denatonium and chloroquine the magnitude of relaxation was 
comparable to that of salbutamol (Figure 10E) and formoterol (Paper II, Figure 7D), 
however with markedly lower potencies. Pre-treatment with either denatonium or 
chloroquine prior to contraction with contractile agonists showed that denatonium 
could only reduce the effect of carbachol, whereas chloroquine decreased the effects to 
histamine, U-46619, LTD4 and OVA. The selective effects of denatonium to only relax 
cholinergic responses raised the possibility that it is a muscarinic antagonist. However, 
this hypothesis was omitted since acetylcholine-mediated relaxation in aorta was 
unaffected by denatonium. 
 
The inability for denatonium to relax endogenous PGE2 was demonstrated as it could 
only cause relaxation to the same contractile level as the spontaneous tone maintained 
by PGE2. Upon indomethacin or ONO-8130 treatment, thus abolishing the spontaneous 
tone by removing endogenously produced PGE2 or antagonising EP1 receptor 
respectively, an enhanced relaxation of GPT was achieved by denatonium. The same 
enhanced phenomenon was displayed with thiamine, suggesting similar relaxant 
pathway as for denatonium which clearly differ from both chloroquine and noscapine. 
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Figure 10. Concentration-response curves to the TAS2R agonists (A) denatonium, (B) 
chloroquine, (C) thiamine and (D) noscapine as well as (E) the β2-adrenoceptor agonist 
salbutamol, in presence or absence of indomethacin. 
 
The previously proposed general pathways for TAS2Rs relaxation are 
hyperpolarization through large conductance potassium channels (BKCa) channel 
opening (Deshpande et al., 2010) and cAMP production (Dasso et al., 2011). In our 
study, production of cAMP after TAS2R agonist revealed no change in produced levels 
compared to salbutamol which caused a marked increase. BKCa channels are also 
shown to be involved in the relaxation mediated by β2-adrenoreceptors (Jones et al., 
1993; Miura et al., 1992). Blockers of the BKCa channel (iberiotoxin, charybdotoxin 
and paxilline) did not affected chloroquine relaxation, whereas the potency, but not 
efficacy was slightly shifted for denatonium. Furthermore, the relaxation by 
denatonium was not mediated through PKA, PKC and PKG-dependent pathway as 
selective kinase inhibitors for these kinases involved in cAMP, contractile machinery 
and NO-mediated pathways, respectively, had no effect 
 
The level of pre-contraction can influence both the magnitude and the potency of the 
agonist-induced relaxation (Belvisi et al., 2011). When the preload was increased to 
supramaximal levels both denatonium and chloroquine induced maximal relaxations 
whereas neither of the β2-adrenoceptor agonists did. There was an inverse relationship 
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regarding the potency and preload for denatonium, whereas the potency for chloroquine 
was unaffected. This confirmed the observation that bitter taste agonists induced a 
stronger effect than β2-adrenoceptor agonists (Deshpande et al., 2010). 
 
Taken together, the difference detected during characterisation suggests that 
denatonium and chloroquine mediates relaxations through different signalling pathways 
and that activation of BKCa channels is only one part of the denatonium mediated 
smooth muscle relaxation.  
 
5.3.2 Human bronchi 
The smooth muscle relaxing properties of bitter tasting agonists denatonium, noscapine 
quinine and chloroquine could be replicated in isolated human small bronchi pre-
contracted with carbachol (preliminary results; Figure 11). Similar as in the guinea pig 
trachea the potency was low whereas the efficacy was high.  
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Figure 11. Comparison between concentration-response to the TAS2R agonist noscapine in 
guinea pig trachea and isolated human bronchi. 
 
5.3.3 Summary 
It was documented that bitter taste receptors are expressed in the guinea pig trachea and 
that agonists for these receptors can induce strong relaxations. In carbachol contracted 
preparations, denatonium and chloroquine relaxed maximally contracted preparations 
whereas the β2-adrenoceptor agonist salbutamol under these conditions had a lower 
efficacy. Where denatonium only reduced the effects of cholinergic contractions, 
chloroquine uniformly inhibited contractions evoked also by histamine, contractile 
prostanoids and cysteinyl-leukotrienes. The different effects on different contractile 
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agonists suggest that they act through different pathways. In addition, although we 
could not identify the primary signalling mechanisms for the bitter taste agonist 
response, relaxations induced by denatonium were sensitive to inhibitors of BKCa 
activation. Furthermore, the relaxation could be replicated in human small bronchi 
suggesting that the mechanism exists in both species and thus could provide a target for 
bronchorelaxant drugs. In regards of the relaxant mechanism, initially it was described 
as the activation of BKCa resulting in hyperpolarization of the cell membrane 
(Deshpande et al., 2010), however, a recent study oppose that proposal instead 
suggesting inhibition of L-type voltage-dependent Ca2+ channels (VDCCs) (Zhang et 
al., 2013). As of today, none of these hypothesis presented have been confirmed as the 
sole mechanism of ASM relaxation by bitter tasting compounds. 
 
 
5.4 PROSTANOIDS INVOLVED IN THE ANTIGEN-INDUCED 
CONTRACTION (PAPERS III AND IV) 
5.4.1 Guinea pig trachea 
In the organ bath, cumulative concentrations of OVA (0.1 ng/mL to 0.1 mg/mL) 
induced a concentration-dependent antigen-induced contraction irrespectively of initial 
smooth muscle tone in guinea pigs actively sensitized against OVA (Figure 12). By 
removing the spontaneous tone with NSAIDs the maximum contractile response to the 
antigen was increased. When the EP2 receptor was antagonised, the maximum 
contraction was increased both with and without EP1 receptor antagonism, confirming 
and further specifying that the increased response observed by NSAIDs was due to 
inhibition of the relaxant effect by PGE2 on EP2 receptors (Paper III, Figure 1). This 
phenomenon was also seen when only the EP1 receptor was antagonised, where a 
reduced maximal effect was obtained.  
 
Blocking H1-2 receptors or inhibiting the response to CysLTs using the selective FLAP 
inhibitor MK-886 and nonselective CysLT1-2 receptor antagonist BAY-u9773 alone or 
in combination did not affect the maximum antigen response, suggesting that the 
receptor responses to each separate agonist are close to ASM maximum making 
additive effects indistinguishable. Combining antihistamines with inhibition of CysLT 
and prostanoid production caused a marked inhibition resulting in a 70% reduction of 
the antigen response. This was irrespectively of whether the antigen-induced 
contraction was reduced using antihistamines in combination with complete inhibition 
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of COX and 5-LOX enzymes, or by the use of antagonists targeting EP1-2, TP or 
CysLT1-2 receptors. The remaining 30% contraction was completely inhibited by the 
relaxing effect of the EP2 receptor (when not antagonised), but was resistant to atropine, 
ketanserin and HOE-140 indicating that muscarinic M1-5 receptors, serotonin 5-HT2A 
and bradykinin BK-B2 receptors respectively are not involved antigen-induced 
contraction in the guinea pig trachea and that there is a, yet undetermined, residual 
component(s) released. 
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Figure 12. Maximal effect of the antigen-induced responses after treatment with different 
receptor antagonists and enzyme inhibitors. COX=cyclooxygenase inhibitor indomethaicn; H1-
2=histamine 1 and 2 receptor antagonist mepyramine and metiamide; FLAP=5-lipoxygenase 
activating protein inhibitor MK-886; CysLT1= Cysteinyl-leukotriene 1 receptor antagonist 
montelukast; CysLT1-2=Cysteinyl-leukotriene 1 and 2 receptor antagonist BAY-u9773; EP1= 
EP1 receptor antagonist ONO-8130; EP2=EP2 receptor antagonist PF-04418948; TP=TP 
receptor antagonist SQ-29,548. 
 
To study the release pattern regarding prostanoids in the GPT subsequent antigen 
exposure, bath fluid was collected during specific time points and analysed by a triple 
quadrupole mass spectrometer. In control segments, only PGE2 and PGI2 (measured as 
6-ketoPGF1α) were detected in quantifiable amount in the organ bath fluid (Figure 13). 
Both increased with a similar rate over time (preliminary data). After antigen-exposure 
there was two distinct patterns of prostanoid release; immediate and slow. Both PGD2 
and TXA2 (measured as TXB2) belong to the immediate profile with a substantial 
release after 15 minutes that continued to increase over time (preliminary data). PGE2, 
6-keto PGF1α and PGF2α were also detected, with a minor immediate release and 
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displaying a slower gradual increase over time (preliminary data). The levels of all 
prostanoids were completely abolished upon stimulation with COX inhibitor, whereas 
the FLAP inhibitor MK-886 did not affect the release (not shown).  
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Figure 13. Prostanoid release in relation to wet weight of the tracheal segment during PBS 
treatment (open symbols) and antigen exposure (closed symbols). Only PGE2 and PGI2 
(measured as 6-ketoPGF1α) were detected in quantifiable amount in the organ bath fluid after 
PBS treatment. 
 
There was a major release of PGD2, which is a known mediator in the early phase 
reaction recognized to mediate their contractile effect through the TP receptor (Larsson 
et al., 2011; Turner et al., 1988). Solely antagonising the TP receptor did not affect the 
contraction due to the other contractile mediators in the background, but when 
histamine and CysLT responses were inhibited, a component exerting a 30% 
contraction could be unmasked that was susceptible to SQ-29,548. Thus, we could for 
the first time show the magnitude of the antigen-induced contraction mediated through 
the activation of TP receptors.  
 
5.4.2 Human bronchi 
Antigen -induced contractions of human bronchi were studied by challenge with a 
human monoclonal anti-IgE antibody (anti-IgE).  This causes degranulation of the mast 
cells present in the isolated airway by cross-linking of IgE molecules on their surface.  
The response to the highest concentration of anti-IgE was close to the maximal 
contraction of the bronchi. Maximal contraction was reached within 15 min.  The IgE-
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dependent contraction was abolished by the combination of H1 receptor antagonist, 
FLAP enzyme inhibitor and TP receptor antagonist, supporting that the three classes of 
mast cell mediators histamine, CysLTs and PGD2 mediated the response.  The findings 
show that the IgE-dependent contraction of small human airways has the same 
mediators as previously shown in larger bronchi (Bjorck et al., 1993; Dahlen et al., 
1983; Schmidt et al., 2000).  
 
In line with the above reported relaxation of HB by PGE2 acting on EP4 receptors, 
previous data have suggested that activation of EP4 receptors by exogenous PGE2 may 
relax bronchial segments pre-contracted with anti-IgE (Benyahia et al., 2012).  
However, pre-stimulation with an EP4 receptor antagonist prior to anti-IgE challenge 
did not affect the anti-IgE induced contraction (Figure 14A).  This indicates that the 
endogenous levels of PGE2 are insufficient to reach a concentration that effectively 
activates EP4 receptors in small airways.  Furthermore, as expected, incubation with the 
EP2 receptor antagonist prior to anti-IgE treatment had no effect on the contraction 
(Figure 14A). 
 
As it is known that inhaled PGE2 protects against allergen-induced bronchoconstriction 
in subjects with asthma (Pavord et al., 1995), it was investigated if such an effect could 
be mimicked in the isolated small airways.  It was hypothesised that the 
bronchoprotective action of PGE2 might be due to inhibition of mast cell mediator 
release, as this mode of action is well established in animal models (Raud et al 1987) 
and in human purified mast cells (Kay et al., 2006).  In order to remove the contractile 
effect of PGE2, the experiments were performed in the presence of a TP receptor 
antagonist.  It was indeed found that pre-treatment with exogenous PGE2 completely 
abolished the anti-IgE contractile response (Figure 14B).  Moreover, antagonism of the 
relaxant EP4 receptors prior to PGE2 administration did not block the effect of PGE2 on 
the anti-IgE induced contraction.  In contrast, pre-treatment with the EP2 receptor 
antagonist completely blocked the inhibitory effect of PGE2 on the anti-IgE response 
(Figure 14B). Although studies of mediator release are required to prove the 
mechanism, the findings support the hypothesis that the bronchoprotective effect of 
PGE2 is exerted at the level of the mast cell rather than involving bronchodilation.  
Taken together, the findings suggest that the EP2 receptors are more important in 
regulating airway responsiveness to exogenous PGE2 than are the EP4 receptors.  
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Figure 14. Contractile response in human bronchi after anti-IgE exposure (1/1000 dilution) in 
presence or absence of EP2 (PF-04418948) and EP4 (ONO-AE3-208) receptor antagonists with 
or without PGE2 treatment. (A) Only treated with EP receptor antagonists prior to anti-IgE 
exposure. (B) Treated with EP receptor antagonists followed by PGE2 treatment prior to anti-
IgE exposure. 
 
5.4.3 Summary 
In the central airway of the guinea pig, the antigen-induced contractile responses to 
OVA was due to the release of histamine (acting on H1), leukotrienes (acting on 
CysLT1-2) and a COX product acting on TP receptors.  The latter component has not 
been identified previously as it is masked by the powerful effects of PGE2 on basal tone 
of the preparation.  Using the EP1 and EP2 receptor antagonists it was however possible 
to uncover this component.  It is likely that TXA2 and PGD2 mediated this part of the 
response because both are agonists at the TP receptor and both prostanoids were 
released by challenge.  Theoretically, the contractile effect of PGE2 at the EP1 receptor 
might also contribute to the COX component of the antigen response, but the data 
suggest that PGE2 predominantly controls the spontaneous tone of the guinea pig.  The 
slow increase of the bath concentration of PGE2 after the antigen challenge is also 
consistent with the interpretation that PGE2 is a modulator rather than a mediator of the 
antigen-induced contraction.   
The mediators of the IgE dependent contractions of small human bronchi were the 
same as in the guinea pig trachea, namely histamine, CysLTs and prostanoid acting at 
the TP receptor.  There were differences between the preparations however inasmuch 
that there was no residual response in the human bronchi when all three mediator 
classes had been blocked and there was no need to use a CysLT2 antagonist in this 
tissue.  The same complete abolishment of the antigen response by combined 
antagonist of these three receptors (H1, CysLT1 and TP) has previously been found in 
the perfused and ventilated guinea pig lung (Sundström et al 2003) and the precision 
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cut guinea pig lung parenchyma (Ressmeyer et al., 2006).  Furthermore, in the latter 
two guinea pig models, it was possible to identify an inhibitory component by single 
intervention with any of the three receptors whereas it was remarkable in the GPT that 
combined antagonism of all three mediator classes was required to have significant 
effects on the antigen response.  Presumably differences with respect to local tissue 
concentrations of the mediators in relation to the operative ranges for receptor 
activation explain these differences in sensitivity to receptor antagonism.  Nevertheless, 
by and large, the guinea pig trachea provides a model to study antigen-induced 
responses which includes the main components of the mast cell dependent contractions 
of human airways.  The model is relevant as mast cell activation is a prominent feature 
of asthma exacerbations in humans.   
The study confirmed that the protective in vivo effect of PGE2 on allergic 
bronchoconstriction could be replicated in the isolated small human airways.  
Moreover, it was shown that the effect was mediated by activation of the EP2 receptor 
and therefore seemed unrelated to bronchodilation.  This is in fact consistent with the 
effect of inhaled PGE2 in subjects with asthma where the inhibition of the allergen 
response occurred at time point when the initial bronchodilation had ceased (Pavord et 
al 1995).   
Focusing on the role of prostanoids, the studies indicate that in humans the TP receptor 
is a suitable target to block the bronchoconstrictive effects of in particular the major 
mast cell product PGD2, but also TXA2 and possibly PGE2 if its levels in the tissue are 
high.  Furthermore, the experiment where PGE2 was administered prior to antigen 
challenge suggests that EP2 agonists have potential as inhibitors of mast cell dependent 
bronchoconstriction.  However, combined EP2 and EP4 antagonism may be an 
additional approach as that would add bronchodilation.   
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6 CONCLUSIONS 
 
The main conclusions obtained from this thesis are: 
 
 
• In guinea pig trachea, PGE2 induces a concentration-dependent ASM 
contraction followed by a relaxation, whereas in HB the actions are reversed. 
 
• Contractile EP1 receptors and relaxant EP2 receptors are responsible for the 
bell-shaped response in the guinea pig trachea whereas relaxant EP4 receptors 
and contractile TP mediates the U-shaped action of PGE2 in HB. 
 
• The spontaneous ASM tone in guinea pig trachea is solely mediated and 
maintained by PGE2 simultaneously acting on EP1 and EP2 receptors whereas in 
HB PGE2 does not regulate. 
 
• In the guinea pig trachea, PGE2 is produced primarily via COX-2 in the airway 
epithelium, but also to some extent, by the ASM. 
 
• During antigen-induced response PGE2 is not one of the major components 
released from the mast cell in either guinea pig or HB. However, in the guinea 
pig trachea, PGE2 plays an important modulatory role on the antigen response 
by controlling the ASM tone via EP1 and EP2. In HB, PGE2 acts on EP2 
receptors on the mast cell to prevent degranulation. 
 
• Bitter tasting substances have the capability to mediate ASM relaxation in both 
guinea pig trachea and HB, however, the mechanism is still unknown. 
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7 GENERAL DISCUSSION 
 
Is PGE2 really important enough to justify a whole thesis being written on the subject, 
despite the fact that its structure and biological activities were first described over 50 
years ago? 
The guinea pig trachea was chosen as the main model to address this question 
because the anatomy, pharmacological responses and functions resemble those of 
human airways (Canning et al., 2008; McKenniff et al., 1988; Ressmeyer et al., 2006).  
Indeed, in the guinea pig trachea and human bronchi, PGE2 induced both contractions 
and relaxations.  These effects are achieved by PGE2 activating different subsets of 
receptors.  In the guinea pig trachea, the EP1 and EP2 receptors mediate contraction and 
relaxation, respectively, whereas in human bronchi the same effects are mediated by TP 
and EP4 receptors.  Thus, both similarities and differences exist regarding the functional 
properties of the receptors in the two different species. 
It was furthermore shown that both in the guinea pig trachea and in human 
bronchi, lipid mediators maintain the spontaneous tone of isolated airways.  However 
whereas the guinea pig airway mainly employed the COX pathway for this function, 
the tone of the human airways was mainly underpinned by products of the 5-LOX 
pathway.  This role of eicosanoids for the basal tone of the airways was especially 
prominent in the guinea pig trachea due to extensive constitutive release of PGE2 with 
dual effects on the preparation.  The interaction between this effect of endogenous 
PGE2 and the direct effects of tested substances needs to be considered when 
investigating the specific effect of contractile agonists, or relaxant compounds.  Indeed, 
the awareness of this effect led to the discovery that different bitter taste agonists have 
distinct properties to relax contractions evoked by stimuli that activate different 
pathways.  
The powerful effect of constitutive release of PGE2 was also present during 
culture of the guinea pig trachea where it was implicated in the down regulation of the 
EP1 receptor.  This effect may limit the use of guinea pig trachea for culture procedures 
as successfully performed with mouse trachea (Adner et al., 2002).  Culturing of the 
human small airways was however established.  Perhaps the less prominent constitutive 
release of PGE2 and leukotrienes in the human airways explains why culturing of 
human bronchi was successful.  This model is suggested to be useful for investigations 
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of how human airway smooth muscle cells in their natural surroundings respond to 
different inflammatory agents.  
The present study shows many similarities between the antigen-induced 
responses in guinea pig trachea and human bronchi. Both are due to the combined 
action of histamine and CysLTs (Bjorck et al., 1993). Previous data in larger human 
bronchi have shown that histamine and CysLTs are the major mediators involved. This 
clearly differs from the isolated airways of mice where serotonin released by mast cells 
stimulates neural and epithelial release of acetylcholine, that in turn induces 
contractions (Lei et al., 2013).  In the guinea pig experiments, it was furthermore 
shown that activation of the TP receptor, at which both TXA2 and PGD2 act, mediates a 
significant component of the antigen response.  In the human bronchi, the combination 
of a H1-antihistamine, a leukotriene biosynthesis inhibitor and a TP receptor antagonist 
completely abolished the IgE dependent contraction whereas there remained a small yet 
unidentified component of the antigen response in the guinea pig trachea.  The study 
also confirms and extends the triple antagonism concept, which is that several pathways 
need to be blocked in order to achieve maximal prevention of bronchoconstriction. Due 
to the strong action of each agonist, inhibition of only one pathway is not sufficient 
since the other pathways can still maintain a powerful contraction.  Further experiments 
need to be performed to determine the relative importance of the different mediators in 
the antigen-induced contraction of small human airways.   
In human bronchi, which do not relax in response to EP2 receptor activation, it 
was demonstrated that PGE2 activation of the EP2 receptor caused a marked inhibition 
of the antigen-induced response, most likely through inhibition of mast cell activation 
(Kay et al., 2006; Raud et al., 1987).  When the effect of the EP2 receptor was 
unopposed during the antigen-induced responses in the guinea pig, a decreased 
contraction is observed.  However, it cannot be concluded from these experiments 
whether this is due to inhibition of the mast cell response or due to the strong relaxant 
effect of the EP2 receptor in the guinea pig.   
Clearly, chloroquine, but not denatonium could relax antigen constricted guinea 
pig trachea, these effects need to be investigated further.  In analogy with the suggested 
capacity for PGE2 to inhibit mast cell responses, the possibility that bitter taste agonists 
may inhibit mast cell degranulation also needs to be studied. This is especially 
important because some bitter taste agonists were found to have anti-inflammatory 
properties in leukocytes (Pietras et al., 2012).  
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Despite the introduction of modern therapies, a substantial number of patients 
suffering from airway ailments still remain insufficiently controlled.  Novel 
bronchorelaxant therapies, utilising both known and unknown pathways for relaxation 
should therefore be explored further.  Inhaled β2 adrenoceptor agonists are currently the 
gold standard of bronchodilators, however, since the introduction of long-acting β 
agonists (LABA) and ultra-LABAs, there has been increasing concern regarding their 
safety, particularly when used as a monotherapy in the treatment of asthma (Rodrigo et 
al., 2012).  A selective EP4 receptor agonist would be beneficial and has recently been 
shown to relax human airways with a higher potency than the β2 adrenoceptor agonists 
salbutamol and salmeterol (Benyahia et al., 2012; Gorenne et al., 1995). However, 
potential cardiovascular side effects needs to be monitored carefully since the EP4 
receptor is involved in the control of vascular tone in e.g. cerebral and uterine arteries 
(Baxter et al., 1995; Davis et al., 2004). Also, activation of the EP4 receptor has 
recently been shown to facilitate Th1 differentiation and Th17 expansion, two Th-
subsets involved in inflammation (Sakata et al., 2010). For these reasons, alternative 
bronchodilator therapies with an increasing safety profile should be premiered possibly 
coupled with an anti-inflammatory activity, such as a dual EP2 and EP4 receptor 
agonists. Such a configuration would also not trigger the EP3 receptor induced cough 
(Maher et al., 2009), an adverse effect often observed following inhalation of PGE2 
(Cuthbert, 1969).  Finally, since current treatment is unable to provide bronchial relief 
for some patients, the bitter taste agonists might represent a novel therapeutic approach 
for bronchorelaxation through unknown relaxant pathways.  As no previously described 
pathways have been proven to meditate the relaxation induced by bitter taste agonists, 
these new findings suggest the presence of new powerful relaxant pathways. 
In relation to the question raised in the beginning of this section, it is indeed clear 
that it has been meaningful to investigate the actions of PGE2 in airways. With the aid 
of a new generation of subtype selective receptor antagonists and enzyme inhibitors, it 
has been possible to perform an extended characterisation of the role of PGE2 as an 
important mediator and modulator of airway function, both directly at the level of the 
smooth muscle and indirectly be control of mast cell mediator release.  It is possible 
that these PGE2 receptors may become new targets for treatment of asthma and other 
airway diseases.  
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8 POPULÄRVETENSKAPLIG SAMMANFATTNING 
 
Astma är en sjukdom som drabbar andningsorganen. Förekomsten av astma är 5-10% 
av befolkningen och i nuläget sker en ökning i de flesta länder.  Astma kännetecknas av 
svårigheter att andas och ger symptom i form av hosta och andnöd, i svåra fall kan man 
avlida genom kvävning.  Sjukdomen beror på inflammation och ökad retbarhet i 
luftrören.  En central komponent i astmaattacken är bronkkontraktion, dvs. 
sammandragning av luftrörens glatta muskulatur.  Behandlingen är främst 
antiinflammatoriska steroider (kortison) och luftrörsvidgande läkemedel som β2 
stimulerare.  Detta till trots är det många individer som inte blir symptomfria och 
behovet av nya terapier är stort. Astma är starkt kopplad till allergen-specifika 
antikroppar (IgE) mot t.ex. katt, pollen eller kvalster. Genom att IgE binder till 
mastceller, vilka är vävnadsspecifika vita blodkroppar, har de möjlighet att, vid 
allergenkontakt, aktivera dessa celler. Vid aktivering utsöndrar mastcellerna en mängd 
olika substanser, däribland histamin, leukotriener och prostanoider vilka åstadkommer 
sammandragning av luftrören.  Effekterna av dessa substanser förmedlas av specifika 
mottagarmolekyler, receptorer, som i sin tur kan orsaka kontraktion, relaxation eller 
ytterligare utsöndring av substanser. Kontraktion av glatt muslukatur, muskelvävnaden 
i luftvägarna, är den dominerande effekten vid mastcell-aktivering även om substanser 
som relaxerar också utsöndras. En substans som har förmågan att både kontrahera och 
relaxera glatt muslukaturen samt påverka mastcellseffekten är prostanoiden 
prostaglandin E2. Huvudsyftet med studierna i denna avhandling är att karaktärisera 
verkan av prostaglandin E2 i luftvägarna och undersöka vilken roll den har i normala 
luftvägar samt under allergiska betingelser.  
 
Marsvin valdes som djurmodell då luftvägspreparat från djurslaget uppvisar både 
fysiologiska och farmakologiska likheter med människa. Ändock viktigare är att 
marsvin uppvisar ett reaktionsmönster vid allergiska reaktioner som är väldigt likt det 
man ser hos människan. Bekräftande observationer utfördes även i lungvävnad från 
människa. 
 
Prostaglandin E2 har tidigare visat sig primärt binda till fyra olika receptorer, så kallade 
EP receptorer, men den kan även binda ytterligare receptorer, så som TP receptorn. I 
luftväg hos både marsvin och människa har den förmåga att kontrahera och relaxera 
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beroende på vilken receptor som aktiveras. Det visade sig att hos marsvin är det primärt 
EP1 receptorn som förmedlar kontraktion samtidigt som EP2 receptorn orsaker 
relaxation. Dessa två receptorer medierar även en spontan luftvägstonus, vars syfte är 
att upprätthålla en dynamisk muskelspänning. I isolerade luftvägar från människa är det 
TP receptorn som medierar kontraktion och EP4 receptorn som medierar relaxation vid 
tillförsel av prostaglandin E2 med effekten på spontan luftvägstonus mindre 
framträdande. 
 
Under allergiska förhållanden visades att läkemedel mot histamin, leukotriener och 
prostanoider (främst via TP receptorn) motverkade majoriteten av 
luftvägskontraktionen i både marsvin och människa samt att alla tre klasser behövder 
hämmas för full effekt.  Detta ger rationellt underlag att föreslå att liknande 
kombinationsbehandling borde vara värdefullt vid behandling av astmaattacker och 
kanske även för att förebygga anfall.  Prostaglandin E2 roll under allergiska 
förhållanden var olika för marsvin och människa.  Hos marsvin påverkade 
prostaglandin E2 främst kontraktionen indirekt genom att ändra den spontana 
luftvägstonusen medan prostaglandin E2 hos människa kunde hämma den allergiska 
kontraktionen totalt via en verkan på EP2 receptorer sannolikt belägna på mast-celler. 
 
Under tiden då arbetet med prostaglandin E2 fortgick publicerades nya rön som pekade 
på att bittra substanser, ex. kinin som återfinns i ”gin&tonic”, kunde vara 
luftrörsvidgande samt att en eventuell koppling till prostaglandin E2 kunde finnas.  Det 
visade sig att relaxationen kunde replikeras hos både marsvin och människa samt att det 
handlade om aktivering av nya, ännu inte karaktäriserade, signalvägar. Vidare kunde 
vissa, men inte alla, av de bittra substanserna relaxera luftvägar som kontraherats i en 
allergisk modell.  
 
Sammanfattningsvis har avhandlingsarbetet identifierat flera nya möjliga 
angreppspunkter som kan bli mål för utveckling av framtida astmamediciner. 
 
 56 
9 ACKNOWLEDGEMENTS 
 
Since this is the page most people will read, here is the take-home message: PGE2 is a 
molecule, highly integrated in vital mammalian homeostatic functions, with the 
influence to cause both excitatory and inhibitory responses within the same tissue, 
some of them considered pro- while others anti-inflammatory. The data gathered 
support that PGE2 activated EP receptors are potential targets for development of 
drugs to treat asthma and other forms of airway obstruction. 
 
My work was performed at Karolinska Institutet, Institute of Environmental Medicine, 
Division of Physiology – Experimental Asthma and Allergy Research and I am very 
grateful for this opportunity. I would also like to express my gratitude to all people who 
contributed to completion of my different research papers, directly or indirectly. In 
particular I wish to thank the following people:  
 
My supervising team, a unique combination of excellent scientists: 
Main supervisor associate Professor Mikael Adner, for allowing me to explore the 
wonderful world of pharmacology! Thank you for all the support, dedication and fun 
times together. It has been an honour working with you. 
Co-supervisor Professor Sven-Erik Dahlén, for introducing me to the field of 
eicosanoids and asthma. Thank you for the “no boundary”-feeling, allowing me to 
pursue science wherever it went. 
Co-supervisor Professor Lars-Olaf Cardell, for believing in me and allowing me to 
“live” in the lab. Thank you for all valuable inputs regarding science and beyond.  
 
Anita Sydbom – for interesting histamine discussions 
Anna Hedelin – for interesting non-histamine related discussions 
Anna James – for being a wonderful friend. It is never boring when you are around. 
Furthermore, I am grateful for all the help with the thesis 
Anna-Karin Larsson Callerfelt – for teaching me PCLS and the organ bath 
Anquan Li – for your emergency participation during my half-time seminar 
Barbara Fuchs – for being German (and also friendly and helpful) 
Bengt Björksten – for fun discussions regarding probiotics 
Britt-Marie Sundblad – for fun discussions during “fika” 
   57 
Cecilia Kemi – for all the discussions, laughter and joy in our room 
David Balgoma – for being an Oxylipid-wizard 
Eliisa Kekäläinen – for our fun logistics with the human tissue 
Emrah Bozkurt – for being very nice and wonderful to work with in the lab 
Esther Edlundh-Rose – for being friendly and a master organiser 
Gunilla Hedelin – for fun times during CFA seminars 
Ingrid Delin – for all the fun and for being exceptionally good at ELISA 
Joan Deutsch – for all the help in the organ bath 
Johan Larsson – for fun discussions, at work and during conferences 
Joshua Gregory – for being a nice roomie and for pleasant discussions 
Lena Palmberg – for fun discussions at work and during the Educational board 
Linda Swedin – for being a good and helpful friend 
Lisa Sjöberg – for fun discussions and good times in the lab 
Lotta Tengroth – for being happy and friendly 
Maciek Kupczyk – for your friendship and good taste in beers 
Margareta Andersson – for all the help, both in and out of the lab 
Maria Kumlin – for stimulating discussions regarding eicosanoids 
Martijn Manson – for all the fun and interesting discussions within the lab and also 
fun times outside. Also for your exquisite taste of bred 
Melinda Verriere – for wonderful animal care and assistance 
Na Guan – for GP related discussions 
Piet Boels – for all the discussions in the lab 
Roelinde Middelveld – for being friendly and helpful 
Sandra Ekstedt – for fun times in the lab 
Susanna Kumlien Georén – for all the help with the thesis and also fun discussions 
Ville Pulkkinen – for fun and interesting discussions in the lab and at the pub 
Yuan Xu – for fun discussions in the lab 
Yvonne Nygren – for being friendly, funny and helpful 
Åke Ryrfeldt – for your enthusiasm 
 
Professor Kjell Larsson with co-workers – for sharing your expertise in lung 
physiology and providing a stimulating atmosphere. 
Professor Anders Lindén and Professor Johan Frostegård with co-workers – for 
bringing fresh breath of air to the Division of Physiology. 
 58 
Professor Gunnar Nilsson with co-workers – for fun and interesting discussions with 
all of you. 
 
Susanne, Hylander Ann-Charlotte Orre, Per Bergman and Mamdoh Al-Ameri at 
Department of Cardiovascular and Thoracic surgery – for excellent collaboration 
regarding human tissue. 
Inhalation Sciences, Per Gärde, Ewa Selg, Fernando Acevedo and Maria Börjel – 
for friendship and fun discussions. 
 
I also wish to express an enormous gratitude to my friends in the “real world”, 
especially Peter, Marie, Mathias, Tuti, Dansken, Maria, Olof, Moa, Katarina, 
Rickard, Emma, Niclas, David and Evelina. Thank you for all the good times, 
support and encouragement over the years! 
 
I would also like express my appreciation to all my previous co-workers at AstraZeneca 
Safety Assessment in Södertälje. Those week-ends and summers (without my cell 
phone turned on) were a perfect time to reflect and relax. 
 
To my wonderful parents, Christer and Birgitta Säfholm, who has always been there 
for me and supported me over the years, for which I am eternally grateful! 
Also, I’m hugely thankful for my sister and brother; Malin and Fredrik Säfholm. You 
are the greatest siblings one could wish for! 
Stort tack till farmor Astrid Rosvall – min mest okritiska supporter. Din tilltro ger mig 
styrka. Stort tack till mina, sedan några månader bortgånga, morföräldrar; Casper och 
Elvira Holm – er entusiasm och livsfilosofi är något jag kommer att föra vidare! 
Stort tack även till stora Kvarnryds-släkten för trevliga stunder tillsammans och 
härliga diskussioner där allt mellan himmel och jord avhandlats. 
 
Slutligen, ett enormt stort tack skall tillägnas min underbara fru Moa Säfholm! Tack 
för din förståelse, ditt stöd, ditt underbart varma hjärta och din fantastiska personlighet. 
Även min underbara son Kejsare William Säfholm skall tackas då han, med egenskap 
som min personliga väckarklocka, möjliggjort att denna avhandling blivit klar i tid. 
   59 
10 REFERENCES 
 
Aalbers, R, Kauffman, HF, Vrugt, B, Smith, M, Koeter, GH, Timens, W, et al. (1993). 
Bronchial lavage and bronchoalveolar lavage in allergen-induced single early and dual 
asthmatic responders. Am Rev Respir Dis 147: 76-81. 
 
Abramovitz, M, Adam, M, Boie, Y, Carrière, M-C, Denis, D, Godbout, C, et al. (2000). 
The utilization of recombinant prostanoid receptors to determine the affinities and 
selectivities of prostaglandins and related analogs. Biochimica et Biophysica Acta 
(BBA) - Molecular and Cell Biology of Lipids 1483: 285-293. 
 
Adams, GK, 3rd, Lichtenstein, LM (1985). Indomethacin enhances response of human 
bronchus to antigen. Am Rev Respir Dis 131: 8-10. 
 
Adams, SS, McCullough, KF, Nicholson, JS (1969). The pharmacological properties of 
ibuprofen, an anti-inflammatory, analgesic and antipyretic agent. Arch Int 
Pharmacodyn Ther 178: 115-129. 
 
Adner, M, Rose, AC, Zhang, Y, Sward, K, Benson, M, Uddman, R, et al. (2002). An 
assay to evaluate the long-term effects of inflammatory mediators on murine airway 
smooth muscle: evidence that TNF[alpha] up-regulates 5-HT2A-mediated contraction.  
137: 971-982. 
 
Akdis, CA (2012). Therapies for allergic inflammation: refining strategies to induce 
tolerance. Nat Med 18: 736-749. 
 
Almqvist, C, Worm, M, Leynaert, B (2008). Impact of gender on asthma in childhood 
and adolescence: a GA2LEN review. Allergy 63: 47-57. 
 
An, S, Yang, J, So, SW, Zeng, L, Goetzl, EJ (1994). Isoforms of the EP3 subtype of 
human prostaglandin E2 receptor transduce both intracellular calcium and cAMP 
signals. Biochemistry 33: 14496-14502. 
 
An, SS, Bai, TR, Bates, JH, Black, JL, Brown, RH, Brusasco, V, et al. (2007). Airway 
smooth muscle dynamics: a common pathway of airway obstruction in asthma. Eur 
Respir J 29: 834-860. 
 
Andersson, CK, Mori, M, Bjermer, L, Lofdahl, CG, Erjefalt, JS (2009). Novel site-
specific mast cell subpopulations in the human lung. Thorax 64: 297-305. 
 
Andersson, P (1980). Antigen-induced bronchial anaphylaxis in actively sensitized 
guinea-pigs. Pattern of response in relation to immunization regimen. Allergy 35: 65-
71. 
 
Aso, H, Ito, S, Mori, A, Suganuma, N, Morioka, M, Takahara, N, et al. (2013). 
Differential regulation of airway smooth muscle cell migration by e-prostanoid receptor 
subtypes. Am J Respir Cell Mol Biol 48: 322-329. 
 
 60 
Balzar, S, Fajt, ML, Comhair, SA, Erzurum, SC, Bleecker, E, Busse, WW, et al. 
(2011). Mast cell phenotype, location, and activation in severe asthma. Data from the 
Severe Asthma Research Program. Am J Respir Crit Care Med 183: 299-309. 
 
Bara, I, Ozier, A, Tunon de Lara, JM, Marthan, R, Berger, P (2010). Pathophysiology 
of bronchial smooth muscle remodelling in asthma. Eur Respir J 36: 1174-1184. 
 
Barnes, PJ (1991). Histamine receptors in the lung. Agents Actions Suppl 33: 103-122. 
 
Baroody, RA, Bito, LZ (1981). The impermeability of the basic cell membrane to 
thromboxane-B2' prostacyclin and 6-keto-PGF 1 alpha. Prostaglandins 21: 133-142. 
 
Baxter, GS, Clayton, JK, Coleman, RA, Marshall, K, Sangha, R, Senior, J (1995). 
Characterization of the prostanoid receptors mediating constriction and relaxation of 
human isolated uterine artery. Br J Pharmacol 116: 1692-1696. 
 
Beasley, RC, Featherstone, RL, Church, MK, Rafferty, P, Varley, JG, Harris, A, et al. 
(1989). Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced 
bronchoconstriction. J Appl Physiol 66: 1685-1693. 
 
Behrens, M, Meyerhof, W (2011). Gustatory and extragustatory functions of 
mammalian taste receptors. Physiol Behav 105: 4-13. 
 
Belvisi, MG, Dale, N, Birrell, MA, Canning, BJ (2011). Bronchodilator activity of 
bitter tastants in human tissue. Nat Med 17: 776; author reply 776-778. 
 
Benyahia, C, Gomez, I, Kanyinda, L, Boukais, K, Danel, C, Leseche, G, et al. (2012). 
PGE(2) receptor (EP(4)) agonists: potent dilators of human bronchi and future asthma 
therapy? Pulm Pharmacol Ther 25: 115-118. 
 
Bergstroem, S, Danielsson, H, Samuelsson, B (1964). The Enzymatic Formation of 
Prostaglandin E2 from Arachidonic Acid Prostaglandins and Related Factors 32. 
Biochim Biophys Acta 90: 207-210. 
 
Bergström, S, Dressler, F, Krabisch, L, Ryhage, R, Sjövall, J (1962). The isolation and 
structure of a smooth muscle stimulating factor in normal sheep and pig. Arkiv. Kemi 
20. 
 
Billington, CK, Penn, RB (2003). Signaling and regulation of G protein-coupled 
receptors in airway smooth muscle. Respir Res 4: 2. 
 
Birrell, MA, Maher, SA, Buckley, J, Dale, N, Bonvini, S, Raemdonck, K, et al. (2013). 
Selectivity profiling of the novel EP(2) receptor antagonist, PF-04418948, in functional 
bioassay systems: atypical affinity at the guinea pig EP(2) receptor. Br J Pharmacol 
168: 129-138. 
 
Bito, LZ, Baroody, RA (1975). Impermeability of rabbit erythrocytes to prostaglandins. 
Am J Physiol 229: 1580-1584. 
 
Bjorck, T, Dahlen, SE (1993). Leukotrienes and histamine mediate IgE-dependent 
contractions of human bronchi: pharmacological evidence obtained with tissues from 
asthmatic and non-asthmatic subjects. Pulm Pharmacol 6: 87-96. 
   61 
 
Black, JL, Johnson, PR (2002). Factors controlling smooth muscle proliferation and 
airway remodelling. Curr Opin Allergy Clin Immunol 2: 47-51. 
 
Boie, Y, Sawyer, N, Slipetz, DM, Metters, KM, Abramovitz, M (1995). Molecular 
cloning and characterization of the human prostanoid DP receptor. J Biol Chem 270: 
18910-18916. 
 
Borgeat, P, Samuelsson, B (1979). Transformation of arachidonic acid by rabbit 
polymorphonuclear leukocytes. Formation of a novel dihydroxyeicosatetraenoic acid. J 
Biol Chem 254: 2643-2646. 
 
Bos, CL, Richel, DJ, Ritsema, T, Peppelenbosch, MP, Versteeg, HH (2004). 
Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol 36: 
1187-1205. 
 
Bourne, N, Milligan, GN, Stanberry, LR, Stegall, R, Pyles, RB (2005). Impact of 
immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into 
the genital tract in guinea pigs that become infected. J Infect Dis 192: 2117-2123. 
 
Boyce, JA (2007). Mast cells and eicosanoid mediators: a system of reciprocal 
paracrine and autocrine regulation. Immunol Rev 217: 168-185. 
 
Bradding, P, Walls, AF, Holgate, ST (2006). The role of the mast cell in the 
pathophysiology of asthma. J Allergy Clin Immunol 117: 1277-1284. 
 
Brightling, CE, Bradding, P, Symon, FA, Holgate, ST, Wardlaw, AJ, Pavord, ID 
(2002). Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 346: 
1699-1705. 
 
Brink, C, Grimaud, C, Guillot, C, Orehek, J (1980). The interaction between 
indomethacin and contractile agents on human isolated airway muscle. Br J Pharmacol 
69: 383-388. 
 
Brunnberg, FJ (1978). Application of prostaglandins in obstetrics and gynecology. Acta 
Biol Med Ger 37: 917-921. 
 
Buckley, J, Birrell, MA, Maher, SA, Nials, AT, Clarke, DL, Belvisi, MG (2011). EP4 
receptor as a new target for bronchodilator therapy. Thorax 66: 1029-1035. 
 
Burr, GO, Burr, MM (1929). A NEW DEFICIENCY DISEASE PRODUCED BY 
THE RIGID EXCLUSION OF FAT FROM THE DIET. Journal of Biological 
Chemistry 82: 345-367. 
 
Busse, WW, Lemanske, RF, Jr., Gern, JE (2010). Role of viral respiratory infections in 
asthma and asthma exacerbations. Lancet 376: 826-834. 
 
Bäck, M (2002). Studies of receptors and modulatory mechanisms in functional 
responses to cysteinyl-leukotrienes in smooth muscle. Acta Physiol Scand Suppl 648: 
1-55. 
 
 62 
Bäck, M, Dahlen, SE, Drazen, JM, Evans, JF, Serhan, CN, Shimizu, T, et al. (2011). 
International Union of Basic and Clinical Pharmacology. LXXXIV: leukotriene 
receptor nomenclature, distribution, and pathophysiological functions. Pharmacol Rev 
63: 539-584. 
 
Canning, BJ, Chou, Y (2008). Using guinea pigs in studies relevant to asthma and 
COPD. Pulmonary Pharmacology & Therapeutics 21: 702-720. 
 
Cartier, A, Thomson, NC, Frith, PA, Roberts, R, Hargreave, FE (1982). Allergen-
induced increase in bronchial responsiveness to histamine: relationship to the late 
asthmatic response and change in airway caliber. J Allergy Clin Immunol 70: 170-177. 
 
Ciana, P, Fumagalli, M, Trincavelli, ML, Verderio, C, Rosa, P, Lecca, D, et al. (2006). 
The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-
leukotrienes receptor. EMBO J 25: 4615-4627. 
 
Clarke, DL, Giembycz, MA, Patel, HJ, Belvisi, MG (2004). E-ring 8-isoprostanes 
inhibit ACh release from parasympathetic nerves innervating guinea-pig trachea 
through agonism of prostanoid receptors of the EP3-subtype. Br J Pharmacol 141: 600-
609. 
 
Cockcroft, DW (1988). Airway hyperresponsiveness and late asthmatic responses. 
Chest 94: 178-180. 
 
Coleman, RA, Kennedy, I (1985). Characterisation of the prostanoid receptors 
mediating contraction of guinea-pig isolated trachea. Prostaglandins 29: 363-375. 
 
Coleman, RA, Kennedy, I (1980). Contractile and relaxant actions of prostaglandins on 
guinea-pig isolated trachea. Br J Pharmacol 68: 533-539. 
 
Coleman, RA, Nials, AT, Rabe, KF, Vardey, CJ, Watson, N (1996). Isolated, 
electrically-stimulated airway preparations--their use in determining beta-adrenoceptor 
agonist activity. Pulm Pharmacol 9: 107-117. 
 
Coleman, RA, Sheldrick, RL (1989). Prostanoid-induced contraction of human 
bronchial smooth muscle is mediated by TP-receptors. Br J Pharmacol 96: 688-692. 
 
Coleman, RA, Smith, WL, Narumiya, S (1994). International Union of Pharmacology 
classification of prostanoid receptors: properties, distribution, and structure of the 
receptors and their subtypes. Pharmacol Rev 46: 205-229. 
 
Cuthbert, MF (1969). Effect on airways resistance of prostaglandin E1 given by aerosol 
to healthy and asthmatic volunteers. Br Med J 4: 723-726. 
 
Dahlen, SE (2006). Treatment of asthma with antileukotrienes: first line or last resort 
therapy? Eur J Pharmacol 533: 40-56. 
 
Dahlen, SE, Bjork, J, Hedqvist, P, Arfors, KE, Hammarstrom, S, Lindgren, JA, et al. 
(1981). Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary 
venules: in vivo effects with relevance to the acute inflammatory response. Proc Natl 
Acad Sci U S A 78: 3887-3891. 
 
   63 
Das, UN (2006a). Essential Fatty acids - a review. Curr Pharm Biotechnol 7: 467-482. 
 
Das, UN (2006b). Essential fatty acids: biochemistry, physiology and pathology. 
Biotechnol J 1: 420-439. 
 
Dasso, M, Pagotto, R, Pignataro, OP, Diez, RA, Sales, ME (2011). Effect of bitter 
compounds on amylase secretion in murine submandibular glands: Signaling pathway 
mechanisms. Biochim Biophys Acta 1810: 1212-1219. 
 
Davis, RJ, Murdoch, CE, Ali, M, Purbrick, S, Ravid, R, Baxter, GS, et al. (2004). EP4 
prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. Br J 
Pharmacol 141: 580-585. 
 
Deshpande, DA, Wang, WC, McIlmoyle, EL, Robinett, KS, Schillinger, RM, An, SS, 
et al. (2010). Bitter taste receptors on airway smooth muscle bronchodilate by localized 
calcium signaling and reverse obstruction. Nat Med 16: 1299-1304. 
 
Devillier, P, Bessard, G (1997). Thromboxane A2 and related prostaglandins in 
airways. Fundam Clin Pharmacol 11: 2-18. 
 
Dey, I, Lejeune, M, Chadee, K (2006). Prostaglandin E2 receptor distribution and 
function in the gastrointestinal tract. Br J Pharmacol 149: 611-623. 
 
Drazen, JM, Israel, E, O'Byrne, PM (1999). Treatment of asthma with drugs modifying 
the leukotriene pathway. N Engl J Med 340: 197-206. 
 
Drews, J (2006). Case histories, magic bullets and the state of drug discovery. Nat Rev 
Drug Discov 5: 635-640. 
 
Dube, LM, Swanson, LJ, Awni, W (1999). Zileuton, a leukotriene synthesis inhibitor in 
the management of chronic asthma. Clinical pharmacokinetics and safety. Clin Rev 
Allergy Immunol 17: 213-221. 
 
Dunford, PJ, Holgate, ST (2010). The role of histamine in asthma. Adv Exp Med Biol 
709: 53-66. 
 
Eder, W, Ege, MJ, von Mutius, E (2006). The asthma epidemic. N Engl J Med 355: 
2226-2235. 
 
Ediger, TL, Danforth, BL, Toews, ML (2002). Lysophosphatidic acid upregulates the 
epidermal growth factor receptor in human airway smooth muscle cells. Am J Physiol 
Lung Cell Mol Physiol 282: L91-98. 
 
Esser, R, Berry, C, Du, Z, Dawson, J, Fox, A, Fujimoto, RA, et al. (2005). Preclinical 
pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J 
Pharmacol 144: 538-550. 
 
Fahy, JV, Fleming, HE, Wong, HH, Liu, JT, Su, JQ, Reimann, J, et al. (1997). The 
effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to 
allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155: 1828-1834. 
 
 64 
Fay, MP, Pfeiffer, R, Cronin, KA, Le, C, Feuer, EJ (2003). Age-conditional 
probabilities of developing cancer. Stat Med 22: 1837-1848. 
 
Featherstone, RL, Robinson, C, Holgate, ST, Church, MK (1990). Evidence for 
thromboxane receptor mediated contraction of guinea-pig and human airways in vitro 
by prostaglandin (PG) D2, 9 alpha,11 beta-PGF2 and PGF2 alpha. Naunyn 
Schmiedebergs Arch Pharmacol 341: 439-443. 
 
Fireman, P (2003). Understanding asthma pathophysiology. Allergy Asthma Proc 24: 
79-83. 
 
FitzGerald, GA (2003). COX-2 and beyond: Approaches to prostaglandin inhibition in 
human disease. Nat Rev Drug Discov 2: 879-890. 
 
Folli, C, Descalzi, D, Scordamaglia, F, Riccio, AM, Gamalero, C, Canonica, GW 
(2008). New insights into airway remodelling in asthma and its possible modulation. 
Curr Opin Allergy Clin Immunol 8: 367-375. 
 
Ford-Hutchinson, AW, Bray, MA, Doig, MV, Shipley, ME, Smith, MJ (1980). 
Leukotriene B, a potent chemokinetic and aggregating substance released from 
polymorphonuclear leukocytes. Nature 286: 264-265. 
 
Forselles, KA, Root, J, Clarke, T, Davey, D, Aughton, K, Dack, K, et al. (2011). In 
vitro and in vivo characterisation of PF-04418948, a novel, potent and selective 
prostaglandin E(2) receptor-2 (EP(2) ) antagonist. Br J Pharmacol 164: 1847-1856. 
 
Forsythe, P, McGarvey, LP, Heaney, LG, MacMahon, J, Ennis, M (2000). Sensory 
neuropeptides induce histamine release from bronchoalveolar lavage cells in both 
nonasthmatic coughers and cough variant asthmatics. Clin Exp Allergy 30: 225-232. 
 
Fortier, MA, Krishnaswamy, K, Danyod, G, Boucher-Kovalik, S, Chapdalaine, P 
(2008). A postgenomic integrated view of prostaglandins in reproduction: implications 
for other body systems. J Physiol Pharmacol 59 Suppl 1: 65-89. 
 
Fortner, CN, Breyer, RM, Paul, RJ (2001). EP2 receptors mediate airway relaxation to 
substance P, ATP, and PGE2. Am J Physiol Lung Cell Mol Physiol 281: L469-474. 
 
Fuller, RW (1996). The asthma death problem revisited. Br J Clin Pharmacol 42: 11-
14. 
 
Funk, CD (2001). Prostaglandins and leukotrienes: advances in eicosanoid biology. 
Science 294: 1871-1875. 
 
Galli, SJ, Tsai, M (2012). IgE and mast cells in allergic disease. Nat Med 18: 693-704. 
 
Galli, SJ, Tsai, M, Piliponsky, AM (2008). The development of allergic inflammation. 
Nature 454: 445-454. 
 
Giles, H, Leff, P, Bolofo, ML, Kelly, MG, Robertson, AD (1989). The classification of 
prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, 
selective and potent competitive antagonist. Br J Pharmacol 96: 291-300. 
 
   65 
Gillard, J, Ford-Hutchinson, AW, Chan, C, Charleson, S, Denis, D, Foster, A, et al. 
(1989). L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5-isopropylindol-2-
yl]-2,2 - dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis 
inhibitor. Can J Physiol Pharmacol 67: 456-464. 
 
GINA (2011). From the Global Strategy for Asthma Management and Prevention, 
Global Initiative for Asthma (GINA). Available from: http://www.ginasthma.org/. 
 
Gorenne, I, Labat, C, Norel, X, De Montpreville, V, Guillet, MC, Cavero, I, et al. 
(1995). Effects of beta 2-adrenoceptor agonists on anti-IgE-induced contraction and 
smooth muscle reactivity in human airways. Br J Pharmacol 114: 935-940. 
 
Gulliksson, M, Palmberg, L, Nilsson, G, Ahlstedt, S, Kumlin, M (2006). Release of 
prostaglandin D2 and leukotriene C4 in response to hyperosmolar stimulation of mast 
cells. Allergy 61: 1473-1479. 
 
Gyllfors, P, Dahlen, SE, Kumlin, M, Larsson, K, Dahlen, B (2006). Bronchial 
responsiveness to leukotriene D4 is resistant to inhaled fluticasone propionate. J 
Allergy Clin Immunol 118: 78-83. 
 
Haeggstrom, JZ, Tholander, F, Wetterholm, A (2007). Structure and catalytic 
mechanisms of leukotriene A4 hydrolase. Prostaglandins Other Lipid Mediat 83: 198-
202. 
 
Hamberg, M, Samuelsson, B (1971). On the Metabolism of Prostaglandins E1 and E2 
in Man. Journal of Biological Chemistry 246: 6713-6721. 
 
Hamberg, M, Svensson, J, Samuelsson, B (1975). Thromboxanes: a new group of 
biologically active compounds derived from prostaglandin endoperoxides. Proc Natl 
Acad Sci U S A 72: 2994-2998. 
 
Hamid-Bloomfield, S, Payne, AN, Petrovic, AA, Whittle, BJ (1990). The role of 
prostanoid TP- and DP-receptors in the bronchoconstrictor effect of inhaled PGD2 in 
anaesthetized guinea-pigs: effect of the DP-antagonist BW A868C. Br J Pharmacol 
100: 761-766. 
 
Harris, SG, Padilla, J, Koumas, L, Ray, D, Phipps, RP (2002). Prostaglandins as 
modulators of immunity. Trends Immunol 23: 144-150. 
 
Hay, DW, Muccitelli, RM, Horstemeyer, DL, Raeburn, D (1988). Is the epithelium-
derived inhibitory factor in guinea-pig trachea a prostanoid? Prostaglandins 35: 625-
637. 
 
Heederik, D, von Mutius, E (2012). Does diversity of environmental microbial 
exposure matter for the occurrence of allergy and asthma? J Allergy Clin Immunol 130: 
44-50. 
 
Heise, CE, O'Dowd, BF, Figueroa, DJ, Sawyer, N, Nguyen, T, Im, DS, et al. (2000). 
Characterization of the human cysteinyl leukotriene 2 receptor. J Biol Chem 275: 
30531-30536. 
 
 66 
Hirai, H, Tanaka, K, Takano, S, Ichimasa, M, Nakamura, M, Nagata, K (2002). Cutting 
edge: agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2. J 
Immunol 168: 981-985. 
 
Hirai, H, Tanaka, K, Yoshie, O, Ogawa, K, Kenmotsu, K, Takamori, Y, et al. (2001). 
Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, 
and basophils via seven-transmembrane receptor CRTH2. J Exp Med 193: 255-261. 
 
Hirshman, CA, Emala, CW (1999). Actin reorganization in airway smooth muscle cells 
involves Gq and Gi-2 activation of Rho. Am J Physiol 277: L653-661. 
 
Hogg, JC, Chu, F, Utokaparch, S, Woods, R, Elliott, WM, Buzatu, L, et al. (2004). The 
nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J 
Med 350: 2645-2653. 
 
Holgate, ST (2012). Innate and adaptive immune responses in asthma. Nat Med 18: 
673-683. 
 
Holgate, ST (2011). The sentinel role of the airway epithelium in asthma pathogenesis. 
Immunol Rev 242: 205-219. 
 
Holz, Jorres, RA, Magnussen, H (2000). Monitoring central and peripheral airway 
inflammation in asthma. Respir Med 94 Suppl D: S7-12. 
 
Hutas, I, Hadhazy, P, Debreczeni, L, Vizi, ES (1981). Relaxation of human isolated 
bronchial smooth muscle. Role of prostacyclin and prostaglandin F2 alpha in muscle 
tone. Lung 159: 153-161. 
 
Illes, P, Knoll, J (1975). Specific desensitition to PGE1 and PGE2 in guinea-pig ileum; 
evidence for a common receptor site. Pharmacol Res Commun 07: 37-47. 
 
Irani, AA, Schechter, NM, Craig, SS, DeBlois, G, Schwartz, LB (1986). Two types of 
human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci 
U S A 83: 4464-4468. 
 
Ito, Y, Suzuki, H, Aizawa, H, Hakoda, H, Hirose, T (1989). The spontaneous electrical 
and mechanical activity of human bronchial smooth muscle: its modulation by drugs. 
Br J Pharmacol 98: 1249-1260. 
 
Jackson, DJ, Sykes, A, Mallia, P, Johnston, SL (2011). Asthma exacerbations: origin, 
effect, and prevention. J Allergy Clin Immunol 128: 1165-1174. 
 
Jakobsson, PJ, Thoren, S, Morgenstern, R, Samuelsson, B (1999). Identification of 
human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible 
enzyme, constituting a potential novel drug target. Proc Natl Acad Sci U S A 96: 7220-
7225. 
 
James, A, Gyllfors, P, Henriksson, E, Dahlen, SE, Adner, M, Nilsson, G, et al. (2012a). 
Corticosteroid treatment selectively decreases mast cells in the smooth muscle and 
epithelium of asthmatic bronchi. Allergy 67: 958-961. 
 
   67 
James, AL, Elliot, JG, Jones, RL, Carroll, ML, Mauad, T, Bai, TR, et al. (2012b). 
Airway smooth muscle hypertrophy and hyperplasia in asthma. Am J Respir Crit Care 
Med 185: 1058-1064. 
 
Jones, RL, Giembycz, MA, Woodward, DF (2009). Prostanoid receptor antagonists: 
development strategies and therapeutic applications. Br J Pharmacol 158: 104-145. 
 
Jones, TR, Charette, L, Garcia, ML, Kaczorowski, GJ (1993). Interaction of iberiotoxin 
with beta-adrenoceptor agonists and sodium nitroprusside on guinea pig trachea. J Appl 
Physiol 74: 1879-1884. 
 
Kanai, N, Lu, R, Satriano, JA, Bao, Y, Wolkoff, AW, Schuster, VL (1995). 
Identification and characterization of a prostaglandin transporter. Science 268: 866-
869. 
 
Kanaoka, Y, Maekawa, A, Austen, KF (2013). Identification of GPR99 as a potential 
third cysteinyl leukotriene receptor with a preference for leukotriene E4. J Biol Chem. 
 
Kato, M, Nishida, S, Kitasato, H, Sakata, N, Kawai, S (2001). Cyclooxygenase-1 and 
cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation 
using human peripheral monocytes. J Pharm Pharmacol 53: 1679-1685. 
 
Kawakami, Y, Uchiyama, K, Irie, T, Murao, M (1973). Evaluation of aerosols of 
prostaglandins E1 and E2 as bronchodilators. Eur J Clin Pharmacol 6: 127-132. 
 
Kay, LJ, Yeo, WW, Peachell, PT (2006). Prostaglandin E2 activates EP2 receptors to 
inhibit human lung mast cell degranulation. Br J Pharmacol 147: 707-713. 
 
Knox, AJ, Pang, L, Johnson, S, Hamad, A (2000). Airway smooth muscle function in 
asthma. Clin Exp Allergy 30: 606-614. 
 
Koga, Y, Satoh, S, Sodeyama, N, Hashimoto, Y, Yanagisawa, T, Hirshman, CA 
(1992). Role of acetylcholinesterase in airway epithelium-mediated inhibition of 
acetylcholine-induced contraction of guinea-pig isolated trachea. Eur J Pharmacol 220: 
141-146. 
 
Kraft, M (1999). The distal airways: are they important in asthma? Eur Respir J 14: 
1403-1417. 
 
Krawiec, ME, Wenzel, SE (1999). Inhaled nonsteroidal anti-inflammatory medications 
in the treatment of asthma. Respir Care Clin N Am 5: 555-574. 
 
Kudo, I, Murakami, M (2005). Prostaglandin E synthase, a terminal enzyme for 
prostaglandin E2 biosynthesis. J Biochem Mol Biol 38: 633-638. 
 
Kuehl, FA, Jr., Dougherty, HW, Ham, EA (1984). Interactions between prostaglandins 
and leukotrienes. Biochem Pharmacol 33: 1-5. 
 
Kumlin, M, Dahlen, B, Bjorck, T, Zetterstrom, O, Granstrom, E, Dahlen, SE (1992). 
Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to 
bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in 
asthmatics. Am Rev Respir Dis 146: 96-103. 
 68 
 
Kurumbail, RG, Stevens, AM, Gierse, JK, McDonald, JJ, Stegeman, RA, Pak, JY, et al. 
(1996). Structural basis for selective inhibition of cyclooxygenase-2 by anti-
inflammatory agents. Nature 384: 644-648. 
 
Kurzrok, R, Lieb, CC (1930). Biochemical Studies of Human Semen. II. The Action of 
Semen on the Human Uterus. Proceedings of the Society for Experimental Biology and 
Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 28: 268-
272. 
 
Laekeman, GM, Herman, AG (1979). Indomethacin increases the production of SRS-A 
by the ileum from sensitized guinea-pigs. Arch Int Pharmacodyn Ther 242: 307-309. 
 
Laneuville, O, Breuer, DK, Dewitt, DL, Hla, T, Funk, CD, Smith, WL (1994). 
Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by 
nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 271: 927-934. 
 
Larsson, AK, Hagfjard, A, Dahlen, SE, Adner, M (2011). Prostaglandin D(2) induces 
contractions through activation of TP receptors in peripheral lung tissue from the 
guinea pig. Eur J Pharmacol 669: 136-142. 
 
Legler, DF, Bruckner, M, Uetz-von Allmen, E, Krause, P (2010). Prostaglandin E2 at 
new glance: novel insights in functional diversity offer therapeutic chances. Int J 
Biochem Cell Biol 42: 198-201. 
 
Lei, Y, Gregory, JA, Nilsson, GP, Adner, M (2013). Insights into mast cell functions in 
asthma using mouse models. Pulm Pharmacol Ther. 
 
Lemanske, RF, Jr., Busse, WW (2010). Asthma: clinical expression and molecular 
mechanisms. J Allergy Clin Immunol 125: S95-102. 
 
Linden, A, Lofdahl, CG, Ullman, A, Skoogh, BE (1991). In vitro characteristics of 
spontaneous airway tone in the guinea-pig. Acta Physiol Scand 142: 351-357. 
 
Lindstrom, EG, Andersson, RG, Granerus, G, Grundstrom, N (1991). Is the airway 
epithelium responsible for histamine metabolism in the trachea of guinea pigs? Agents 
Actions 33: 170-172. 
 
Lloyd-Jones, DM, Larson, MG, Beiser, A, Levy, D (1999). Lifetime risk of developing 
coronary heart disease. Lancet 353: 89-92. 
 
Lydford, SJ, McKechnie, K (1994). Characterization of the prostaglandin E2 sensitive 
(EP)-receptor in the rat isolated trachea. Br J Pharmacol 112: 133-136. 
 
Lynch, KR, O'Neill, GP, Liu, Q, Im, DS, Sawyer, N, Metters, KM, et al. (1999). 
Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 399: 
789-793. 
 
Macklem, PT (1998). The physiology of small airways. Am J Respir Crit Care Med 
157: S181-183. 
 
   69 
Magalhaes, AC, Dunn, H, Ferguson, SS (2012). Regulation of GPCR activity, 
trafficking and localization by GPCR-interacting proteins. Br J Pharmacol 165: 1717-
1736. 
 
Maher, SA, Birrell, MA, Belvisi, MG (2009). Prostaglandin E2 mediates cough via the 
EP3 receptor: implications for future disease therapy. Am J Respir Crit Care Med 180: 
923-928. 
 
Marieb, EN (2004) Human Anathomy & Physiology. Sixth edn. 
 
Masoli, M, Fabian, D, Holt, S, Beasley, R (2004). The global burden of asthma: 
executive summary of the GINA Dissemination Committee report. Allergy 59: 469-
478. 
 
Mathe, AA, Hedqvist, P (1975). Effect of prostaglandins F2 alpha and E2 on airway 
conductance in healthy subjects and asthmatic patients. Am Rev Respir Dis 111: 313-
320. 
 
McCullough, L, Wu, L, Haughey, N, Liang, X, Hand, T, Wang, Q, et al. (2004). 
Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 
24: 257-268. 
 
McGraw, DW, Mihlbachler, KA, Schwarb, MR, Rahman, FF, Small, KM, Almoosa, 
KF, et al. (2006). Airway smooth muscle prostaglandin-EP1 receptors directly 
modulate beta2-adrenergic receptors within a unique heterodimeric complex. J Clin 
Invest 116: 1400-1409. 
 
McKenniff, M, Rodger, IW, Norman, P, Gardiner, PJ (1988). Characterisation of 
receptors mediating the contractile effects of prostanoids in guinea-pig and human 
airways. Eur J Pharmacol 153: 149-159. 
 
Melillo, E, Woolley, KL, Manning, PJ, Watson, RM, O'Byrne, PM (1994). Effect of 
inhaled PGE2 on exercise-induced bronchoconstriction in asthmatic subjects. Am J 
Respir Crit Care Med 149: 1138-1141. 
 
Metcalfe, DD, Baram, D, Mekori, YA (1997). Mast cells. Physiol Rev 77: 1033-1079. 
 
Meyerhof, W, Batram, C, Kuhn, C, Brockhoff, A, Chudoba, E, Bufe, B, et al. (2010). 
The molecular receptive ranges of human TAS2R bitter taste receptors. Chem Senses 
35: 157-170. 
 
Mitchell, JA, Warner, TD (2006). COX isoforms in the cardiovascular system: 
understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug 
Discov 5: 75-86. 
 
Miura, M, Belvisi, MG, Stretton, CD, Yacoub, MH, Barnes, PJ (1992). Role of 
potassium channels in bronchodilator responses in human airways. Am Rev Respir Dis 
146: 132-136. 
 
Moffatt, MF, Gut, IG, Demenais, F, Strachan, DP, Bouzigon, E, Heath, S, et al. (2010). 
A large-scale, consortium-based genomewide association study of asthma. N Engl J 
Med 363: 1211-1221. 
 70 
 
Morita, I, Schindler, M, Regier, MK, Otto, JC, Hori, T, DeWitt, DL, et al. (1995). 
Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J 
Biol Chem 270: 10902-10908. 
 
Munakata, M, Masaki, Y, Sakuma, I, Ukita, H, Otsuka, Y, Homma, Y, et al. (1990). 
Pharmacological differentiation of epithelium-derived relaxing factor from nitric oxide. 
J Appl Physiol 69: 665-670. 
 
Murakami, M, Nakatani, Y, Tanioka, T, Kudo, I (2002). Prostaglandin E synthase. 
Prostaglandins Other Lipid Mediat 68-69: 383-399. 
 
Murphy, RC, Hammarstrom, S, Samuelsson, B (1979). Leukotriene C: a slow-reacting 
substance from murine mastocytoma cells. Proc Natl Acad Sci U S A 76: 4275-4279. 
 
Nagao, K, Tanaka, H, Komai, M, Masuda, T, Narumiya, S, Nagai, H (2003). Role of 
prostaglandin I2 in airway remodeling induced by repeated allergen challenge in mice. 
Am J Respir Cell Mol Biol 29: 314-320. 
 
Nakahata, N (2008). Thromboxane A2: physiology/pathophysiology, cellular signal 
transduction and pharmacology. Pharmacol Ther 118: 18-35. 
 
Narayan, KM, Boyle, JP, Thompson, TJ, Sorensen, SW, Williamson, DF (2003). 
Lifetime risk for diabetes mellitus in the United States. JAMA 290: 1884-1890. 
 
Nishigaki, N, Negishi, M, Ichikawa, A (1996). Two Gs-coupled prostaglandin E 
receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the 
metabolic inactivation of the agonist. Mol Pharmacol 50: 1031-1037. 
 
Norel, X, Walch, L, Labat, C, Gascard, JP, Dulmet, E, Brink, C (1999). Prostanoid 
receptors involved in the relaxation of human bronchial preparations. Br J Pharmacol 
126: 867-872. 
 
O'Byrne, PM, Dolovich, J, Hargreave, FE (1987). Late asthmatic responses. Am Rev 
Respir Dis 136: 740-751. 
 
Ochi, T, Motoyama, Y, Goto, T (2000). The analgesic effect profile of FR122047, a 
selective cyclooxygenase-1 inhibitor, in chemical nociceptive models. Eur J Pharmacol 
391: 49-54. 
 
Okazawa, M, Pare, P, Road, J (1990). Tracheal smooth muscle mechanics in vivo. J 
Appl Physiol 68: 209-219. 
 
Orehek, J, Douglas, JS, Lewis, AJ, Bouhuys, A (1973). Prostaglandin regulation of 
airway smooth muscle tone. Nat New Biol 245: 84-85. 
 
Pavord, ID, Tattersfield, AE (1995). Bronchoprotective role for endogenous 
prostaglandin E2. The Lancet 345: 436-438. 
 
Pavord, ID, Wong, CS, Williams, J, Tattersfield, AE (1993). Effect of inhaled 
prostaglandin E2 on allergen-induced asthma. Am Rev Respir Dis 148: 87-90. 
 
   71 
Penn, RB, Pascual, RM, Kim, YM, Mundell, SJ, Krymskaya, VP, Panettieri, RA, Jr., et 
al. (2001). Arrestin specificity for G protein-coupled receptors in human airway smooth 
muscle. J Biol Chem 276: 32648-32656. 
 
Peters-Golden, M (1999). Pulmonary diseases other than asthma as potential targets for 
antileukotriene therapy. Clin Rev Allergy Immunol 17: 247-260. 
 
Peters-Golden, M, Henderson, WR, Jr. (2007). Leukotrienes. N Engl J Med 357: 1841-
1854. 
 
Picot, D, Loll, PJ, Garavito, RM (1994). The X-ray crystal structure of the membrane 
protein prostaglandin H2 synthase-1. Nature 367: 243-249. 
 
Pietras, CO, James, A, Konradsen, JR, Nordlund, B, Soderhall, C, Pulkkinen, V, et al. 
(2012). Transcriptome analysis reveals upregulation of bitter taste receptors in severe 
asthmatics. Eur Respir J. 
 
Piper, PJ, Vane, JR, Wyllie, JH (1970). Inactivation of prostaglandins by the lungs. 
Nature 225: 600-604. 
 
Pulaski, L, Jedlitschky, G, Leier, I, Buchholz, U, Keppler, D (1996). Identification of 
the multidrug-resistance protein (MRP) as the glutathione-S-conjugate export pump of 
erythrocytes. Eur J Biochem 241: 644-648. 
 
Raud, J, Dahlen, SE, Hedqvist, P (1987). Prostaglandin E2 reverses indomethacin-
induced enhancement of acute allergic inflammation in the hamster cheek pouch. Adv 
Prostaglandin Thromboxane Leukot Res 17B: 908-912. 
 
Raychowdhury, MK, Yukawa, M, Collins, LJ, McGrail, SH, Kent, KC, Ware, JA 
(1994). Alternative splicing produces a divergent cytoplasmic tail in the human 
endothelial thromboxane A2 receptor. J Biol Chem 269: 19256-19261. 
 
Reid, G, Wielinga, P, Zelcer, N, van der Heijden, I, Kuil, A, de Haas, M, et al. (2003). 
The human multidrug resistance protein MRP4 functions as a prostaglandin efflux 
transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci 
U S A 100: 9244-9249. 
 
Ressmeyer, AR, Larsson, AK, Vollmer, E, Dahlen, SE, Uhlig, S, Martin, C (2006). 
Characterisation of guinea pig precision-cut lung slices: comparison with human 
tissues. Eur Respir J 28: 603-611. 
 
Riendeau, D, Percival, MD, Brideau, C, Charleson, S, Dube, D, Ethier, D, et al. (2001). 
Etoricoxib (MK-0663): preclinical profile and comparison with other agents that 
selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296: 558-566. 
 
Rodrigo, GJ, Castro-Rodriguez, JA (2012). Safety of long-acting beta agonists for the 
treatment of asthma: clearing the air. Thorax 67: 342-349. 
 
Rome, LH, Lands, WE (1975). Structural requirements for time-dependent inhibition of 
prostaglandin biosynthesis by anti-inflammatory drugs. Proc Natl Acad Sci U S A 72: 
4863-4865. 
 
 72 
Roquet, A, Dahlen, B, Kumlin, M, Ihre, E, Anstren, G, Binks, S, et al. (1997). 
Combined antagonism of leukotrienes and histamine produces predominant inhibition 
of allergen-induced early and late phase airway obstruction in asthmatics. Am J Respir 
Crit Care Med 155: 1856-1863. 
 
Rossi, A, Pergola, C, Koeberle, A, Hoffmann, M, Dehm, F, Bramanti, P, et al. (2010). 
The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by 
inhibition of arachidonic acid release in macrophages. Br J Pharmacol 161: 555-570. 
 
Ruan, YC, Zhou, W, Chan, HC (2011). Regulation of smooth muscle contraction by 
the epithelium: role of prostaglandins. Physiology (Bethesda) 26: 156-170. 
 
Sakata, D, Yao, C, Narumiya, S (2010). Prostaglandin E2, an immunoactivator. J 
Pharmacol Sci 112: 1-5. 
 
Sampson, AP (2009). FLAP inhibitors for the treatment of inflammatory diseases. Curr 
Opin Investig Drugs 10: 1163-1172. 
 
Samuelsson, B, Borgeat, P, Hammarstrom, S, Murphy, RC (1979). Introduction of a 
nomenclature: leukotrienes. Prostaglandins 17: 785-787. 
 
Samuelsson, B, Morgenstern, R, Jakobsson, PJ (2007). Membrane prostaglandin E 
synthase-1: a novel therapeutic target. Pharmacol Rev 59: 207-224. 
 
Sarau, HM, Ames, RS, Chambers, J, Ellis, C, Elshourbagy, N, Foley, JJ, et al. (1999). 
Identification, molecular cloning, expression, and characterization of a cysteinyl 
leukotriene receptor. Mol Pharmacol 56: 657-663. 
 
Schaefers, HJ, Haselmann, J, Goppelt-Struebe, M (1996). Regulation of prostaglandin 
synthesis in Madin Darby canine kidney cells: role of prostaglandin G/H synthase and 
secreted phospholipase A2. Biochim Biophys Acta 1300: 197-202. 
 
Schmidt, D, Rabe, KF (2000). The role of leukotrienes in the regulation of tone and 
responsiveness in isolated human airways. Am J Respir Crit Care Med 161: S62-67. 
 
Selg, E, Buccellati, C, Andersson, M, Rovati, GE, Ezinga, M, Sala, A, et al. (2007). 
Antagonism of thromboxane receptors by diclofenac and lumiracoxib. Br J Pharmacol 
152: 1185-1195. 
 
Simons, FE (2004). Advances in H1-antihistamines. N Engl J Med 351: 2203-2217. 
 
Six, DA, Dennis, EA (2000). The expanding superfamily of phospholipase A(2) 
enzymes: classification and characterization. Biochim Biophys Acta 1488: 1-19. 
 
Sjostrom, M, Jakobsson, PJ, Juremalm, M, Ahmed, A, Nilsson, G, Macchia, L, et al. 
(2002). Human mast cells express two leukotriene C(4) synthase isoenzymes and the 
CysLT(1) receptor. Biochim Biophys Acta 1583: 53-62. 
 
Smith, HR, Larsen, GL, Cherniack, RM, Wenzel, SE, Voelkel, NF, Westcott, JY, et al. 
(1992). Inflammatory cells and eicosanoid mediators in subjects with late asthmatic 
responses and increases in airway responsiveness. J Allergy Clin Immunol 89: 1076-
1084. 
   73 
 
Smith, WL (1989). The eicosanoids and their biochemical mechanisms of action. 
Biochem J 259: 315-324. 
 
Smith, WL, DeWitt, DL, Garavito, RM (2000). Cyclooxygenases: structural, cellular, 
and molecular biology. Annu Rev Biochem 69: 145-182. 
 
Sparrow, MP, Omari, TI, Mitchell, HW (1995). The epithelial barrier and airway 
responsiveness. Can J Physiol Pharmacol 73: 180-190. 
 
Stephens, NL (2001). Airway smooth muscle. Lung 179: 333-373. 
 
Tager, AM, Luster, AD (2003). BLT1 and BLT2: the leukotriene B(4) receptors. 
Prostaglandins Leukot Essent Fatty Acids 69: 123-134. 
 
Tai, HH, Ensor, CM, Tong, M, Zhou, H, Yan, F (2002). Prostaglandin catabolizing 
enzymes. Prostaglandins Other Lipid Mediat 68-69: 483-493. 
 
Tashkin, DP (2002). The role of small airway inflammation in asthma. Allergy Asthma 
Proc 23: 233-242. 
 
Theroux, P, Ouimet, H, McCans, J, Latour, JG, Joly, P, Levy, G, et al. (1988). Aspirin, 
heparin, or both to treat acute unstable angina. N Engl J Med 319: 1105-1111. 
 
Tilley, SL, Hartney, JM, Erikson, CJ, Jania, C, Nguyen, M, Stock, J, et al. (2003). 
Receptors and pathways mediating the effects of prostaglandin E2 on airway tone. Am 
J Physiol Lung Cell Mol Physiol 284: L599-606. 
 
To, T, Wang, C, Guan, J, McLimont, S, Gershon, AS (2010). What is the lifetime risk 
of physician-diagnosed asthma in Ontario, Canada? Am J Respir Crit Care Med 181: 
337-343. 
 
Tulic, MK, Hamid, Q (2006). New insights into the pathophysiology of the small 
airways in asthma. Clin Chest Med 27: 41-52, vi. 
 
Turner, NC, Dollery, CT (1988). Release of arachidonic acid metabolites and histamine 
from sensitized guinea-pig lung following antigen challenge. Br J Pharmacol 93: 751-
758. 
 
Walker, JL (1980). Interrelationships of SRS-A production and arachidonic acid 
metabolism in human lung tissue. Adv Prostaglandin Thromboxane Res 6: 115-119. 
 
Walters, EH, Bevan, M, Davies, BH (1982). Interactions between response to inhaled 
prostaglandin E2 and chronic beta-adrenergic agonist treatment. Thorax 37: 430-437. 
 
Vane, JR (1971). Inhibition of prostaglandin synthesis as a mechanism of action for 
aspirin-like drugs. Nat New Biol 231: 232-235. 
 
Wasserfallen, JB, Schaller, MD, Feihl, F, Perret, CH (1990). Sudden asphyxic asthma: 
a distinct entity? Am Rev Respir Dis 142: 108-111. 
 
 74 
Welsch, DJ, Creely, DP, Hauser, SD, Mathis, KJ, Krivi, GG, Isakson, PC (1994). 
Molecular cloning and expression of human leukotriene-C4 synthase. Proc Natl Acad 
Sci U S A 91: 9745-9749. 
 
Wenzel, SE (2012). Asthma phenotypes: the evolution from clinical to molecular 
approaches. Nat Med 18: 716-725. 
 
Vermue, NA, Den Hertog, A, Zaagsma, J (1987). Desensitization of PGE2 and PGI2 
induced contractions in different smooth muscles of guinea-pig unmasking relaxing 
properties of prostanoids. Eur J Pharmacol 144: 399-403. 
 
West, KL, McGrane, M, Odom, D, Keller, B, Fernandez, ML (2005). SC-435, an ileal 
apical sodium-codependent bile acid transporter inhibitor alters mRNA levels and 
enzyme activities of selected genes involved in hepatic cholesterol and lipoprotein 
metabolism in guinea pigs. J Nutr Biochem 16: 722-728. 
 
White, MV (1990). The role of histamine in allergic diseases. J Allergy Clin Immunol 
86: 599-605. 
 
Winter, CA, Risley, EA, Nuss, GW (1963). Anti-Inflammatory and Antipyretic 
Activities of Indomethacin, 1-(P-Chlorobenzoyl)-5-Methoxy-2-Methylindole-3-Acetic 
Acid. J Pharmacol Exp Ther 141: 369-376. 
 
von Euler, US (1934). An adrenaline-like action in extracts from the prostatic and 
related glands. J Physiol 81: 102-112. 
 
Xie, WL, Chipman, JG, Robertson, DL, Erikson, RL, Simmons, DL (1991). Expression 
of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA 
splicing. Proc Natl Acad Sci U S A 88: 2692-2696. 
 
Yokomizo, T, Izumi, T, Shimizu, T (2001). Leukotriene B4: metabolism and signal 
transduction. Arch Biochem Biophys 385: 231-241. 
 
Yoshisue, H, Kirkham-Brown, J, Healy, E, Holgate, ST, Sampson, AP, Davies, DE 
(2007). Cysteinyl leukotrienes synergize with growth factors to induce proliferation of 
human bronchial fibroblasts. J Allergy Clin Immunol 119: 132-140. 
 
Zhang, CH, Lifshitz, LM, Uy, KF, Ikebe, M, Fogarty, KE, Zhuge, R (2013). The 
cellular and molecular basis of bitter tastant-induced bronchodilation. PLoS Biol 11: 
e1001501. 
 
 
 
I

RESEARCH PAPER
PGE2 maintains the tone
of the guinea pig trachea
through a balance between
activation of contractile EP1
receptors and relaxant
EP2 receptors
J Säfholm1, S-E Dahlén1, I Delin1, K Maxey2, K Stark1, L-O Cardell3 and
M Adner1
1Unit for Experimental Asthma and Allergy Research, Centre for Allergy Research, The Institute
of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 2Cayman Chemicals, Ann
Arbor, Michigan, USA, and 3Department of Clinical Science, Intervention and Technology,
Karolinska Institutet, Stockholm, Sweden
Correspondence
Mikael Adner, Unit for
Experimental Asthma and Allergy
Research, The Institute of
Environmental Medicine,
Scheeles väg 1, BOX 287,
Karolinska Institutet, SE-171 77
Stockholm, Sweden. E-mail:
mikael.adner@ki.se
----------------------------------------------------------------
Keywords
PGE2; airway smooth muscle;
trachea; spontaneous tone; EP1;
EP2; EP3; EP4; guinea pig
----------------------------------------------------------------
Received
21 March 2012
Revised
23 July 2012
Accepted
20 August 2012
BACKGROUND AND PURPOSE
The guinea pig trachea (GPT) is commonly used in airway pharmacology. The aim of this study was to define the expression
and function of EP receptors for PGE2 in GPT as there has been ambiguity concerning their role.
EXPERIMENTAL APPROACH
Expression of mRNA for EP receptors and key enzymes in the PGE2 pathway were assessed by real-time PCR using
species-specific primers. Functional studies of GPT were performed in tissue organ baths.
KEY RESULTS
Expression of mRNA for the four EP receptors was found in airway smooth muscle. PGE2 displayed a bell-shaped
concentration–response curve, where the initial contraction was inhibited by the EP1 receptor antagonist ONO-8130 and the
subsequent relaxation by the EP2 receptor antagonist PF-04418948. Neither EP3 (ONO-AE5-599) nor EP4 (ONO-AE3-208)
selective receptor antagonists affected the response to PGE2. Expression of COX-2 was greater than COX-1 in GPT, and the
spontaneous tone was most effectively abolished by selective COX-2 inhibitors. Furthermore, ONO-8130 and a specific PGE2
antibody eliminated the spontaneous tone, whereas the EP2 antagonist PF-04418948 increased it. Antagonists of other
prostanoid receptors had no effect on basal tension. The relaxant EP2 response to PGE2 was maintained after long-term
culture, whereas the contractile EP1 response showed homologous desensitization to PGE2, which was prevented by
COX-inhibitors.
CONCLUSIONS AND IMPLICATIONS
Endogenous PGE2, synthesized predominantly by COX-2, maintains the spontaneous tone of GPT by a balance between
contractile EP1 receptors and relaxant EP2 receptors. The model may be used to study interactions between EP receptors.
Abbreviations
cPGES, cytosolic PGE synthase; GPT, guinea pig trachea; mPGES, microsomal PGE synthase; NSAID, non-steroidal
anti-inflammatory drug; PGI2, prostacyclin; TX, thromboxane
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Introduction
PGE2 is a central messenger molecule with diverse biological
effects. The action of non-steroidal anti-inflammatory drugs
(NSAIDs), which inhibit the COX reaction that catalyses its
biosynthesis, have implicated PGE2 as a mediator of pain
and inflammation (Flower, 2006). Nevertheless, PGE2 is
continuously released in the airways (Brink et al., 1981;
Selg et al., 2009) where it is involved in protective and
anti-inflammatory responses. For example, refractoriness to
repeated bouts of exercise-induced bronchoconstriction
appears to depend upon local formation of PGE2 (Manning
et al., 1993), and accordingly, inhalation of PGE2 will inhibit
bronchoconstriction evoked by exercise, as well as several
other triggers of asthma attacks (Pavord and Tattersfield,
1995). Furthermore, the inhalation of PGE2 is also associated
with cough (Pavord and Tattersfield, 1995). The multiple
effects of PGE2 are obviously explained by the presence of
several EP receptors that may mediate different and some-
times opposing responses (Coleman et al., 1984).
The first observations of contractile and relaxant effects of
PGE2 in the airways were made in the isolated guinea pig
trachea (GPT) (Anggard and Samuelsson, 1965; Coleman and
Kennedy, 1980; Gardiner and Collier, 1980) where the cumu-
lative concentration–response curve for PGE2 was found to be
biphasic (Coleman and Kennedy, 1980). In fact, experiments
using this standard preparation for airway pharmacology pro-
vided early data for the general classification of prostanoid
receptors (Coleman and Kennedy, 1980; 1985; Gardiner and
Collier, 1980; Kennedy et al., 1982). Along with the observa-
tions that aspirin and other NSAIDs (Orehek et al., 1973), as
well as the PG antagonist SC-19220 (Farmer et al., 1974),
caused relaxation of GPT basal tone, it was assumed that
endogenous PGs in this preparation predominantly acted on
receptors that mediated contractions. Initially, it was thought
that PGF2a or thromboxane (TX) A2 were the contractile com-
pounds responsible for maintaining the smooth muscle tone
(Farmer et al., 1974; Raeburn et al., 1987), but more recent
evidence favours PGE2 as responsible for this role in GPT by
activation of contractile EP1 receptors (Ndukwu et al., 1997).
Research on the mechanisms involved in the actions of
PGE2 in the airways has however been limited by the low
selectivity and potency of the pharmacological tools avail-
able. Although experiments using the previous generation of
drugs support a general concept where bronchoconstriction
is mediated by EP1 and EP3 receptors, and airway relaxation
by EP2 and EP4 receptors, (Jones et al., 2009; Buckley et al.,
2011), it has not so far been possible to simultaneously assess
the role of each EP receptor in any airway preparation. For
example, a role for the EP1 receptor in maintaining the basal
tone of the GPT was implied by experiments using the com-
pound AH6809 (Ndukwu et al., 1997), an unselective antago-
nist with similar affinities for EP1, EP2, EP3, DP1 and TP
receptors (Abramovitz et al., 2000).
More selective agonists and antagonists for the EP recep-
tors have recently become available (Aihara et al., 2007; For-
selles et al., 2011). In this study, we have used a new
generation of subtype-selective EP receptor antagonists to
establish which receptors mediate the contractions and
relaxations of GPT to exogenous PGE2. Intervention with
antagonists for each of the EP receptors has to the best of our
knowledge not been investigated simultaneously in any
airway preparation, although some of the new antagonists
have been tested individually (Buckley et al., 2011). The
present study in particular examined the role of the different
EP receptors in controlling the basal tone of the preparation.
As there are considerable species differences regarding
responsiveness to prostanoids (Martin et al., 1988; Held et al.,
1999; Ressmeyer et al., 2006), one intended outcome of this
study was to demonstrate the usefulness of the much
employed GPT model for future research on PGE2 in the
airways and in general.
On the basis of experiments with one selective COX-2
inhibitor, it has been proposed that PGE2 in GPT is generated
by COX-2 (Charette et al., 1995). In order to clarify the path-
ways for PGE2 formation, we used several isotype selective
COX inhibitors in this study. Another objective of the present
investigation was to establish whether PGE2 alone is the criti-
cal COX product that maintains basal tone of the prepara-
tion, or if other COX products are involved. We therefore
assessed the effects of all known prostanoid receptor antago-
nists, as well a highly specific PGE2 antibody (Mnich et al.,
1995), on GPT basal tone.
In an attempt to provide a stronger molecular framework
behind the observed functional responses, the present study
for the first time uses real time-PCR with guinea pig-specific
primers to document the expression of mRNA for the four EP
receptors in different parts of the guinea pig lung and aorta.
Although the study is focused on the characterization of EP
receptors, we took advantage of the methodology for con-
struction of species specific primers and also explored the
mRNA expression of COX and PGE synthase (PGES) enzymes
in the pathway for biosynthesis of PGE2 in the same tissues
used for mapping of the receptors.
Methods
Tissue preparation and organ culture
All studies involving animals are reported in accordance with
the ARRIVE guidelines for reporting experiments involving
animals (McGrath et al., 2010). The study was approved by
the regional animal experimentation ethical review board
(N63/07 and N257/09). Trachea and aorta from male albino
guinea pigs (Dunkin–Hartley; 350–600 g) and trachea from
male albino rats (Sprague–Dawley; 300–350 g) were prepared
as previously described (Adner et al., 2002; Morin et al., 2005;
Larsson et al., 2007) with some minor changes (Supplemen-
tary methods).
Tissue organ bath
Intact guinea pig tracheal and aorta or rat tracheal segments
cut as rings were set up in 5 mL organ baths with Tyrode’s
buffer (Supplementary methods). Changes in smooth muscle
force were detected using an isometric force displacement
transducer linked to a Grass polygraph. The response was
displayed using the IOX data acquisition system (EMKA,
Paris, France). During an equilibration period of 60 min with
washes every 15 min, the resting force was adjusted to either
30 mN for the guinea pig trachea (GPT), 8 mN for guinea pig
aorta and 10 mN for the rat trachea. As a control of guinea pig
BJPReceptors & function of PGE2 in guinea pig trachea
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tracheal reactivity, histamine (0.1 nM to 0.3 mM) was cumu-
latively added, whereas for the guinea pig aorta and rat
trachea, 60 mM KCl was applied. Before the pharmacological
studies, a second wash period and a further 30–45 min equi-
libration period was completed. In aorta, the presence of an
intact endothelium was assessed at the end of the experiment
by relaxation to acetylcholine (0.1–10 mM) after pre-
contraction with phenylephrine (10 mM).
To investigate the involvement of COX-activity on the
spontaneous tone of the trachea, unselective COX inhibitors
indomethacin, diclofenac and ibuprofen, selective COX-1
inhibitors FR-122047 and SC-560, selective COX-2 inhibitors
lumiracoxib and etoricoxib, monoclonal PGE2 antibody
(2B5), selective DP1 antagonist BWA868c, EP1 receptor
antagonist ONO-8130, EP2 antagonist PF-04418948, FP
antagonist AL-8810, IP antagonist CAY10441 or TP antago-
nist SQ-29548 were given either as a single concentration or
by cumulative dosing subsequent to the second equilibration
period. At the end of these experiments, a single concentra-
tion of theophylline (1 mM) or a combination of papaverine
(0.1 mM) and sodium nitroprusside (0.1 mM) was given as a
reference for the maximal relaxation. To study the action of
PGE2 and other agonists, these were given in a cumulative
manner either during spontaneous tone or after 30 min incu-
bation with indomethacin (3 mM). Antagonists were added a
minimum of 45 min prior to the agonists. When investigat-
ing contractile properties, the experiments were finished by
adding histamine (1 mM), acetylcholine (1 mM) and KCl
(60 mM) as a reference for the maximal contraction and
contractile responses presented as a percentage of this
maximum. In cases where maximal contractibility was not
obtainable, the contraction was measured as absolute force in
Newtons. Histamine was excluded from experiments using
rat tissue. Relaxation was studied in segments exposed to
carbachol (0.3 mM), to give a stable pre-contraction, prior to
addition of the agonists. These experiments were ended with
a single concentration of theophylline (1 mM) or a combina-
tion of papaverine (0.1 mM) and sodium nitroprusside
(0.1 mM) as a reference for the maximal relaxation.
Measurements of mediator release
PGE2 was measured by enzyme immunoassay (EIA, Cayman
Chemical, Ann Arbor, MI, USA; Supplementary methods).
RNA preparation and real-time PCR
Guinea pig RNA was isolated using the RNeasy Mini Kit
(Qiagen, Hilden, Germany) and real-time PCR, employing
primers designed towards available guinea pig sequences, was
performed using Power SYBR® Green PCR Master Mix (ABI,
Foster City, CA) according to the manufacturers’ instructions
(Supplementary methods).
Calculations and statistics
All data are presented as mean � SEM. For agonists, a non-
linear regression with a variable slope fit was used to calculate
Emax, pEC50 and Hill slope. Statistical analysis was performed
using the one-way ANOVA test, followed by Bonferroni’s mul-
tiple comparisons test and the Mann–Whitney U-test for
comparisons between two groups using GraphPad Prism 5.01
software (GraphPad Software Inc., San Diego, CA).
For the antagonist assay, agonist concentration–response
curves were globally fitted to the modified Gaddum/Schild
model using GraphPad Prism 5.01 (Supplementary methods).
Drugs and suppliers
Stock solutions and dilutions were performed according to
manufacturers and suppliers instructions (Supplementary
methods).
Results
Expression of mRNA for COX-1, COX-2,
mPGES-1, mPGES-2, cPGES and EP1–4 in
guinea pig ASM, airway epithelium, aorta
and lung parenchyma
There was expression of mRNA for all the studied proteins
(Figure 1: Supplementary results, Figure S1 and Table S1). For
the initial step in the biosynthesis of PGE2, semi-quantitative
analysis revealed a significantly higher expression of COX-2
compared with COX-1 in ASM and airway epithelium (P <
0.05; Figure 1A–B). In contrast, the expression of COX-1 was
significantly higher than COX-2 in lung parenchyma and
aorta (P < 0.05; Figure 1C–D).
For the enzymes catalysing the isomerization of PGH2 to
PGE2, there was a similar expression pattern in all investi-
gated tissues; viz. the expression of cPGES was significantly
greater than mPGES-1 and mPGES-2 (P < 0.05; Figure 1E–H).
The expression of mRNA for mPGES-1 and mPGES-2 was
similar in epithelium and aorta, whereas mPGES-2 was
numerically higher than mPGES-1 in ASM and significantly
higher (P < 0.05; Figure 1G) in the lung parenchyma.
Tissue-specific patterns of expression were observed for
PGE2 receptors. Thus, the expression of mRNA for EP4 was
significantly higher in ASM compared with EP1, EP2, and EP3
(P < 0.05; Figure 1I). The expression of mRNA for EP1, EP2 and
EP4 receptors was similar in the airway epithelium, whereas
the expression of the EP3 receptor was lower (P < 0.05;
Figure 1J). In the lung parenchyma, the expression of mRNA
for EP1, EP3 and EP4 receptors was similar, whereas the expres-
sion of EP2 receptors was lower (P < 0.05; Figure 1K). The
pattern of mRNA expression for the EP receptors was however
different in the aorta with the expression of EP3 being signifi-
cantly greater than that of EP1, EP2 and EP4 (P < 0.05;
Figure 1L).
Influence of indomethacin on the
concentration–response curve to PGE2 in GPT
After the wash and resting period, following the initial stand-
ard assessment of histamine responsiveness, tracheal seg-
ments develop a spontaneous contractile tone that stabilizes
within 30 min. This spontaneous tone could be relaxed by
administration of indomethacin (3 mM). In line with previous
observations (Coleman and Kennedy, 1980), exogenous PGE2
(0.1–10 000 nM) produced a bell-shaped concentration–
response curve, and this response was observed both in
absence and presence of indomethacin. Moreover, the peak
contraction reached the same amplitude (29.4 � 3.9 mN and
30.3 � 2.2 mN) at the same concentration of PGE2 (100 nM),
BJP J Säfholm et al.
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irrespective of whether or not the concentration–response
curve was raised in the presence of indomethacin. The pEC50-
values of PGE2 for the contractile part (8.2 � 0.2 and 8.0 �
0.1, respectively) and the relaxant part (6.7 � 0.1 and 6.3 �
0.3, respectively) were similar for both untreated segments
and those relaxed by indomethacin.
PGE2 mediates contraction through the EP1
receptor in GPT
To characterize the receptors involved in the PGE2 response,
initial experiments were performed using the selective EP1
antagonist ONO-8130. For PGE2, ONO-8130 caused a
concentration-dependent reduction of the peak contraction
response concomitant with a rightwards shift. Concentra-
tions of ONO-8130 above 10 nM abolished the contractile
response to exogenous PGE2 (Figure 2A). To further investi-
gate the action of PGE2 on the EP1 receptor and to be able to
estimate the potency of ONO-8130, experiments were per-
formed using the EP1/EP3 receptor agonist 17-phenyl trinor
PGE2. In these experiments, ONO-8130 caused a parallel shift
to the right of concentration-response curve (no changes in
Emax or Hill slopes). Schild plot analysis resulted in a slope of
1.04 [95% confidence interval (95% CI): 0.88–1.19] not dif-
ferent from unity (Figure 2B). Constraining the Schild slope
to unity resulted in a pKB value of 8.93 for ONO-8130 (95%
CI: 8.83–9.04; Supporting Figure S3A).
The possible involvement of EP3 and EP4 receptors on the
responses to PGE2 were investigated using the EP3 receptor
antagonist ONO-AE5-599, or the EP4 receptor antagonist
ONO-AE3-208 (1 mM). Neither ONO-AE5-599 nor ONO-AE3-
208 changed the maximal contractile response or the
potency, for either the contractile (7.9 � 0.1 for both) or
the relaxant part (6.2 � 0.1 and 6.1 � 0.0, respectively) of
the concentration–response curve for PGE2, compared with
controls (8.2 � 0.2 for the contraction and 6.2 � 0.1 for the
relaxation; Figure 2C).
The absence of any effect attributable to the EP3 receptor
in the GPT was further supported by the observation that the
EP1/EP3 receptor agonist sulprostone did not induce either a
contraction or relaxation of the GPT in the presence of ONO-
8130 (100 nM; n = 7). Moreover, ONO-AE5-599 failed to
antagonize the contraction generated by 17-phenyl trinor
PGE2 (9.1 � 0.2 and 8.7 � 0.3, with and without antagonist
respectively; Figure 2D).
PGE2 mediates relaxation through the EP2
receptor in GPT
To examine the role of the apparent relaxant receptor, the
new selective EP2 receptor antagonist PF-04418948 (Forselles
et al., 2011) was used. PF-04418948 caused a concentration-
dependent increase of the peak contraction induced by PGE2,
concomitant with a rightwards shift of only the relaxation
Figure 2
(A) Concentration–response curves to PGE2 in GPT in the presence of the selective EP1 receptor antagonist ONO-8130 (O8130) at different
concentrations. (B) Contraction induced by cumulative concentrations to 17-phenyl trinor PGE2 in guinea pig tracheal segments in the presence
of ONO-8130 (O8130) at different concentrations (1–30 nM). Schild plot analysis yielding a pA2 value of 8.9 with a slope of 1.0. (C)
Concentration–response curves to PGE2 in GPT in the presence or absence of the selective EP3 receptor antagonist ONO-AE5-599 (O599), or
selective EP4 receptor antagonist ONO-AE3-208 (O208). (D) Contraction induced by cumulative concentrations to 17-phenyl trinor PGE2 in the
presence or absence of ONO-AE5-599 (O599). The contraction of each segment in all experiments was calculated as percentage of maximal
contraction (histamine (1 mM), acetylcholine (1 mM) and KCl (60 mM)) in relation to maximal relaxation (theophylline (1 mM) or a combination
of papaverine (0.1 mM) and sodium nitroprusside (0.1 mM)). All experiments were performed in the presence of 3 mM indomethacin (3 mM). Data
represent mean � SEM (n = 4–11).
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part of the concentration–response curve (Figure 3A). In
segments pre-contracted with carbachol (0.3 mM) in the pres-
ence of ONO-8130 (10 nM) and SQ-29548 (1 mM), PGE2
caused a relaxation with a parallel rightwards shift of the
concentration–response curves with increasing concentra-
tions of PF-04418948 (Figure 3B). There was no difference in
Hill slopes and Emin. Performing a Schild plot analysis revealed
a slope of 1.04 (95% CI: 0.97–1.11), which was not different
from unity. Constraining the Schild slope to unity resulted in
a pKB value of 7.48 for PF-04418948 (95% CI: 7.4–7.6; Sup-
porting Figure S3B).
Further investigation of EP receptors revealed that PGE2
induced a concentration-dependent relaxationwith a pEC50 of
6.9� 0.1 and amaximal effect of 87.1� 6.9% that was neither
affected by the EP3 receptor antagonist ONO-AE5-599, nor the
EP4 receptor antagonist ONO-AE3-208 (Figure 3C). Experi-
ments intended to achieve a combined blockade of the
EP2 receptor together with EP4 and IP receptors using
PF-04418948, ONO-AE3-208 and CAY10441, respectively, did
not provide evidence for the presence of a relaxant PGE2 effect,
possibly mediated by EP4 and IP receptors (Figure 3D).
The antagonistic effect of ONO-AE5-599 and
ONO-AE3-208 was verified in assays
displaying EP3- and EP4-mediated responses
Since no antagonistic effect was found for ONO-AE5-599 and
ONO-AE3-208 in GPT, these antagonists were tested in assays
known to display effects mediated by EP3 and EP4 receptors
(Lydford and McKechnie, 1994; Jones and Woodward, 2011).
As a positive control for the EP3 receptor antagonist, it
was shown that ONO-AE5-599 concentration-dependently
antagonized the response to sulprostone in segments from
endothelium-intact guinea pig aorta. These segments were
pre-treated with ONO-8130 to abolish the EP1 component of
the response to sulprostone (Figure 4A). The selectivity of the
EP4 receptor antagonist was assessed in rat tracheal rings
pre-contracted with carbachol. In this preparation, the
relaxation induced by PGE2 shifted to the right by more than
two orders of magnitude, and the maximal relaxation was
54.3 � 3.3% in the presence of ONO-AE3-208, as compared
with 79.6 � 3.8% in its absence (Figure 4B).
PGE2 acting at EP1 and EP2 receptors
maintains spontaneous tone in GPT
As described above, addition of the unselective COX-
inhibitor indomethacin inhibited the spontaneous tone. This
treatment resulted in a prompt relaxation with the force
decreasing by 93.1 � 1.6% in relation to the maximal relaxa-
tion induced by theophylline (Figure 5A–B). The relaxant
effect of indomethacin was reproduced with two other non-
selective COX-inhibitors, ibuprofen and diclofenac (n = 4 and
5 respectively). Addition of the selective EP1 receptor antago-
nist ONO-8130, at concentrations of 10 nM and 1 mM,
decreased the spontaneous tone (91.3 � 1.2% and 90.4 �
Figure 3
Concentration–response curves to PGE2 in GPT. (A) In the presence of the selective EP2 receptor antagonist PF-04418948 (PF) at different
concentrations. (B) In segments pre-contracted with 0.3 mM carbachol (CCh) in the presence of ONO-8130 (100 nM) and SQ-29 548 (1 mM) and
after treatment with PF-04418948 (PF) at different concentrations (0.1–10 mM). (C) In segments pre-contracted with 0.3 mM CCh after treatment
with the selective EP3 receptor antagonist ONO-AE5-599 (O599) or the selective EP4 receptor antagonist ONO-AE3-208 (O208). (D) In segments
pre-contracted with CCh after treatment with PF-04418948 (PF) together with the EP4 receptor antagonist ONO-AE3-208 (O208) and selective
IP receptor antagonist CAY 10441 (CAY), either alone or in combination. The contraction of each segment in all experiments was calculated as
percentage of maximal contraction (histamine (1 mM), acetylcholine (1 mM) and KCl (60 mM)) or 0.3 mM carbachol in relation to maximal
relaxation [theophylline (1 mM) or a combination of papaverine (0.1 mM) and sodium nitroprusside (0.1 mM)]. All experiments were performed
in the presence of indomethacin (3 mM). Data represent mean � SEM (n = 4–6).
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2.2%, respectively) to the same level as indomethacin
(Figure 5A–B). The onset of the effect was more rapid than
that of indomethacin for the highest concentration of the EP1
receptor antagonist. In contrast, treatment with 1 and 10 mM
of the EP2 receptor antagonist PF-04418948 resulted in a
concentration-dependent increase in spontaneous tone,
reaching 64.5 � 3.7% and 75.5 � 3.9% respectively, as com-
pared with the maximal tissue contractility (Figure 5B).
To assess whether COX products other than PGE2 might
contribute to the spontaneous tone, segments were treated
with the DP1 receptor antagonist BWA868c, FP receptor
antagonist AL-8810, IP receptor antagonist CAY10441 or TP
receptor antagonist SQ-29548 under similar conditions.
However, the relaxant effect of these four antagonists was
negligible, 11.3 � 4.3%, 6.4 � 9.9%, 9.8 � 4.7% and 12.3 �
4.5, respectively, with no difference from the spontaneous
decline observed in untreated segments (5.3 � 5.1%) over the
same time period (Figure 5B).
The claim that PGE2 controls the spontaneous tone of
these preparations obtained strong support when it was
found that addition of a high-affinity neutralizing mono-
clonal antibody against PGE2 relaxed the preparations
(Figure 5A). The antibody concentration-dependently de-
creased the spontaneous tonus by 47.7 � 5.5% (8 mg·mL-1)
and 72.5 � 7.4% (16 mg·mL-1), compared with untreated
controls that relaxed 9.2 � 6.5% during the same time (1 h)
(P < 0.05; Figure 5C).
PGE2 is mainly produced by the epithelium in
the GPT
Evidence was obtained to support that a significant part of
the biosynthesis of PGE2, that maintains tone, originate from
the tracheal epithelium. In preparations where the epithe-
lium had been denuded, the spontaneous increase in active
tone did not reach the same level as in segments with an
intact epithelium. This attenuated active tone also resulted in
a significantly reduced relaxant effect towards indomethacin,
compared with segments with an intact epithelium (P < 0.05;
Figure 5D). Thus, the effect of 3 mM indomethacin was only
40% of that observed in control preparations.
COX-2 is the major enzyme catalysing the
formation of PGE2 in the GPT
In an attempt to investigate which COX isoenzyme that
mediated the response, the selective COX-1 inhibitors
FR-122047 (1 mM) and SC-560 (1 mM), as well as the selective
COX-2 inhibitors etoricoxib (1 mM) and lumiracoxib (1 mM)
were applied during the spontaneous tone. It was found that
both COX-2 inhibitors were superior in relaxing the sponta-
neous tone compared with COX-1 inhibitors. Lumiracoxib
was the most efficient, inducing a reduction of 89.5 � 3.1%,
followed by etoricoxib causing a reduction of 54.7 � 7.7%,
SC-560 of 27.4� 9.6% and FR-122047 of 8.7� 3% (Figure 5E).
Homologous desensitization of the contractile,
but not the relaxant response to PGE2 in
the GPT
To assess the how GPT responses are influenced by the endog-
enous production of PGE2 over a longer time period, the
tracheal segments were incubated in tissue culture for 4 days.
After the incubation, it was found that the tracheal segments
had lost responsiveness to the contractile effect of PGE2. In
contrast, when indomethacin was included in the medium
during the incubation period, the responsiveness to exog-
enous PGE2 was retained, and also showed an increase in
potency compared with fresh GPT (P < 0.05; Figure 6A). The
tracheal segments incubated in the presence of indomethacin
responded identically to untreated segments, with respect to
the relaxation induced by PGE2, with an increased potency
compared with fresh segments (P < 0.05; Figure 6B). The
contraction evoked by histamine was not altered by
indomethacin treatment during culture (Figure 6C). Since the
decrease of the EP1 receptor-mediated effect could be due to
homologous desensitization, the levels of PGE2 in the culture
medium were measured. Indeed, very high levels of PGE2
(5–20 ng·mL-1) were found during the 4 days of incubation,
which were almost abolished after incubation with
indomethacin (Figure 6D).
Treatment with another unselective COX inhibitor, ibu-
profen, during the incubation period, mimicked the effect of
indomethacin, causing both a maintained contractile
Figure 4
(A) Concentration–response curves to the selective EP1/EP3 receptor agonist sulprostone in endothelium-intact guinea pig aorta after treatment
with the selective EP3 receptor antagonist ONO-AE5-599 (O599). (B) Concentration–response curves to PGE2 in rat tracheal segments pre-
contracted with 0.3 mM CCh and treated with the EP4 receptor antagonist ONO-AE3-208 (O208). All experiments were performed in the presence
of 3 mM indomethacin and in panel A; 10 nM of the EP1 receptor antagonist ONO-8130 was also added. Data represent mean � SEM (n = 4–8).
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response to PGE2 (Figure 6A) and an inhibition of PGE2 bio-
synthesis (Figure 6D). In order to assess which pathway that
was responsible for the biosynthesis of PGE2 during the incu-
bation, experiments were performed in the presence of the
selective COX-1 inhibitor FR-122047 or the selective COX-2
inhibitor lumiracoxib during the 4 days of incubation. Under
these conditions, both drugs somewhat unexpectedly caused
complete inhibition of PGE2 production (Figure 6D) and
maintained the PGE2 contractions (Figure 6A).
Discussion and conclusions
Using guinea pig-specific primers, we found mRNA expres-
sion of all four EP receptors in GPT. However, using new and
selective pharmacological antagonists, we could only find
evidence for functionally active contractile EP1 receptors and
relaxant EP2 receptors. Furthermore, there was expression of
mRNA for both COX-enzymes and experiments using a range
of COX inhibitors suggest that both enzymes contribute to
the biosynthesis of endogenous PGE2, although the action of
COX-2 seems to predominate. Epithelial denudation sug-
gested that PGE2 originates both from the smooth muscle
and epithelial cells. Moreover, the experiments with COX-
inhibitors, selective receptor antagonists for all prostanoids,
and a specific antibody against PGE2, together provided
strong evidence that the level of spontaneous tone in the
tracheal segments is maintained by PGE2. Because of the
relaxant effects of COX inhibitors, and previous data using
unselective antagonists, it has been assumed that the basal
Figure 5
(A) Experimental trace showing the relaxation of tone in guinea pig trachea (GPT) induced by treatment with indomethacin (INDO), ONO-8130
(O8130) or monoclonal PGE2 antibody (2B5) added at the arrow. (B) Time course of change in spontaneous tone in GPT after addition of the
selective DP1 receptor antagonist BWA868c (BWA), EP1 receptor antagonist ONO-8130 (O8130), EP2 receptor antagonist PF-04418948 (PF), FP
receptor antagonist AL-8810 (AL), IP receptor antagonist CAY10441 (CAY), TP receptor antagonist SQ-29548 (SQ) or COX inhibitor INDO. (C)
Relaxation of spontaneous tone in GPT subsequent to addition of monoclonal PGE2 antibody (2B5) in the absence of indomethacin. (D) Removal
of spontaneous tone in guinea pig tracheal segments with or without tracheal epithelium, treated with 3 mM indomethacin. (E) Relaxation of
spontaneous tone in guinea pig trachea subsequent to addition of FR-122047 (FR; 1 mM), SC-560 (SC; 1 mM), etoricoxib (ETO; 1 mM) or
lumiracoxib (LUMI; 1 mM). Data represent mean � SEM (n = 4–6).
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tone is solely mediated by EP1 receptors (Ndukwu et al.,
1997). This view seems to be in line with the observation that
initial part of the concentration–response curve to PGE2 is
contractile, suggesting that relaxations only occur at higher
and perhaps un-physiological concentrations of PGE2. In the
present study, we were able to test the new EP2 antagonist
PF-04418948 (Forselles et al., 2011). It was revealed that basal
tone immediately increased after EP2 blockade. This leads to
the new understanding that basal tone is maintained by a
balance of the effects of PGE2, and that both EP1 and EP2
receptors are active simultaneously.
This is the first report of mRNA expression for key
enzymes and receptors in the PGE2 pathway, analysed in a
study that also examined functional responses of the same
tissues, and furthermore, used primers that were designed
based on actual guinea pig genetic sequence. The character-
istics of the in-house designed primers were excellent (Sup-
porting Figure S1), whereas we failed to get homogeneous
melting curve data for previously published primers targeting
human EP receptor mRNA (Rehal et al., 2009). As described
below, there were not only correlations between the mRNA
data and functional experiments but also certain discrepan-
cies suggesting that expression of the enzymes and receptors
is regulated at several levels.
The expression of mRNA for EP1–4 receptors, in both tra-
cheal smooth muscle and epithelium, suggested a possible
involvement in functional responses. In line with previous
observations (Coleman and Kennedy, 1980), PGE2 produced a
bell-shaped concentration–response curve with contraction
at low, and relaxation at high concentrations, indicating acti-
vation of multiple signalling pathways. In the present study,
ONO-8130 shifted the contractile part of the bell-shaped
concentration–response curve for exogenous PGE2 to the
right and depressed the peak contractions at higher concen-
trations. The decrease in maximal effect was presumably due
to simultaneous antagonism of the EP1 receptor, in combina-
tion with PGE2-mediated relaxation. When the antagonistic
properties of ONO-8130 were further investigated using the
selective EP1/EP3 receptor agonist, 17-phenyl trinor PGE2, the
analysis demonstrated a pKB of 8.93 with a Schild slope not
different from unity indicating a competitive effect at a single
receptor site. The potency of ONO-8130 is in accordance with
the earlier established binding affinity (Ki) of 1.9 nM, and
antagonist activity (pIC50) of 9.3 nM for the mouse EP1 recep-
tor (Data on file, Ono Pharmaceuticals Corp), which also
showed that ONO-8130 exerts a more than 1000-fold selec-
tivity for EP1 compared with the other EP receptors. Thus,
ONO-8130 is a far more potent and selective EP1 receptor
antagonist than the earlier used AH6809 with estimated pA2
values of 6.4–7.0 for the EP1 receptor and similar affinities for
EP2, EP3, DP1 and TP receptors (Abramovitz et al., 2000).
Further evidence in support of the PGE2-induced contraction
being solely mediated via EP1 receptors was obtained since
neither the EP3 antagonist ONO-AE5-599 (Aihara et al., 2007)
nor the EP4 antagonist ONO-AE3-208 (Ohinata et al., 2006)
had any effect on the concentration–response curves to PGE2
or 17-phenyl trinor PGE2. Accordingly, using the selective EP1
receptor antagonist ONO-8130, we were able to conclusively
confirm and extend the previous suggestions obtained using
AH6809 (Ndukwu et al., 1997).
Figure 6
(A) Concentration–response curves to PGE2 in GPT following culture for 4 days in the absence (Control) or presence of indomethacin (INDO;
3 mM), ibuprofen (IBU; 3 mM), FR-122047 (FR; 3 mM) or lumiracoxib (LUMI; 3 mM). (B) Concentration–response curves to PGE2 in cultured guinea
pig tracheal segments in the absence or presence of INDO (3 mM) and pre-contracted with 0.3 mM CCh. (C) Concentration–response curves to
histamine in cultured guinea pig tracheal segments in the absence or presence of INDO (3 mM). (D) PGE2 immunoreactivity measured in culture
media from tracheal segments cultured for up to 96 h (n = 4–17).
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The recently developed selective EP2 receptor antagonist
PF-04418948 (Forselles et al., 2011) made it possible to char-
acterize the EP-receptor-mediated relaxation. PF-04418948
did not antagonize the contractile part of the PGE2-induced
bell-shaped response. Instead, the contraction was further
increased, due to PF-04418948 shifting the relaxant part
of the PGE2 induced bell-shaped curve to the right. In seg-
ments pre-contracted with carbachol in presence of both EP1
and TP receptor antagonists, increasing concentrations of
PF-04418948 caused a parallel rightwards shift of the
concentration–response curve for PGE2-induced relaxation.
The Schild plot slope, which was not different from unity,
indicated a competitive effect at a single receptor site and
resulted in a pKB value of 7.5. Interestingly, this value is lower
compared with the pKB value of 8.3 and 8.9 found in human
myometrium and mouse trachea, respectively (Forselles et al.,
2011), suggesting species differences. Furthermore, the selec-
tive EP2 receptor agonist ONO-AE1-259 relaxed carbachol pre-
treated segments in a concentration dependent manner that
was unaffected by the combination EP1, EP3 and EP4 receptor
antagonists (Supporting Figure S2). The conclusion that the
EP2 receptor is the only relaxant receptor for PGE2 in GPT was
confirmed by the current findings, since neither the potency
nor the maximal relaxation was affected by selective EP3, EP4
and IP receptor antagonists for exogenously applied PGE2.
Interestingly, in pre-contracted preparations, the relaxations
occurred at lower PGE2 concentrations than observed for the
relaxant part of the bell-shaped concentration–response
curve, suggesting an overlap in concentrations for the con-
tractile and relaxant effects mediated by activation of EP1 and
EP2 receptors, respectively.
To confirm the activity of ONO-AE5-599 and ONO-AE3-
208, these compounds were tested in tissues known to
express EP3 and EP4 receptors. In the presence of the
EP1 antagonist ONO-8130, ONO-AE5-599 concentration-
dependently antagonized the contractions of guinea pig
aorta induced by the EP1/EP3 receptor agonist sulprostone.
This confirms and extends the evidence for functional EP3
receptors in guinea pig aorta, previously identified using
selective receptor antagonists (Jones et al., 1998; 2011). Fur-
thermore, we found high expression of the EP3 receptor in
guinea pig aorta. Moreover, in line with EP4 receptors medi-
ating relaxation of the rat trachea (Lydford and McKechnie,
1994; Buckley et al., 2011), ONO-AE3-208 potently displaced
the concentration–response curve for exogenous PGE2 in rat
trachea, a feature also observed in experiments using human
bronchus (Buckley et al., 2011). Thus, despite expression of
mRNA for both EP3 and EP4 receptors in the smooth muscle,
neither seems to be involved in contraction or relaxation of
the GPT. As there are no guinea pig-specific antibodies for
EP3 and EP4 available, we were not able to examine protein
expression by Western Blot. The EP3 receptor is implicated in
the modulation of neural responses (Maher et al., 2009) and
activation has been linked to inhibitory responses on para-
sympathetic nerves innervating the GPT (Clarke et al.,
2004), whereas the EP4 receptor has been reported to modu-
late secretory responses and cell growth (Pelletier et al.,
2001; Okuyama et al., 2002; Rao et al., 2007; Yao et al.,
2009). Future experiments are required to examine the
functional relevance of the relatively high levels of EP4
expression.
ONO-8130 was found to reduce the spontaneous tone of
the GPT, and at the highest concentration (1 mM), the
response to ONO-8130 was more rapid than that caused by
indomethacin. This would suggest a mechanism involving
the immediate blockade of receptors rather than a gradually
diminished biosynthesis caused by indomethacin. In con-
trast, blocking other prostaglandin receptors (DP1, FP, IP and
TP receptors) did not affect spontaneous tone. Since EP3
receptors are expressed in the trachea and have a possible
neuronal link, this receptor could theoretically also be
involved in the response to PGE2. However, the cholinergic
tone is essentially abolished by vagotomy or ganglionic
blockade, suggesting that it is dependent upon ongoing pre-
ganglionic input arising from the CNS (Kesler and Canning,
1999) and thus is not relevant in our preparation. Unexpect-
edly, selectively blocking the EP2 receptor induced a
concentration-dependent increase of the spontaneous tone.
This new and interesting finding clearly suggests that endog-
enously released PGE2 also activates this relaxant receptor.
The final piece of evidence that PGE2 maintains spontaneous
tone was shown by the concentration-dependent decrease in
tone caused by addition of a specific high-affinity PGE2 anti-
body, which has been shown to selectively block PGE2
responses in cell models (Mnich et al., 1995). Taken together,
our experiments show that the tone in the GPT is mediated
via endogenous PGE2, and depends on the balance between
EP1-mediated contraction and EP2-mediated relaxation. The
finding that addition of either indomethacin or ONO-8130
sometimes did not produce complete 100% relaxation might
suggest there is a small non-prostanoid mediator contribut-
ing to basal tension, or that there are small compensatory
changes in length–tension relationship within the smooth
muscle during the course of the experiment (Gunst et al.,
1995).
Using the optimized primers designed for this study, both
COX-1 and COX-2 were expressed in all four tissues studied.
COX-2 was predominantly expressed in the tracheal epithe-
lium and smooth muscle, whereas COX-1 was more abun-
dant than COX-2 in the lung parenchyma and thoracic aorta.
Previous reports of COX-1 and COX-2 expression in the
guinea pig lung have been conflicting. A Northern blot study
using guinea pig-specific cDNA revealed constitutive expres-
sion of both enzymes in lung homogenates. This was con-
firmed byWestern blot analysis, although the antibodies used
were primarily raised against other species (Oguma et al.,
2002). An immunoblot study using rabbit antibodies detected
COX-2 but not COX-1 in the smooth muscle and cartilage of
GPT, and one selective COX-2 inhibitor had the same effect as
indomethacin on spontaneous tone (Charette et al., 1995).
However, selective COX-1 inhibition was not tested in that
study. We found that two different, but potent, COX-1 inhibi-
tors (FR-122047 and SC-560) had a smaller effect on sponta-
neous tone compared with two selective COX-2 inhibitors
(etoricoxib and lumiracoxib), confirming that COX-2 appears
to be the quantitatively dominating enzyme catalysing for-
mation of the PGE2 that maintains tone under tissue bath
conditions. Our study has the limitation that concentration–
effect relations for the inhibitors not have been established in
the tissue bath setting; however, the compounds were used in
concentrations that in other models have shown high degree
of selectivity (Ochi et al., 2000; Esser et al., 2005).
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Since the epithelium has been suggested to be an impor-
tant source of PGE2 (Hay et al., 1988), experiments were per-
formed comparing the active tension between intact and
epithelium-denuded segments. The active tension was lower
in denuded segments than in intact segments, indicating that
the epithelium is a major source of PGE2. However, in line
with the high expression of COX-2 in both smooth muscle
and epithelial cells, the airway smooth muscle is also likely to
contribute to the basal release of PGE2.
Another aim of the current study was to examine how the
endogenous production of PGE2 affects the responses of EP1
and EP2 receptors over a longer period of time. We found that
4 days of culture resulted in a completely abolished contrac-
tion, yet maintained relaxation towards exogenously added
PGE2. This difference in response to PGE2 is consistent with
the described homologous desensitization of the EP1 receptor,
which has not been observed for the EP2 receptor (Illes and
Knoll, 1975; Vermue et al., 1987; Penn et al., 2001). Further-
more, the observed desensitization did not occur when the
endogenous biosynthesis of PGE2 was inhibited by indometh-
acin, ibuprofen, FR-122047 or lumiracoxib during the culture
period. We cannot explain why under these conditions the
inhibitors did not show selectivity. Both compounds (FR-
122047 and lumiracoxib) were used at concentrations that in
other models are very selective (Ochi et al., 2000; Esser et al.,
2005); therefore, a lack of selectivity at the level of COX
inhibition is an unlikely explanation of our results. It may
also be that the kinetics of enzyme inhibition is altered
during long-term incubation, enabling an inhibitor with a
low potency to induce an effect. The mechanism underlying
this phenomenon requires further investigation. Interest-
ingly, after culturing, both the contractile and relaxant
response towards PGE2 was increased in potency. This type of
hyperreactivity has been described previously for other exci-
tatory and inhibitory stimuli in this culture model and is
thought to be due to an enhanced coupling efficiency of the
effectors involved (Morin et al., 2005).
To put our main findings in perspective, using new,
potent and selective pharmacological tools, we have not only
confirmed that the EP1 receptor is involved in the spontane-
ous tone of the GPT, but also discovered that the endogenous
biosynthesis of PGE2 simultaneously mediates relaxation
through EP2 receptors. We show for the first time that con-
stitutively released PGE2 induces a basal tone in GPT that
depends upon the balance between the actions of these two
opposing receptor functions. As the response of human
airways towards prostanoids is known to be complex
(Coleman and Kennedy, 1980; Brink et al., 1981; Muccitelli
et al., 1987; Ressmeyer et al., 2006; Canning and Chou, 2008;
Ricciardolo et al., 2008), and constitutively released PGE2 can
induce both contraction and relaxation, we suggest that PGE2
may also play a similar regulatory role in human airways.
Clearly, the net effect of PGE2 regulation in human bronchi
appears to be opposite to that in guinea pig airways, with
indomethacin increasing tone, at least under tissue bath con-
ditions (Bjorck and Dahlen, 1993; Coleman et al., 1996;
Watson et al., 1997). Neither is the relative contribution of
COX-1 or COX-2 to formation of PGE2 in human bronchi
known, whereas COX-1 appears to dominate in the upper
airways (Harrington et al., 2008). Further indications of
species differences are the findings that in human bronchi
relaxant EP4 receptors appear to have a significant role
(Buckley et al., 2011; Benyahia et al., 2012), although it
remains to examine the effect of EP2 receptor antagonism in
the human tissue. The desensitization of EP1 receptors by
endogenous PGE2 is also an observation with potential impli-
cations of relevance to human disease. One may speculate
that this mechanism is important in situations where the
local release of PGE2 is increased, for example during chronic
airway inflammation. This would change the balance
between the contractile and relaxant response to PGE2 in
favour of a protective relaxation. In fact, there is good evi-
dence that PGE2 has a protective function in asthmatic
airways (Melillo et al., 1994; Pavord and Tattersfield, 1995;
Gauvreau et al., 1999).
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Figure S1 Target primers were designed in-house towards
available sequences from the Ensemble database and the
NCBI Genebank Sequences from the second scaffold of the
guinea pig genome comprised by Broad Institute (Feb. 2008
Cavia porcellus draft assembly cavPor3). Validation included a
melt curve analysis and dilution series of cDNA expressed as
a slope regression line.
Figure S2 Concentration–response curves to selective EP2
receptor agonist ONO-AE1-259 in guinea pig tracheal seg-
ments pre-contracted with 0.3 mM carbachol (CCh) and
treated with selective receptor antagonists; ONO-8130
(O8130), ONO-AE5-599 (O599) and ONO-AE3-208 (O208).
All experiments are performed in the presence of indometh-
acin (3 mM). Data represent mean � SEM (n = 4–6).
Figure S3 (A) Schild plot derived from Figure 2B revealed a
slope of 1.04 (95% CI: 0.88–1.19), which was not different
from unity. Constraining the Schild slope to unity resulted in
a pKB value of 8.93 for ONO-8130 (95% CI: 8.83–9.04). (B)
Schild plot derived from Figure 3B revealed a slope of 1.07
(95% CI: 0.97–1.11), which was not different from unity.
Constraining the Schild slope to unity resulted in a pKB value
of 7.48 for PF-04418948 (95% CI: 7.4–7.6).
Table S1 Real-time PCR expression of mRNA in guinea pig
tissue in relation to 105 mol·mol-1 b-actin.
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Supplementary material and methods 
 
Tissue preparation and organ culture 
Animals used in the functional studies were sacrificed either by inhalation of CO2 gas or 
overdose of sodium pentobarbital (Apoteket AB, Stockholm, Sweden) followed by removal of 
the heart-lung-package which was placed in ice-cold Tyrode’s buffer. Animals from which 
mRNA was extracted were all sacrificed by an overdose of sodium pentobarbital and tissue 
preparations were removed and stored in RNAlater® (Applied Biosystems Foster City, Ca) at 
room temperature until use (0-4 days later). Trachea, lung parenchyma and thoracic aorta 
were gently dissected from the surrounding connective tissue, and for mRNA experiments, 
tracheal epithelium was denuded using a scalpel after which the airway smooth muscle layer 
was cut out. For functional studies, tracheal segments were cut along the cartilage into eight 
intact rings of equal length whereas the thoracic aorta was cut into four intact ring-segments. 
In experiments with denuded epithelium the tracheal lining was removed by gently rubbing 
the luminal surface with a scalpel. This was carried out under a preparation microscope 
(Lundblad et al., 1988) 
 
During organ culture, intact individual guinea pig tracheal rings were placed in separate wells 
containing Dulbecco’s modified Eagle medium (DMEM)-F12 (Gibco, Auckland, NZ) 
supplemented with 1% penicillin (100 IU·mL-1) and streptomycin (100 μg·mL-1) (Gibco) 
under sterile conditions.  The culture plates were placed in a humidified incubator at 38 °C at 
95% O2 and 5% CO2. Segments were incubated for 96 hours in total and transferred into new 
wells containing fresh media every 24 hours. Freshly made compounds were then added, as 
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described by Adner et al., 2002. All animals were housed in cages (5 animals together) under  
12-hour light/dark cycle with food and water ad lib. Adner et al., 2002)  
  
Tissue organ bath  
Tyrode’s buffer composition (NaCl [149.2 mM], KCl [2.7 mM], NaHCO3 [11.9 mM], glucose  
[5.5 mM], CaCl2 [1.8 mM], MgCl2 [0.5 mM] and NaH2PO4 [0.4 mM] dissolved in  
demineralised water) solution at 37 °C, bubbled with carbogen (5% CO2 in O2) to maintain a  
pH of 7.4.  
  
Measurements of mediator release  
PGE2 was measured by enzyme immunoassay (EIA, Cayman Chemical). The detection limit  
was 15 pg·mL-1and the PGE2 monoclonal antibody displayed cross-reactivity towards PGE3  
(43%), 8-iso PGE2 (37.4 %), PGE1 (18.7%), 6-keto PGF1α (1%), 8-iso PGF2α (0.25%), 13,14- 
dihydro-15-keto prostaglandin E2 (0.02%) and <0.01% to PGD2, PGF2α and TXB2.  
  
RNA preparation and real time-PCR  
Guinea pig RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany)  
according to manufacturer’s instructions.  The concentration and purity of the RNA was  
measured using a Nanodrop 3300 (Thermo Scientific, Wilmington, U.S.A.). Aliquots of RNA  
were reverse-transcribed into cDNA using a QuantiTect® Reverse Transcription Kit (Qiagen)  
according to the instructions provided.  
All PCR primers (Figure 1) were designed towards available guinea pig sequences from the  
Ensembl database (www.ensembl.org) and the NCBI Genebank Sequences  
(www.ncbi.nih.gov) from the 2nd scaffold of the guinea pig (Cavia porcellus) genome  
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comprised by the Feb. 2008 Cavia porcellus draft assembly (Broad Institute cavPor3) using 
the OligoCalc (Kibbe, 2007) and PrimerExpress 3.0 (ABI) software’s.  The oligonucleotides 
were synthesized at Cybergene, Stockholm Sweden according to standard procedures.  
Primers for the housekeeping genes glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
andβ-actin were adapted from previous studies (West et al., 2005).  All primers were titrated 
using increasing concentrations of cDNA to get a shift of the CT values, expressed as a 
regression slope of 3.32 (23.32 = 10) with 10% deviation.  Furthermore, a melt curve analysis 
was performed to ensure the quality of the amplification product (Supplementary figure 1). 
Real-time PCR was performed using Power SYBR® Green PCR Master Mix (Applied 
Biosystems Foster City, Ca) according to the manufacturers’ instructions.  Each sample was 
analysed in duplicate in MicroAmp® Fast optical 96-well Reaction Plates (ABI) using an 
Applied Biosystems 7500 Real-Time PCR system (Applied Biosystems Foster City, Ca).  The 
program was set to 50 °C 2 min followed by a hot start at 95 °C for 15 min, followed by 6 
cycles; 94 °C 30 sec, 66 °C 1 min, followed by 40 cycles; 94 °C 30 sec, 55 °C 1 min and 
followed by a melt curve analysis.  mRNA levels were calculated using the comparative CT 
method and normalized to the housekeeping gene β-actin and expressed as mol in relation to 
105 mol β-actin. 
 
Drugs and suppliers  
NaCl, KCl, CaCl2, MgSO4, NaHCO3, KH2PO4 and glucose were obtained from VWR (West 
Chester, PA).  Histamine dihydrochloride, DMSO, acetylcholine, indomethacin, diclofenac, 
ibuprofen, phenylephrine, papaverine, sodium nitroprusside, carbachol and theophylline were 
purchased from Sigma-Aldrich (St. Louis, MO). Etoricoxib was purchased from Carbone 
Scientific (London, UK). Prostaglandin E2, FR-122047, SC-560, monoclonal PGE2 antibody 
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(2B5) 17-phenyl trinor PGE2, CAY10441 and sulprostone were obtained from Cayman 
Chemical (Ann Arbor, MI).  Lumiracoxib was obtained from SynphaBase AG (Switzerland).  
ONO-8130 (4-{[(6-{isobutyl[(4-methyl-1,3-thiazol-2-yl)sulfonyl]amino}-2,3-dihydro-1H-
inden-5-yl)oxy]methyl}benzoic acid), ONO-AE5-599 (3-{2-({[(1R)-1-(3,5-dimethylphenyl)-
3-methylbutyl] amino}carbonyl)-4-[(2-methylphenoxy)methyl] phenyl}propanoic acid), 
ONO-AE3-208 (4-[4-cyano-2-[2-(4-fluoronaphthalen-1-yl)propanoylamino]phenyl]butanoic 
acid) and ONO-AE1-259 ((Z)-7-[(1R,2R,3R,5R)-5-chloro-3-hydroxy-2-[(E,4S)-4-hydroxy-4-
(1-prop-2-enylcyclobutyl)but-1-enyl]cyclopentyl]hept-5-enoic acid) were kind gifts from 
ONO Pharmaceuticals (Japan).  PF-04418948 (1-(4-fluorobenzoyl)-3-{[(6-methoxy-2-
naphthyl)oxy]methyl} azetidine-3-carboxylic acid) was a kind gift from Pfizer Central 
Research Division (Groton, CT). Stock solutions of indomethacin, PGE2 (100 mM), and SC-
560 were dissolved in 99% ethanol, ONO-8130, ONO-AE5-599, ONO-AE3-208, ONO-AE1-
259, CAY10441, PF-04418948, 17-phenyl trinor PGE2, FR-122047, lumiracoxib and 
etoricoxib were dissolved in DMSO.  All stock solutions were stored at -20 °C. The other 
drugs were dissolved in Tyrode’s solution or deionized H2O on the day of the experiment.  
Dilutions of drugs were freshly made from stocks prior to each experiment. 
 
Calculations and statistics 
 
The Top and Bottom denotes the highest and lowest, asymptote of the curves respectively, 
LogEC50 denotes the logarithm of the agonist EC50 in the absence of the agonist [A], nH 
denotes the Hill slope of the agonist curve, S denotes the Schild slope and pA2 denotes the 
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negative logarithm of the concentration of antagonist [B] that shifts the agonist EC50 by a 
factor of 2.  
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Supplementary results 
Expression of mRNA for COX-1, COX-2, mPGES-1, mPGES-2, cPGES and EP1-4 in 
guinea pig ASM, airway epithelium, aorta and lung parenchyma 
By the use of primers designed by alignment of the respective guinea pig gene sequences with 
their human counterparts, regression analysis with correlations and slope values together with 
melt curve analysis indicated a successful amplification of a single amplicon (Supplementary 
Figure 1).  
 
The ratio of COX-2 to COX-1 mRNA in ASM and airway epithelium was 2±0 and 11±2, 
respectively. The ratio of COX-1 to COX-2 mRNA was 7±1 and 165±21 in lung parenchyma 
and aorta, respectively. The ratio of cPGES mRNA compared to mPGES-1 mRNA in ASM, 
airway epithelium, lung parenchyma and aorta was 130±22, 22±6, 2557±702 and 45±9, 
respectively.  Furthermore, the ratio of cPGES mRNA to mPGES-2 was 24±3, 24±5, 5±3 and 
40±10 for ASM, airway epithelium, lung parenchyma and aorta, respectively. The ratio 
between mPGES-2 and mPGES-1 in the parenchyma was 167±29. 
 
Although the numerical expression of EP1 mRNA in ASM was higher than that of either EP2 
or EP3, neither difference reached statistical significance. The ratio of EP4 mRNA to EP1, EP2 
and EP3 in ASM was 7±2, 32±3 and 39±5, respectively. The expression of EP4 mRNA in the 
epithelium was 16±5 times higher than EP3. The ratio of expression of EP4 to EP2 mRNA was 
12±3 in the parenchyma. The ratio between EP3 mRNA levels and EP1, EP2 and EP4 mRNA 
was 104±16, 25±3 and 18±4, respectively. 
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The EP2 receptor agonist ONO-AE1-259 induced a concentration-dependent relaxation of 
segments pre-contracted with carbachol.  The pEC50 for the relaxation was 6.7±0.1 and the 
amplitude of the relaxation reached at the highest tested concentration (10 M) was 
78.8±2.3%. Pre-treatment with ONO-8130, ONO-AE5-599 and ONO-AE3-208 did neither 
affect the sensitivity nor maximal relaxation in response to the EP2 agonist (Supplementary 
figure 2). 
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Supplementary figures 
 
 
Supplementary figure 1: Target primers were designed in-house toward available sequences 
from the Ensemble database and the NCBI Genebank Sequences from the 2nd scaffold of the 
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guinea pig genome comprised by Broad Institute (Feb. 2008 Cavia porcellus draft assembly 
cavPor3). Validation included a melt curve analysis and dilution series of cDNA expressed as 
a slope regression line. 
 
 
 
Supplementary figure 2: Concentration-response curves to selective EP2 receptor agonist 
ONO-AE1-259 in guinea pig tracheal segments pre-contracted with 0.3 μM carbachol (CCh) 
and treated with selective receptor antagonists; ONO-8130 (O8130), ONO-AE5-599 (O599) 
and ONO-AE3-208 (O208). All experiments are performed in the presence of indomethacin 
(3 μM). Data represent mean ± S.E.M (n = 4-6). 
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Supplementary figure 3: (A) Schild plot derived from Figure 2B revealed a slope of 1.04 
(95% CI: 0.88 to 1.19) which was not different from unity. Constraining the Schild slope to 
unity resulted in a pKB value of 8.93 for ONO-8130 (95% CI: 8.83 to 9.04). (B) Schild plot 
derived from Figure 3B revealed a slope of 1.07 (95% CI: 0.97 to 1.11) which was not 
different from unity. Constraining the Schild slope to unity resulted in a pKB value of 7.48 for 
PF-04418948 (95% CI: 7.4 to 7.6). 
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Supplementary tables  
  
Supplementary table 1: Real-time PCR expression of mRNA in guinea pig tissue in relation  
to 105 mol·mol-1 β-actin  
mRNA ASM Epithelium Lung parenchyma Aorta 
COX-1 2004 ± 438 79 ± 19 456 ± 14a 3467 ± 1396a 
COX-2 3683 ± 528b 691 ± 158b 68 ± 6 19 ± 5 
mPGES-1 180 ± 14 460 ± 99 2 ± 1 110 ± 36 
mPGES-2 993 ± 170 366± 57 197 ± 35c 109 ± 14 
cPGES 22173 ± 1270d 7795 ± 723d 2536 ± 78d 3830 ± 398d 
EP1 181 ± 37 87 ± 46 73 ± 30 7 ± 1 
EP2 34 ± 4 116 ± 30 9 ± 1 27 ± 6 
EP3 28 ± 3 15± 4 38 ± 5 632 ± 97e 
EP4 1107 ± 203f 1878 ± 33g 103± 25h 51 ± 22 
Real-time PCR expression of guinea pig mRNA for COX-1, COX-2, mPGES-1, mPGES-2,  
cPGES and EP1-4 in airway smooth muscle (ASM), airway epithelium, lung parenchyma and  
aorta. Significant differences (p < 0.05) was found between aCOX-1 vs. COX-2, bCOX-2 vs.  
COX-1, cmPGES-2 vs. mPGES-1, dcPGES vs. both mPGES-1 and mPGES-2, eEP3 vs. EP1,  
EP2 and EP4, fEP4 vs. EP1, EP2 and EP3, gEP4 vs. EP3 and hEP4 vs. EP2. All values are  
represented as mean ± SEM (n ≥ 5).  
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Pulkkinen V, Manson ML, Säfholm J, Adner M, Dahlén S. The
bitter taste receptor (TAS2R) agonists denatonium and chloroquine
display distinct patterns of relaxation of the guinea pig trachea. Am J
Physiol Lung Cell Mol Physiol 303: L956–L966, 2012. First pub-
lished September 7, 2012; doi:10.1152/ajplung.00205.2012.—Activa-
tion of taste receptors (TAS2Rs) by bitter taste agonists has been
reported to cause bronchodilation. The aim of this study was to extend
the information on the effects of bitter taste agonists on responses
induced by different contractile mediators in a standard airway phys-
iology preparation. Isometric responses were assessed in guinea pig
trachea (GPT). TAS2R agonists were administered either to segments
precontracted with different agonists for contraction or given before
challenge with the different contractile stimuli, including antigen in
tissues from ovalbumin-sensitized animals. TAS2R mRNA expres-
sion on GPT epithelium and smooth muscle was measured with
real-time PCR. Denatonium, chloroquine, thiamine, and noscapine
induced concentration-dependent relaxations (Rmax: 98.3 � 1.6,
100.0 � 0.0, 100.0 � 0.0, and 52.3 � 1.1% of maximum, respec-
tively, in the presence of indomethacin) in segments precontracted
with carbachol. The receptors for denatonium (TAS2R4, TAS2R10)
and chloroquine (TAS2R3, TAS2R10) were expressed in GPT.
Whereas denatonium selectively inhibited contractions induced by
carbachol, chloroquine uniformly inhibited contractions evoked by
prostaglandin E2, the thromboxane receptor agonist U-46619, leuko-
triene D4, histamine, and antigen. The effects of denatonium, but not
those of chloroquine, were partly inhibited by blockers of the large
Ca2�-activated K� channels and decreased by an increase of the level
of precontraction. In conclusion, TAS2R agonists mediated strong
relaxations and substantial inhibition of contractions in GPT. Chloro-
quine and denatonium had distinct patterns of activity, indicating
different signaling mechanisms. The findings reinforce the hypothesis
that TAS2Rs are potential targets for the development of a new class
of more efficacious agonists for bronchodilation.
bronchodilation; asthma; prostaglandins; airway smooth muscle
BITTER TASTE-SENSING TYPE 2 receptors (TAS2Rs) are G protein-
coupled receptors (GPCRs) on cell surface that mediate gus-
tatory taste perception on the tongue (16). The properties of
TAS2Rs are different from many other GPCRs, as the recep-
tors are promiscuous and capable of binding a wide range of
compounds with relatively low specificity and affinity (16).
TAS2Rs have recently been suggested to have important ex-
traoral functions in the respiratory and gastrointestinal tracts
(4, 11). In the human airway epithelium, TAS2Rs are ex-
pressed on the solitary chemosensory cells (25, 26) and ciliated
epithelial cells (23), where they sense chemical irritation and
promote ciliary beat frequency, respectively. Thus TAS2Rs
may be protective and part of the defense against inhaled
noxious compounds.
Recently airway smooth muscle cells were found to express
TAS2Rs that mediated relaxations in both mouse and human
isolated airway preparations (7). Stimulation of TAS2Rs in-
creased intracellular Ca2� signaling that was suggested to
activate large conductance potassium channels (BKCa) and
result in hyperpolarization of the cell membrane. However, in
further studies BKCa blockers either failed to prevent (28) or
only partially blocked (2) relaxation caused by the bitter tastant
chloroquine, and direct recording of the channel current with
patch clamp revealed that bitter tastants did not activate BKCa
channels in mouse airway preparations (28). As the effects of
TAS2R agonists appeared independent of the cyclic adenosine
monophosphate (cAMP) and the protein kinase A (PKA)
pathways (7), the mechanisms of TAS2Rs in causing airway
relaxation are still unsolved. Nevertheless, the TAS2R agonists
showed both greater relaxation and inhibition of airway hyper-
responsiveness than a �2-adrenoceptor agonist in mouse air-
ways (7). Given the large selection of known natural and
synthetic agonists recognized by the 25 TAS2Rs (16), the
findings have introduced bitter taste receptors as a potential
new family of targets for asthma pharmacotherapy. Moreover,
we have recently found that leukocytes of patients with severe
asthma have increased expression of TAS2Rs (Orsmark-Pietras
C, James A, Konradsen J, Nordlund B, Söderhäll C, Pulkkinen V,
Pedroletti C, Daham K, Kupczyk M, Dahlén B, Kere J, Dahlén
SE, Hedlin G, Melén E, unpublished observations), suggesting
also that TAS2Rs may represent a protective endogenous mech-
anism upregulated in disease.
The isolated guinea pig trachea (GPT) is a commonly used
model in airway pharmacology, where the receptors for ago-
nists and mediators of mast cell activation are closely similar to
those of human airways (6). Accordingly, the antigen-induced
contraction in guinea pig airways is caused by the concerted
action of cysteinyl-leukotrienes, histamine, and prostanoids
(24), mediators also known to cause allergen-induced broncho-
constriction in human subjects with asthma (20). In the present
study, we characterized the expression of TAS2Rs in guinea
pig airways, as well the effects of prototype TAS2R agonists
on contractions induced by the different mediators of the
antigen responses. The bitter taste agonists for the study were
selected on the basis of the particular receptors expressed in the
guinea pig genome. We examined both the “therapeutic” ef-
fects of TAS2R agonists on tracheal segments precontracted
with different contractile agonists and the “prophylactic” ef-
fects of pretreatments with TAS2R agonists on agonist-medi-
ated contractions. Our results extend the previous findings and
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provide a more detailed analysis of the mode of action of
TAS2Rs in the airways. This includes assessment of interac-
tions with different pathways for contractions and the relation
between the response and the level of precontraction. As the
basal tone of GPT is kept by prostaglandin (PG) E2 (9, 21), we
in particular compared the effects of several of the tested
TAS2R agonists in the presence and absence of indomethacin,
which inhibits spontaneous tone and biosynthesis of PGE2.
MATERIALS AND METHODS
Tissue preparation. The study was approved by the Swedish
Animal Experimentation Ethical Review Board (N257/09 and N323/
11). Male albino guinea pigs (Dunkin-Hartley; 350–600 g) were
killed by an overdose of pentobarbital sodium (Apoteket, Stockholm,
Sweden), followed by rapid removal of the heart-lung-package and
placement in ice-cold Krebs-Henseleit (KH) buffer solution (compo-
sition in mM: 118.5 NaCl, 4.7 KCl, 1.2 KH2PO4, 1.2 MgCl2, 2.5
CaCl2, 25 NaHCO3, and 11.1 D-glucose). For sensitization procedure,
a single dose of 100 �g of ovalbumin (OVA) grade 5 and 0.1 g of
aluminum hydroxide dissolved in 0.8 ml of sterile PBS was injected
peritoneally, and animals were killed 14–28 days later. Trachea was
gently dissected from the surrounding connective tissue. For mRNA
expression, the epithelium in the trachea was scraped off with a
scalpel, and the airway smooth muscle layer was cut out. Tissue
preparations were extracted and stored in RNAlater (Applied Biosys-
tems, Foster City, CA) at room temperature until use (0–4 days later).
For the functional studies, tracheal segments were cut along the
cartilage into eight intact rings of equal length. For denudation
experiments, epithelium was removed by mechanical scraping with a
scalpel.
Selection of the TAS2R agonists used for the study. Of the 25
human TAS2Rs identified, we found guinea pig orthologs for eight
TAS2Rs, namely TAS2R1, TAS2R3, TAS2R4, TAS2R10, TAS2R14,
TAS2R16, TAS2R40, and TAS2R41 by queries against the Ensemble
database (www.ensembl.org). We selected agonists used in a previous
study (7), namely chloroquine (TAS2R3 and TAS2R10 in guinea pig),
denatonium (TAS2R4 and TAS2R10), and saccharin (as a negative
control because the guinea pig genome lacks TAS2R8, TAS2R43, and
TAS2R44 sequences). In addition, we selected agonists that bind to
TAS2R1 (thiamine) and TAS2R14 (noscapine). No suitable agonists
were available for TAS2R16 and TAS2R40, as well as the orphan
receptor TAS2R41.
In vitro pharmacology. Intact GPT segments were set up in 5-ml
organ baths with KH buffer solution at 37°C, bubbled with carbon gas
(5% CO2 in O2). Changes in smooth muscle force were detected using
an isometric force-displacement transducer linked to a Grass poly-
graph. During an equilibration period of 60 min, the resting force was
adjusted to 30 mN. As a control of the tracheal reactivity, histamine
(0.1 nM to 0.3 mM) was cumulatively added. Before the pharmaco-
logical studies, a further 30-min equilibration period was completed.
Maximal relaxation was obtained by adding a combination of papav-
erine (0.1 mM) and sodium nitroprusside (0.1 mM), and maximal
contraction was obtained by adding histamine (1 mM), acetylcholine
(1 mM), and KCl (40 mM) at the end of the experiments. Parts of the
experiments were performed in the presence of 3 �M indomethacin to
abolish the constitutive release of prostaglandins.
GPT segments were precontracted with 100 nM carbachol, in both
the absence and the presence of indomethacin. Precontraction by 100
�g/mL OVA was induced in the absence of indomethacin. To dissect
the effects of PGE2 and thromboxane A2 (TXA2) on TAS2R agonist-
mediated relaxation, the EP1 receptor antagonist ONO-8130 (10 nM)
or the TP receptor antagonist SQ-29548 (1 �M) was added to the
organ bath 30 min before precontraction. Experiments with different
levels of carbachol precontraction (3 �M, 100 nM, and 30 nM) were
performed in the presence of indomethacin. When a stable contraction
was obtained after 40 min, the segments were exposed to the bitter
taste agonists or salbutamol in a cumulative manner. In addition, a
similar approach was used to study the effects of chloroquine and
denatonium on stable precontractions induced by 0.1 �M U46619, 0.1
�M leukotriene D4 (LTD4), and 3 nM 17-phenyl trinor PGE2, all in
the presence of indomethacin.
To study the prophylactic effects of the bitter taste agonists, 300
�M denatonium or 300 �M chloroquine was given after 30-min
incubation with indomethacin. The effects of 30-min denatonium and
chloroquine prestimulation were studied on contractions induced by
increasing concentrations of carbachol, U46619, PGE2, LTD4, or
histamine.
To test whether denatonium could antagonize muscarinic receptors,
acetylcholine-induced dilatation of guinea pig aorta was studied.
During equilibration, segments were adjusted to a basal tension of 2
mN. The tissues were tested for viability by demonstrating a contrac-
tile response to 60 mM KCl and a relaxant response to 10 �M
acetylcholine when precontracted with 10 �M phenylephrine. There-
after, the segments were washed and exposed to 300 �M denatonium,
precontracted with 3 �M PGF2�, and again exposed to 10 �M
acetylcholine.
RNA preparation and real-time PCR. Guinea pig total RNA was
isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany)
according to manufacturer’s instructions. The concentration and pu-
rity of the RNA was measured using a Nanodrop 3300 (Thermo
Scientific, Wilmington, DE). Aliquots of RNA were reverse-tran-
scribed into cDNA using QuantiTect Reverse Transcription Kit (Qia-
gen) according to the manufacturer’s instructions.
All PCR primers were designed toward available guinea pig se-
quences from the Ensembl database (www.ensembl.org) and the
NCBI Genebank Sequences (www.ncbi.nih.gov) from the second
scaffold of the guinea pig (Cavia porcellus) genome comprised by the
Feb 2008 Cavia porcellus draft assembly (Broad Institute cavPor3)
using the Primer-BLAST software. Primers for TAS2R3 were: Fwd:
5=-GGTCAGTGGCAGCAGCTGGTT-3= and Rev: 5=-TGGAGAG-
GGCCAGGTTGGTGA-3=, for TAS2R4: Fwd: 5=-TCACCAGAC-
TTCTGCTGGGCTGT-3= and Rev: 5=-ACTCCCAGGCCCATCCT-
TGCA-3=, and for TAS2R10: Fwd: 5=-TGCCAAGTGCAGTGGA-
AATCTTCC-3= and Rev: 5=-ACCCATTCCCTAGAAGCCCCAGG-
3=. The oligonucleotides were synthesized at Cybergene (Stockholm,
Sweden) according to standard procedures. Primers for the house-
keeping gene for �-actin were adapted from previous studies (27).
Real-time PCR was performed using Power SYBR Green PCR
Master Mix (Applied Biosystems) and in MicroAmp fast optical
96-well Reaction Plates (Applied Biosystems). Each sample was
analyzed in duplicate. PCR reactions (20 �l) were performed with
final concentrations of 100 nM each of forward and reverse primers.
Real-time PCR was performed on an Applied Biosystems 7500
Real-Time PCR system using default settings according to the man-
ufacturers= instructions. To ensure the quality of the amplification
product, a melt curve analysis was performed as a final step. mRNA
levels were calculated using the comparative CT method, normalized
to the housekeeping gene �-actin, and expressed as 105 mol/mol
�-actin.
PGE2 measurements. PGE2 levels were determined by using an
enzyme immunoassay (EIA) with a PGE2 monoclonal EIA kit (Cay-
man Chemical, Ann Arbor, MI). Detection limit was 15 pg/ml with
cross-reactivity to 8-iso PGE2 (37.4%), 8-iso PGF2� (0.025%), and
12,14-dihydro-15-keto PGE2 (0.02%). Samples for these measure-
ments were collected directly from the organ bath between 0 and 7
min at 1-min intervals after stimulation with denatonium and chloro-
quine. Bradykinin was used as a positive control for PGE2 release.
cAMP measurements. Determination of cAMP levels was per-
formed from tracheal segments as described previously (1). The
segments were equilibrated for 60 min in tissue bath conditions as
described above. This was followed by 30-min incubation of indo-
methacin (3 �M) and a further 30-min incubation of 200 �M 3-isobu-
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tyl-1-methylxanthine, a nonspecific inhibitor of phosphodiesterases.
Thereafter, the tracheas were precontracted with carbachol for 40 min
and exposed to a single concentration of 300 �M denatonium, 300
�M chloroquine, or 300 nM salbutamol for 20 min to achieve stable
and maximal effect for all three agonists. When the experiments were
completed, the segments were snap-frozen in liquid nitrogen and
stored in �80°C until preparation for the EIA (581002, Cayman
Chemical). The tracheas were purified in accordance with the manu-
facturer’s instruction for the EIA; the frozen tissues were placed in 5%
trichloroacetic acid and homogenized on ice. After centrifugation at
1,500 g for 10 min, the trichloroacetic acid was extracted from the
supernatant by water-saturated ether. The ether was removed by
heating to 70°C before analysis by EIA (detection limit� 3 pmol/ml).
Calculations and statistics. All data are presented as means � SE.
The concentration-response curve values for pEC50, Emax, and Hill
slopes were calculated using nonlinear regression analysis. Statistical
analysis was performed using one-way ANOVA followed by Bonfer-
roni’s multiple-comparison test or Mann Whitney t-test for compari-
son between two groups. For the analyses, GraphPad Prism 5.01
(GraphPad Software, San Diego, CA) was used.
Drugs and suppliers. Iberiotoxin, charybdotoxin, paxilline, H89,
GF109203, and KT5823 were purchased from Tocris Bioscience
(Bristol, UK). NaCl, KCl, CaCl2, MgSO4, NaHCO3, KH2PO4 and
glucose were obtained from VWR (West Chester, PA). Denatonium
benzoate, dextromethorphan, chloroquine hydrochlorate, noscapine,
thiamine, histamine dihydrochloride, DMSO, acetylcholine, indo-
methacin, papaverine, sodium nitroprusside, and salbutamol were
purchased from Sigma-Aldrich (St. Louis, MO). Formoterol was a
kind gift from AstraZeneca (Stockholm, Sweden). SQ-29548, PGE2,
17-phenyl trinor PGE2, U-46619, PGF2�, and LTD4 were purchased
from Cayman Chemical. ONO-8130 was a kind gift from ONO
Pharmaceuticals (Tokyo, Japan). Stock solutions of indomethacin and
U-46619 were dissolved in 95% ethanol, whereas ONO-8130 was
dissolved in DMSO. All stock solutions were stored at �20°C. The
other drugs were dissolved in KH solution or deionized H2O or
organic solvents on the experimental day. Dilutions of drugs were
freshly made from stocks before each experiment, and parallel exper-
iments with solvent controls were always performed.
RESULTS
Bitter taste agonists are effective bronchodilators against
muscarinic contraction. To examine relaxant effects of the
selected compounds, GPT was precontracted with 100 nM
carbachol both in the absence and presence of indomethacin or
prostanoid receptor antagonists. The segments were either
exposed to cumulative concentrations of thiamine, denato-
nium, chloroquine, noscapine, or saccharin or kept untreated as
controls for spontaneous relaxation. The partial �2-adrenocep-
tor agonist salbutamol was used as a positive control for airway
relaxation to allow for comparison with data previously ob-
tained in mouse and human airways (7).
Although indomethacin prevented the spontaneous increase
of basal tone in naïve preparations, carbachol induced a similar
stable magnitude of precontraction in the presence or absence
of indomethacin [precontraction levels: 73.5 � 3.8% (n � 19)
and 75.2 � 4.2% (n � 18) of Emax, respectively]. Thiamine,
chloroquine, denatonium, and noscapine evoked concentra-
tion-dependent relaxations, whereas saccharin had no effect
(Fig. 1, Table 1). Indomethacin had no effects on the potency
of the TAS2R agonists (Table 1). However, the magnitudes
(Rmax) of the relaxations induced by thiamine (72.7 � 6.6%)
and denatonium (57.5 � 5.2%) were enhanced by indometh-
acin (100.0 � 0.0 and 98.3 � 1.6%, respectively). In contrast,
chloroquine induced an almost complete relaxation also in the
naïve preparation (98.2 � 1.1%; n � 6) that was unaffected by
indomethacin (100.0 � 0.0%). Compared with denatonium,
chloroquine was eightfold less potent (pEC50: 3.8 � 0.1 and
4.5 � 0.1, respectively) and had a Hill slope that was signif-
icantly steeper (�5.5� 0.7 and�1.5� 0.1, respectively). The
magnitude of the noscapine-induced relaxation was somewhat
decreased by indomethacin (Fig. 1, Table 1).
Because cyclooxygenase inhibition with indomethacin en-
hanced airway relaxation for denatonium and thiamine, we
tested the hypothesis that these two TAS2R agonists were
opposed by PGE2, the contractile prostanoid that is known to
regulate tone in the preparation (9, 18, 21). The magnitude of
denatonium-induced relaxation was thus indeed enhanced by
the EP1 receptor antagonist ONO-8130 (99.3 � 0.7%) (Fig.
1E, Table 1) but not by the TP receptor antagonist SQ-29,648.
Similar results were obtained with thiamine (Fig. 1C). Neither
the EP1 nor the TP receptor antagonist, however, had any
influence on the relaxation induced by noscapine (Fig. 1F).
Expression of functional TAS2Rs in GPT. There was signif-
icant real-time PCR expression of receptors for TAS2R3,
TAS2R4, and TAS2R10 in smooth muscle and epithelium of
the trachea (Fig. 2A). The rank order of bitter taste receptor
expression was TAS2R3 � TAS2R10 � TAS2R4. The ex-
pression was generally higher in the tracheal epithelium than in
the smooth muscle cells.
In addition, we screened the expression pattern for other
TAS2Rs, namely TAS2R1, TAS2R14, and TAS2R16 (data not
shown). For TAS2R1, the lack of complete whole genome
sequences for guinea hampered our efforts, and we were
unable to design properly working primers. The expression
levels of TAS2R14 and TAS2R16 were near the detection
limit, and we did not receive consistent data. In further func-
tional experiments, we, however, found that dextromethorphan
(agonist for TAS2R1 and TAS2R10) induced almost complete
relaxations (94.7 � 1.5%, pEC50 4.4 � 0.1, n � 6) of GPT
segments precontracted by 100 nM carbachol in the presence
of 3 �M indomethacin. The response to dextromethorphan
closely resembled that of denatonium.
On the basis of these patterns of relaxation responses and
expression of mRNA, we chose denatonium and chloroquine
for the extended analysis of pharmacological activities.
Role of epithelium and smooth muscle in the relaxation.
Both denatonium and chloroquine act on receptors that were
found to be expressed (denatonium TAS2R4 and TAS2R10;
chloroquine TAS2R3 and TAS2R10). In view of the expres-
sion data, we next determined whether the epithelial TAS2R
expression was necessary for relaxation mediated by denato-
nium or chloroquine. The potency of chloroquine on airway
relaxation was, however, only marginally changed and, in fact,
enhanced by epithelial removal (pEC50 3.8 � 0.1 and 4.2 � 0.1,
respectively, P � 0.04), and there was no significant effect
compared with the intact trachea for denatonium (Fig. 2, B and C).
Differential effects of denatonium and chloroquine on pre-
contractions induced by agonists other than carbachol. First,
because the cyclooxygenase inhibitor indomethacin as well as
the EP1 receptor antagonist ONO-8130 enhanced denatonium-
mediated airway relaxation, the results suggested that either
denatonium was unable to reduce the component of tone
regulated by PGE2 (18) or that denatonium stimulated release
of PGE2 that opposed its relaxant effect. To assess the latter
possibility, PGE2 was measured by EIA in serial samples from
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the organ bath fluid after addition of denatonium to prepara-
tions precontracted with carbachol. Whereas the positive con-
trol bradykinin caused a marked increase of PGE2 in the bath,
there was no release of PGE2 after exposure to denatonium or
chloroquine (Fig. 3A). In contrast, when the preparation was
precontracted with the EP1/EP3 receptor agonist 17-phenyl
trinor PGE2, denatonium failed to relax the preparation also
in the presence of indomethacin (Fig. 3B). On the other
hand, chloroquine induced complete relaxation of GPT
precontracted with the EP1/EP3 receptor agonist 17-phenyl
trinor PGE2 (Fig. 3B).
A differential effect of the two tested TAS2R agonists was
confirmed in subsequent experiments using several different
means of producing a precontraction. Thus, whereas denato-
nium was unable to reverse the antigen-induced contraction in
preparations from sensitized animals challenged with OVA,
chloroquine induced complete smooth muscle relaxation also
in this setting (Fig. 4A). Likewise, chloroquine was able to
relax preparations precontracted with the thromboxane recep-
tor (TP) agonist U-46619, LTD4, or histamine, whereas dena-
tonium was unable to relax contractions induced by any of
these three agonists (Fig. 4, B–D).
Effects of pretreatment with denatonium or chloroquine on
responses to contractile agonists. In the presence of indometh-
acin, the preparation was preincubated for 30 min with dena-
tonium (300 �M) or chloroquine (300 �M) before establish-
ment of concentration response relations for carbachol,
U-46619, PGE2, LTD4, or histamine. Denatonium pretreatment
partially inhibited (Emax 97.4 � 1.7 vs. 65.6 � 2.9%) and
chloroquine pretreatment abolished (0.1 � 0.1%) the contrac-
tion induced by the cholinergic agonist carbachol (Fig. 5, A and
B). In line with the experiments on precontracted preparations,
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Fig. 1. A: a trace depicting denatonium-mediated relaxation in guinea pig trachea (GPT) precontracted with 100 nM carbachol in the presence of 3 �M
indomethacin. Effects of salbutamol (n � 4) (B), and bitter taste agonists thiamine (n � 7); acting on TAS2R1 (C), chloroquine (n � 6–7; TAS2R3, TAS2R10)
(D), denatonium (n � 5–9; TAS2R4, TAS2R10) (E), noscapine (n � 6–8; TAS2R14) (F), and saccharin (n � 4; no TAS2Rs in guinea pig) (G) on airway
relaxation in GPT precontracted with 100 nM carbachol in the presence and absence of 3 �M indomethacin, 10 nM prostaglandin E2 (PGE2) receptor (EP1)
antagonist ONO-8310 and 1 �M thromboxane TP receptor antagonist SQ29648. Data are expressed as percentages of maximal relaxation obtained with a
combination of papaverine (0.1 mM) and sodium nitroprusside (SNP) (0.1 mM) at the end of each experiment. ACh, acetylcholine.
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chloroquine substantially inhibited the concentration-response
relations for all other tested agonists (U-46619, PGE2, LTD4,
and histamine), whereas denatonium had no significant effect
(Fig. 5, C–F).
The effect of denatonium, but not that of chloroquine, is
partly mediated through the Ca2�-induced large-conductance
potassium channels. To further investigate the mechanisms of
the relaxation induced by denatonium and chloroquine, block-
ers of Ca2�-induced large-conductance potassium channels
(BKCa also known as MaxiK and Slo) were used. These
included the scorpion venoms iberiotoxin and charybdotoxin
that are blockers of the BKCa channels at 100 nM concentration
(12) as well paxilline, an indole alkaloid mycotoxin from
Penicillium paxilli that is a potent BKCa channel blocker at 1
�M (14). None of the BKCa channel blockers altered the
maximal relaxation to the two TAS2R agonists in preparations
precontracted by carbachol. However, the potency of denato-
nium (pEC50 4.5 � 0.1), but not that of chloroquine, was
decreased by iberiotoxin, charybdotoxin, and paxilline (pEC50:
3.5 � 0.2, 3.7 � 0.1, and 3.5 � 0.2, respectively; Fig. 6, A and
B). For all three BKCa blockers, there was thus approximately
one log order of magnitude of shift in the concentration-
response relation for the denatonium-mediated airway relax-
ation. In line with previous observations (12, 17), it was
confirmed that the potency of salbutamol similarly was de-
creased by iberiotoxin without effects on the maximal relax-
ation (Fig. 6C).
To investigate the involvement of other pathways important
for relaxation, the effects of kinase inhibitors for PKA, PKC,
and PKG on denatonium-induced airway relaxation were ex-
amined. However, 30-min pretreatment with 10 �M H89 (PKA
inhibitor), 1 �M GF109203 (a selective inhibitor of PKC), and
Table 1. Effects of TAS2R agonists and salbutamol on guinea pig tracheal segments precontracted with 0.1 �M carbachol
with and without 3 �M indomethacin
Control Saccharin Thiamine Chloroquine Denatonium Noscapine Salbutamol
No indomethacin
n 6 6 7 6 8 8 4
Rmax 10.7 � 2.5 9.5 � 2.1 72.7 � 6.6 98.2 � 1.1 57.5 � 5.2 72.9 � 4.4 98.0 � 0.9
pEC50 n.a. n.a. 3.58 � 0.06 3.75 � 0.07 4.60 � 0.11 4.40 � 0.05 6.91 � 0.19
Hill slope n.a. n.a. �0.91 � 0.07 �4.03 � 1.11 �0.92 � 0.07 �2.27 � 0.28 �1.43 � 0.13
Indomethacin
n 7 4 7 7 9 8 4
Rmax 13.1 � 4.3 14.7 � 5.3 100.0 � 0.0* 100.0 � 0.0 98.3 � 1.6* 52.3 � 1.1† 98.7 � 1.0
pEC50 n.a. n.a. 3.59 � 0.10 3.82 � 0.10 4.48 � 0.10 4.17 � 0.04† 6.85 � 0.20
Hill slope n.a. n.a. �1.61 � 0.06 �5.51 � 0.71 �1.54 � 0.08 �2.12 � 0.15 �1.74 � 0.19
ONO-8130
n 7 5 6
Rmax 99.6 � 0.4* 99.3 � 0.7* 77.5 � 1.8
pEC50 3.95 � 0.19 4.78 � 0.12 4.40 � 0.04
Hill slope �1.36 � 0.05 �1.26 � 0.09 �1.53 � 0.08
SQ29548
n 7 5 6
Rmax 87.4 � 5.6 49.6 � 13.6 70.5 � 6.0
pEC50 3.76 � 0.06 4.74 � 0.12 4.30 � 0.05
Hill slope �1.22 � 0.13 �1.11 � 0.12 �2.06 � 0.15
The effects of denatonium, thiamine, and noscapine on precontracted segments were studied in the presence of 10 nM prostaglandin E2 receptor (EP1)
antagonist ONO-8130 and 1 �M thromboxane A2 receptor TP antagonist SQ29548. *P � 0.0001, †P � 0.005 in comparison to the segments with no
indomethacin.
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Fig. 2. A: real-time PCR analysis of TAS2R mRNA expression in smooth muscle (ASM) and epithelial cells from GPT. Expression levels were calculated using
the comparative CT method and normalized against the housekeeping gene �-actin and expressed as 105 mol/mol �-actin. Data are expressed as means � SE
(n � 7/group). Effects of epithelial denudation on denatonium (n � 4–9) (B) and chloroquine-mediated (n � 4–6) (C) airway relaxation in GPT precontracted
with 100 nM carbachol in the presence of 3 �M indomethacin.
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1 �M KT5823 (a selective inhibitor of PKG) had no significant
effects on denatonium-induced airway relaxation (Fig. 6D).
Because cAMP is essential for �2-adrenoceptor agonist-
mediated airway smooth muscle relaxation, we measured the
levels of intracellular cAMP after denatonium and chloroquine
stimulation with salbutamol as a positive control. Neither
denatonium nor chloroquine had effects via the cAMP signal-
ing pathway, however. As expected, salbutamol stimulation
resulted in increase in intracellular cAMP levels (Fig. 6E).
In view of the apparent selectivity of denatonium against the
cholinergic agonist carbachol, its effect on acetylcholine in-
duced dilatation of phenyepinephrine precontracted guinea pig
aorta was studied. However, the dilatation to acetylcholine was
similar in the presence or absence of denatonium pretreatment
(40.2 � 1.2 vs. 35.2 � 12.9%) (Fig. 6F).
Effect of different levels of precontraction on bitter taste
agonist-mediated airway relaxation. The next set of experi-
ments was performed to examine how the relaxation responses
to denatonium and chloroquine were affected by different
levels of precontraction, using salbutamol for comparison.
Thus the preparations were stimulated with 30 nM, 100 nM,
and 3 �M carbachol to produce precontraction levels of 47.1�
6.5% (n� 11), 73.5� 3.8% (n� 19), and 100.0� 0.0% (n�
9) of the maximal histamine-induced contraction, respectively.
Both denatonium and chloroquine were able to induce maximal
relaxations irrespective of the level of precontraction (Fig. 7, A
and B; note that all levels of precontraction have been set to
100% to clearly illustrate the effect). The potency of denato-
nium, but not that of chloroquine, was, however, gradually
decreased with increasing levels of precontraction. In contrast
to both bitter taste agonists, salbutamol caused only a weak
relaxation at the highest level of precontraction (Fig. 7C).
Moreover, for the two lower levels of precontraction, where
maximum relaxation still could be reached with salbutamol,
the loss of potency with increasing level of precontraction was
significantly greater for salbutamol than for denatonium (12 �
2-fold and 2� 1-fold, respectively). In addition, we studied the
effects of formoterol, which is a stronger agonist for �2-
adrenoceptors than salbutamol. As shown in Fig. 7C, formot-
erol failed to relax the highest level of precontraction. How-
ever, the loss of potency with the two lowest precontraction
levels was similar to that of denatonium (Fig. 7D).
DISCUSSION
Our findings confirm and extend the concept that bitter taste
receptors may represent a new target for bronchodilation in
asthma and obstructive airway diseases. We show that bitter
taste receptors are expressed in the GPT and that agonists for
these receptors can induce strong relaxations. In fact, in car-
bachol-contracted preparations, denatonium and chloroquine
relaxed maximally contracted preparations that were resistant
to the �-adrenergic agonist salbutamol. Taken together, our
results in another species confirm several of the key observa-
tions on the potential of agonists of TAS2Rs as bronchodilators
(7). On the other hand, in our extended analysis, we found that
the properties of the most potent agonist denatonium were
distinct from those of chloroquine. Whereas denatonium only
reduced the effects of cholinergic contractions, chloroquine
uniformly inhibited contractions evoked also by histamine,
contractile prostanoids, and cysteinyl-leukotrienes. This was
observed when the mediators were given alone as agonists or
when they were released together endogenously by the antigen
challenge. In addition, although relaxations induced by dena-
tonium were sensitive to inhibitors of BKCa activation, the
effect was only partial and similar to the effect of that class of
drugs on the �-adrenergic agonist salbutamol.
We identified expression of guinea pig TAS2Rs for denato-
nium (TAS2R4 and TAS2R10) and chloroquine (TAS2R3 and
TAS2R10), consistent with the functional effects of these two
agonists. In addition, we observed relaxations to thiamine
(TAS2R1), dextramethorphan (TAS2R1 and TAS2R10), and
noscapine (TAS2R14). All these agonists induced strong re-
laxation of GPT precontracted with carbachol. For denatonium,
dextramethorphan, chloroquine, and thiamine, the magnitude
of relaxation was comparable to those of salbutamol or for-
moterol, however, with markedly lower potencies. The low
potency is expected and in accordance with the existing liter-
ature on agonists for bitter taste receptors (16). Furthermore,
the potency values of salbutamol and formoterol obtained in
this study are comparable with the results from previous
studies in isolated GPT (pEC50: 6.91 � 0.19 and 6.89 � 0.10
for salbutamol, respectively, and 9.32 � 0.08 and 8.76 � 0.09
for formoterol, respectively) (13). One of the challenges for
A
B
Fig. 3. A: serial samples were collected from the organ bath fluid at 1-min time
intervals after 300 �M denatonium and 300 �M chloroquine stimulation of
GPT precontracted with 100 nM carbachol. Bradykinin (3 �M) was used as a
positive control and negative control samples were left untreated. The absolute
PGE2 release (pg/ml/mg dry weight) was measured with ELISA. PGE2 values
in each bath before the stimulations (timepoint 0) were set as a reference value
of 100, and data are presented as relative values (n � 3). B: effects of
denatonium and chloroquine on GPT precontracted with 3 nM 17-phenyl trinor
PGE2 in the presence of 3 �M indomethacin (n � 3–4).
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any future drug development is obviously to identify more
potent ligands for TAS2Rs.
Another need is to define the TAS2Rs that are most suitable
targets. Despite the lack of available antagonists for TAS2Rs,
the effects of the tested agonists in the guinea pig tissues
already provide relatively clear insight into which receptors
have been activated. Thus the potency of denatonium, known
to selectively activate TAS2Rs, was approximately fivefold
higher in GPT compared with the potency reported for the
same compound against hTAS2R10 in transfected human em-
bryonic kidney (HEK)-293T cells (EC50: 25 �M and 120 �M,
respectively) (16). Because denatonium is 100-fold more po-
tent for hTAS2R10 than for hTAS2R4, the data indicate that
the relaxant effect of denatonium is mediated through the
TAS2R10. This interpretation is further supported by the very
similar potency and pattern of activity of dextromethorphan
and denatonium. Dextromethorphan is known to activate both
TAS2R1 and R10 (16), but, in absence of confirmed expression
of TASR1 in GPT, we interpret our data to support that
denatonium and dextromethorphan mainly evoke the observed
relaxations via TASR10. One explanation for the observed
higher potency of denatonium compared with the transfected
human cells might be an interaction between TAS2R10 and a
concomitant activation of TAS2R4. Although the potency of
chloroquine was low, it was strikingly similar to that obtained
for hTAS2R3 in transfected HEK-293T cells (EC50: 178 �M
and 173 �M, respectively) (16). Because chloroquine has a
1,000-fold lower potency for hTAS2R10 (16), it is assumed
that the relaxant effect of chloroquine solely was mediated
through TAS2R3.
Furthermore, the observation that the guinea pig does not
have sequences for the known saccharin TAS2Rs is consistent
with the observation that saccharin failed to relax GPT. Sac-
charin was active in mice airways, which also express its
receptor (7). Although we could not study expression of
TAS2R1, the potency of its agonist thiamine was similar to that
of chloroquine in GPT. The potency of thiamine was higher
than expected from data in transfected HEK-293T cells (16).
For noscapine, which was as potent as denatonium but did not
induce the same strong relaxation as salbutamol in GPT, the
potency is in accordance with the effect on hTAS2R14 in
transfected HEK-293T cells. The low efficacy may thus relate
to limited receptor expression. Taken together, the analysis
comparing our current data with those on human TAS2Rs
supports that denatonium, chloroquine, dextromethorphan, thi-
amine, and noscapine cause relaxations of GPT through acti-
vation of specific TAS2Rs.
In this study, TAS2R3, TAS2R4, and TAS2R10 transcripts
were detected both in epithelial and smooth muscle cells of
GPT. Although denudation of the tracheal epithelium caused
small shifts of the concentration response curves for the bitter
taste agonists, it did not remove the relaxant effects. Thus these
results support that the relaxations to denatonium and chloro-
quine are mediated almost exclusively through a direct effect
on the airway smooth muscle.
The effects of denatonium and chloroquine differed though.
Whereas relaxations induced by denatonium were enhanced by
treatment with either indomethacin or the EP1 receptor antag-
onist ONO-8130, the response to chloroquine was the same
irrespective of whether spontaneous tone was abolished or not.
The observations suggested that denatonium was unable to
inhibit responses to PGE2, which is established to maintain the
spontaneous tone of the preparation (18, 21). This mode of
action was confirmed because denatonium failed to inhibit the
contraction response both to PGE2 itself and the analog 17-
phenyl trinor PGE2. The finding that the TP receptor antagonist
SQ-29548 did not mimic the effects of indomethacin or the EP1
antagonist provided further strength to this conclusion. As we
also found that denatonium did not induce release of PGE2
from the GPT, we can attribute the reduced response to
denatonium in naïve preparations solely to its inability to
counteract the part of the preload contributed by constitutive
release of PGE2, and the data support that thiamine induces
relaxation by the same PGE2-sensitive mechanism. A similar
A                                                   B
C                                                   D
Fig. 4. A: effects of denatonium and chloro-
quine on airway relaxation of ovalbumin-sen-
sitized guinea pig tracheal segments precon-
tracted with ovalbumin. Data are expressed as
percentages of maximal relaxation obtained
with a combination of papaverine (0.1 mM)
and sodium nitroprusside (0.1 mM) at the end
of each experiment (n � 4–6). Effects of
denatonium and chloroquine on 100 nM
U46619 precontraction (n � 4–6) (B), 100
nM LTD4 precontraction (n � 4) (C), and 10
�M histamine (n � 3) (D) in the presence of
3 �M indomethacin.
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decrease in relaxation has been shown for the �2-adrenoceptor
when the EP1 receptor is activated (15).
Our data furthermore indeed implicate that the TAS2R
agonists denatonium and chloroquine mediated relaxations
through different signaling pathways. Whereas denatonium
failed to reverse on-going antigen-induced contractions in the
OVA-model, as well as the contractions induced by any of the
mediators of that response (histamine, U-46619 for PGD2/
TXA2, and LTD4) (24), chloroquine was able to cause relax-
ations irrespective of contractile agonist. The difference in the
effects of the two agonists was also shown when GPT was
contracted with the different agonists after pretreatment with
either denatonium or chloroquine. In these experiments, dena-
tonium could again only reduce the effect of carbachol,
whereas chloroquine decreased the effects of all contractile
agonist used in the studies. The results further indicated that
the denatonium-induced relaxation is dependent on the type of
intracellular signaling induced by the particular agonist,
whereas chloroquine-mediated relaxation responses appear to
be signaling-independent, or at least via pathways that are able
to counteract a broader range of signaling mechanisms.
As BKCa channels are shown to be involved in the relaxation
mediated by �2-adrenoceptors (12, 17) and TAS2Rs, we fur-
ther investigated the importance of this mechanism in GPT by
the use of three different BKCa channel blockers. The effects of
chloroquine were not affected by iberiotoxin, charybdotoxin,
and paxilline. With denatonium, roughly a one-log shift change
was obtained with all channel blockers, but the maximal effect
B                                                 C                                                   D
E                                                  F
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Fig. 5. A: trace depicting the effects of denatonium, and chloroquine prestimulation on contractions induced by increasing concentrations of carbachol. GPT was
prestimulated with 300 �M denatonium or 300 �M chloroquine for 30 min in the presence of 3 �M indomethacin followed by increasing concentrations of
carbachol (n � 5–6) (B), U46619 (n � 4) (C), PGE2 (n � 5) (D), leukotriene D4 (LTD4) (n � 5–6) (E), and histamine (n � 5–6) (F). Data are expressed as
percentages of maximal contraction obtained with histamine (1 mM), acetylcholine (1 mM), and KCl (60 mM), which were added to the bath at the end of each
experiment. In histamine experiments, the first histamine peak used as a control of the guinea pig trachea reactivity was used as a reference to avoid the effects
of receptor desensitization.
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was not altered. Similar results have been reported for the
channel blockers against salbutamol (12). However, when the
toxins were added, the level of the carbachol precontraction
was increased, which per se was shown to induce a rightward
shift of the concentration-response curve to denatonium (dis-
cussed below). This suggests that bitter taste agonists induce
smooth muscle relaxation by more mechanisms than activation
of BKCa channels. Our findings appear to be in line with the
A                                                B                                             C
D                                                E                                             F
Fig. 6. GPT was treated with 3 �M indomethacin in the presence and absence of Ca2� induced large K� channel blockers iberiotoxin (100 nM), charybdotoxin
(100 nM), and paxilline (1 �M), and precontracted with 100 nM carbachol. The effects of denatonium (A), chloroquine (B), and salbutamol (C) on airway
relaxation are expressed as percentages in relation to maximal relaxation. D: effects of kinase inhibitors on denatonium-induced airway relaxation. KT5823 �
selective inhibitor of protein kinase G (1 �M), GF109203� selective inhibitor of protein kinase C (1 �M), H89� protein kinase A inhibitor (10 �M). E: samples
were collected from the organ bath fluid 20 min after 300 nM salbutamol (n � 4), 300 �M denatonium (n � 4), 300 �M chloroquine (n � 4) and stimulation
of GPT precontracted with 100 nM carbachol for 40 min followed by 30 min incubation of 200 �M 3-isobutyl-1-methylxanthine, a nonspecific inhibitor of
phosphodiesterases. The absolute cAMP release (pg/ml/mg) was measured with enzyme immunoassay. **P � 0.01, ***P � 0.001. F: guinea pig aorta was
precontracted with 10 �M phenylephrine and exposed to 10 �M ACh. Thereafter, the segments were washed and exposed to 300 �M denatonium, precontracted
with 3 �M PGF2�, and again exposed to 10 �M ACh.
A                                                    B
C                                                    D
µ
µ
µµ
Fig. 7. Effects of denatonium (n � 5–9) (A),
and chloroquine (n � 4–9) (B), salbutamol
(n � 4) (C), and formoterol (n � 6) (D) on
airway relaxation in GPT precontracted with
3 �M, 100 nM, and 30 nM carbachol (CCh)
in the presence of 3 �M indomethacin. Data
are expressed as percentages of maximal
relaxation obtained with a combination of
papaverine (0.1 mM) and sodium nitroprus-
side (0.1 mM) at the end of each experiment.
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recent results of Zhang et al. (28), who did not find evidence of
specific contribution of the BKCa channels to the relaxation
caused by chloroquine in isolated mouse airways. However,
An et al. (2) found the chloroquine-induced relaxation of
mouse trachea and human airway smooth muscle to be partially
sensitive to BKCa channel blockers. It is likely that method-
ological issues and species differences in bitter taste receptor
homolog expression could contribute to different results in
different systems. It is possible that BKCa channel activation
may be a general process in smooth muscle regulation and not
specific for responses mediated by TAS2Rs.
As discussed by others (5), the level of precontraction can
influence both the magnitude and the potency of the agonist-
induced relaxation. Indeed, when the preload was increased to
supramaximal levels, both denatonium and chloroquine in-
duced maximal relaxations, whereas neither of the �2-adreno-
ceptor agonists did. This confirmed the observation that bitter
taste agonists induced a stronger effect than �2-adrenoceptor
agonists (7). Furthermore, whereas the potency for denatonium
increased with decreasing preload, the potency for chloroquine
was unaffected. When the preload was decreased, �2-adreno-
ceptor agonists, both with an increase of potency, induced a
maximal relaxation similar to that of the bitter taste agonists.
However, the increase in potency for salbutamol was greater
than for formoterol, which probably is related to salbutamol
being a partial agonist and more sensitive to the level of
preload than formoterol, which is a full agonist. The finding
that neither �2-adrenoceptor agonists produced maximum re-
laxation at the highest preload indicates that the bitter taste
agonists have a greater efficacy than the �2-adrenoceptor
agonists and induce smooth muscle relaxation by other mech-
anisms. These distinct mechanisms between bitter taste ago-
nists and �2-adrenoceptor agonists were recently shown also
by the lack of interference in desensitization experiments (3).
In preliminary attempts to identify the signaling pathways
for the denatonium-mediated relaxation, we used kinase inhib-
itors for PKA, PKC, and PKG, but none of the used inhibitors
had any effects. We also measured the levels of cAMP, which
is a central second messenger for the �2-adrenoceptor-medi-
ated relaxation that can also activate other pathways than PKA
(8). However, we did not find any increase in intracellular
cAMP after maximal stimulation of GPT with denatonium and
chloroquine. Thus we could not identify the signaling mecha-
nisms for the bitter taste agonist-mediated airway relaxations,
and further search for this is currently hampered by the lack of
molecular tools in the guinea pig.
The selective effect of denatonium on cholinergic responses
in the GPT was obviously not due to muscarinic antagonism
because acetylcholine-mediated relaxation in aorta was not
inhibited by denatonium. Although the Hill slope values for
denatonium suggest a GPCR-mediated mechanism for this
agonist in our studies, it should be kept in mind that denato-
nium is able to activate both G protein-dependent and-inde-
pendent pathways in the taste buds (22). In another study,
intragastric administration of TAS2R agonists induced release
of ghrelin and inhibited gastric emptying. However, only the
former effect was abolished in mice lacking the �-gustducin G
protein (11). For chloroquine, the Hill slope was consistently
steep, which suggests an involvement of ion channel activation
(10), which can either be linked through a TAS2R or due to
other mechanisms. Because both agonists induce strong airway
smooth muscle relaxation, it should be of importance to delin-
eate the pathways further.
In conclusion, our results demonstrate that, in this particular
preparation, denatonium may completely relax contractions
induced by muscarinic agonists, but it does not inhibit re-
sponses induced by other contractile agonists. The selective
effect of denatonium on muscarinic responses is most likely
due to TAS2R10 activation, whereas chloroquine via activa-
tion of TAS2R3 and other yet unidentified additional actions
display a pattern of global inhibition of different contractile
responses in GPT. Although we could not find a specific G
protein-coupled pathway in this first description of relaxation
of guinea pig airways induced by activation of bitter taste
receptors, the potency of the bitter taste agonists showed clear
similarities to human expression systems (16). Taken together
with previous findings in other species and models (3, 5, 7, 19),
our findings reinforce that TAS2Rs are potential new targets
for development of a novel class of bronchodilators. Priority
should now be given to define the signaling mechanisms and to
identify agonists, which are more potent and selective.
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Abstract 
The role of different cyclooxygenase (COX) metabolites released after antigen exposure has 
been difficult to assess due to simultaneous release of dominant constrictors such as histamine 
and cysteinyl-leukotrienes (CysLT). In addition prostaglandin E2 (PGE2) also has a powerful 
effect on basal tone. The aim was to exclude PGE2, histamine and CysLTs from the antigen-
induced contraction to define the possible involvement of remaining COX metabolites. 
Isometric force was measured in guinea pig trachea after exposure to cumulatively increasing 
concentrations of ovalbumin (OVA; 0.1 ng∙mL-1 to 0.1 mg∙mL-1) in the absence or presence 
of biosynthesis inhibitors and receptor antagonists. 
Challenge with OVA induced a concentration-dependent contraction that reached 75% of 
maximal tissue response. COX-inhibition or a combination of EP1 and EP2 receptor 
antagonism (ONO-8130 and PF-04418948) completely abolished the tone, resulting in an 
augmented antigen response. COX inhibition in combination with either antihistamines or 
anti-leukotrienes (FLAP inhibitor or CysLT1-2 receptor antagonist) displayed no difference 
compared to COX inhibition alone. However, a combination of all three classes reduced the 
contraction to 30%, revealing an unknown contractile component. Exchanging COX 
inhibition with EP1-2 receptor antagonists together with antihistamines and anti-leukotrienes 
could not decrease the contraction more than to 50%. However, when a TP receptor 
antagonist (SQ-29,548) was further included, the maximal antigen contraction reached 30%, 
similar as previously, clearly revealing a TP-mediated contractile component. 
PGE2 primarily regulate the basal tone via EP1 and EP2, whereas prostanoids, such as TXA2 
and PGD2, contribute as mediator of the antigen-response by activation of the TP receptor. 
 
Keywords: ovalbumin, guinea pig, eicosanoids, TP receptor, EP receptor, trachea 
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1 Introduction 
The early allergic reaction (EAR) displays as an acute bronchoconstriction in asthmatic 
subjects minutes after antigen exposure (Boulet et al., 2007).  In humans and guinea pigs the 
predominant mediators responsible for airway smooth muscle contraction are histamine in 
combination with lipid-derived mediators such as cysteinyl-leukotrienes (CysLTs) and 
cyclooxygenase (COX) metabolites (Bjorck and Dahlen, 1993; Featherstone et al., 1990; 
Roquet et al., 1997; Selg et al., 2008). In addition to being potent bronchoconstrictors, these 
mediators also recruit inflammatory cells, induce mucus secretion and cause vasodilatation, 
factors aggravating the airflow obstruction (Bradding et al., 2006; Jutel et al., 2005; Matsuoka 
et al., 2000).  
Because several potent mediators are released concomitantly during the antigen-challenge, 
single or dual inhibition of the involved mediators have displayed limited effects in several 
guinea pig ex vivo models of antigen-induced airway contraction; such as parenchymal strips 
(Jonsson and Dahlen, 1994), isolated trachea (Bozkurt et al., 2011), precision cut lung slices 
(Ressmeyer et al., 2006) and the isolated, perfused and ventilated lung (Sundstrom et al., 
2003).  However, combining antagonism of histamine receptors with inhibitors of COX and 
the 5-lipoxygenase pathways inhibits the major part of the antigen induced contraction in 
several guinea pig models (Riley et al., 2013; Sundstrom et al., 2003).  Still, the precise roles 
and the interactions between the different mediators and their respective receptors have not 
been established.  In guinea pig trachea, this has been particularly difficult due to a 
constitutive smooth muscle tone maintained by prostaglandin (PG) E2 via EP1 and EP2 
receptors (Safholm et al., 2013). It remains to determine the relative contributions of the large 
number of mediators that have been implicated in the antigen-induced airway constriction.  In 
guinea pig airways PGE2 contract by activation of EP1 receptors, and by the use of a selective 
EP2 receptor antagonist (Forselles et al., 2011) we have recently shown that PGE2 
simultaneously evoke potent relaxation of the GPT by action on EP2 receptors (Safholm et al., 
2013). In particular, most previous studies have focused on the role of cysteinyl-leukotrienes 
and only studied the residual component of the contraction after pre-treatment with anti-
histamines and different NSAIDs globally blocking formation of all COX products. Hence, 
this study aims for the first time to characterise the relative involvement of the individual 
COX-products under conditions when components in the antigen-induced contraction was 
defined by step-wise addition of selective inhibitors or antagonists for the main mediators 
involved. Using both selective EP1 and EP2 receptor antagonists, the role for the basal airway 
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smooth muscle tension could, for the first time, be assessed in relation to the antigen-induced 
contraction and thereby also delineate the role of other prostanoid receptors. 
 
 
2 Methods 
The study was approved by the Swedish animal experimentation ethical review board 
N257/09 and N323/11. 
2.1 Sensitization procedure and tissue preparation 
Male albino guinea-pigs (Dunkin-Hartley; 400-450 g) were sensitized by a single peritoneal 
injection containing 100 µg ovalbumin (OVA) grade V and 0.1 g aluminium hydroxide 
dissolved in 0.8 mL sterile PBS. Animals were sacrificed 14 to 28 days later by an overdose 
of sodium pentobarbital (Apoteket AB, Stockholm, Sweden) followed by the heart-lung-
package rapidly removed and placed in ice-cold Krebs-Ringer PSS buffer (NaCl [118.5 mM], 
KCl [4.7 mM], KH2PO4 [1.2 mM], MgCl2 [1.2 mM], EDTA [0.03 mM], NaHCO3 [25 mM], 
glucose [11.1 mM], CaCl2 [2.5 mM] dissolved in demineralised water). The trachea was 
gently dissected from the surrounding connective tissue, cut into eight intact rings of equal 
length containing between two and three cartilage rings each and placed in a 5 mL tissue 
organ bath containing Krebs-Ringer PSS and kept at 37 °C, constantly bubbled with carbogen 
(5% CO2 in O2) to maintain pH at 7.4). 
2.2 Experimental procedure 
Changes in smooth muscle force were detected using an isometric force-displacement 
transducer linked to a Grass polygraph.  The response was displayed using LabChart 7.0.3 
(ADInstruments, Australia). During an equilibration period of 60 min with washes every 15 
min, the resting force was mechanically adjusted to 30 mN.  As a control of guinea pig 
tracheal reactivity, histamine (0.1 nM) to (0.3 mM) was cumulatively added which was 
followed by a second wash period and a new 45-60 min equilibration period. To study the 
action of OVA, cumulative concentrations, from 0.1 ng/mL to 0.1 mg/mL, generating 
concentration-dependent contraction responses was elicited in the absence and presence of 
pharmacological tools which were given 45 min prior. Only one OVA response was 
investigated in each preparation and at the end of the experiment, histamine (1 mM), 
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acetylcholine (1 mM) and potassium chloride (60 mM) was added to the organ bath for 30 
min which was used as a reference of the maximal contraction. As a reference for the 
maximal relaxation, a combination of papverine (0.1 mM) and sodium nitroprusside (0.1 mM) 
was added to the bath and left for 60 min. The different combinations of receptor antagonists 
and enzyme inhibitors did neither affect maximal contraction nor maximal relaxation. 
2.3 Pharmacological tools 
The unselective cyclooxygenase (COX) inhibitor indomethacin, 5-lipoxygenase (5-LOX) 
inhibitor zileuton, 5-LOX activating protein (FLAP) inhibitor MK-886 was used to 
investigate the involvement of the enzymes participating in producing the prostaglandins and 
leukotriene’s. Furthermore, selective receptor antagonists for EP1 (ONO-8130), EP2 (PF-
04418948), TP (SQ-29,548), H1 (mepyramine), H2 (metiamide), H3 (ciproxifan), H4 (JNJ 
7777120), CysLT1 (montelukast), CysLT1-2 (BAY-u9773), M1-5 (atropine), 5-HT2A 
(ketanserine) and B2 (HOE-140) receptors were used to assess respective involvement during 
the antigen induced contraction.  
2.4 Drugs and suppliers 
NaCl, KCl, CaCl2, MgCl2, NaHCO3, KH2PO4 and glucose were obtained from VWR (West 
Chester, PA). Ovalbumin (grade V), histamine dihydrochloride, DMSO, EDTA, metiamide, 
acetylcholine, indomethacin, ciproxifan, ketanserine, atropine, papverine and sodium 
nitroprusside and were purchased from Sigma-Aldrich (St. Louis, MO).  SQ-29,548, 
montelukast, BAY-u9773 was obtained from Cayman Chemical (Ann Arbor, MI). Zileuton, 
MK-886, mepyramine, JNJ 7777120 and HOE-140 were purchased from Tocris (Ellisville, 
MO). ONO-8130 was a kind gift from ONO Pharmaceuticals (Osaka, Japan). PF-04418948 
was a kind gift from Pfizer Central Research Division (Groton, CT). Stock solutions of 
indomethacin, SQ-29,548 and BAY-u9773 were dissolved in 95% ethanol. ONO-8130, PF-
04418948, JNJ 7777120, ciproxifan, ketanserin, montelukast capsazepine, zileuton, MK-886 
were dissolved in DMSO.  All stock solutions were stored at -20 °C. The other drugs were 
dissolved in deionized H2O on the experimental day. Dilutions of drugs were freshly made 
from stocks prior to each experiment in reducing concentrations of its solvent. 
2.5 Calculations and statistics 
The response generated by OVA is expressed as percentage compared to maximal contraction 
in relation to the total contractile response. All data are presented as mean ± SEM. Statistical 
analysis was performed using One-Way ANOVA followed by Bonferroni’s Multiple 
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Comparison Test. For the analysis GraphPad Prism 5.01 (GraphPad Software Inc., SanDiego, 
CA) was used. 
 
 
3 Results 
3.1 PGE2 modulates the response to antigen challenge via effects of EP1 and EP2 
receptors on the basal tone  
Following the initial resting period, washes and standard assessment of histamine 
responsiveness, tracheal segments developed a spontaneous contractile tone that stabilised 
within 30 min.  In sensitised but otherwise untreated controls, the tonus reached a level of 
33.7 ± 5.5% in relation to maximal tissue contractile response. Treatment with an unselective 
COX inhibitor (indomethacin), an EP1 receptor antagonist (ONO-8130) or a combination of 
EP1 and EP2 receptor antagonists (PF-04418948) completely abolished the tone 
(p < 0.05; Figure 1A-B) whereas single treatment with the EP2 receptor antagonist, in 
contrast, increased the basal tone to 67.1 ± 3.9% (p < 0.05; Figure 1B). Antagonising the TP 
receptor (SQ-29,548), H1-2 receptors (mepyramine and metiamide), inhibiting the FLAP 
enzyme (MK-886) or combinations of these components did not affect the initial smooth 
muscle tone (Table 1). In contrast, zileuton which is considered to inhibit 5-LO enzyme 
caused an almost complete abolishment of the tone (p < 0.05). 
Cumulative administration of OVA (0.1 ng/mL to 0.1 mg/mL) induced reproducible 
concentration-dependent contractions both in presence and absence of COX inhibition. 
However, in the presence of COX inhibition the maximal contractile force to OVA was 
significantly greater (87.1 ± 3.9%; p < 0.05) compared to sensitised untreated controls 
(74.6 ± 2.7%). Treatment with ONO-8130 significantly decreased the response (57.7 ± 1.6%; 
p < 0.05), whereas PF-04418948, alone or in combination with ONO-8130, increased the 
response to a similar level as COX inhibition (86.1 ± 4.5% and 84.8 ± 3.2%, respectively; 
p < 0.05; Figure 1A-B). On the contrary, in absence of COX inhibition, maximal OVA 
response was not affect by single or combined treatment with SQ-29,548, mepramine, 
metiamide and MK-886 (Table 1). 
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3.2 Antagonising the EP1 and the EP2 receptor unmask an antigen driven TP receptor 
contraction  
In order to investigate the relative contribution of prostanoid receptors for the contraction, the 
influence of the constitutively produced PGE2 was excluded by either antagonising both the 
EP1 and EP2 receptors or EP1 receptor only. Further, since the strong contractions to histamine 
and CysLTs, which are known to be released by mast cells (Adams and Lichtenstein, 1979), 
can conceal the prostanoid effects, these experiments were also performed in presence of 
antagonists for H1-2 and CysLT1-2 receptors (BAY-u9773). In addition, as PGD2 and TXA2, 
also released by mast cells, both cause contraction in guinea pig lung through TP receptors 
(Featherstone et al., 1990), this receptor was also antagonized. Thus, when EP1-2, H1-2, 
CysLT1-2 and TP receptors were antagonized the antigen-induced contraction reached an Emax 
of 28.7 ± 0.7% that was significantly lower than using only EP1-2 receptor antagonists 
(p < 0.05; Figure 2A). Keeping the similar set-up however exchanging BAY-u9773 with the 
FLAP-inhibitor MK-886 gave an identical Emax (28.0 ± 2.7%). Distinctly, when the TP 
receptor antagonist was excluded, a marked increase of the Emax was obtained (47.7 ± 6.2%; 
p < 0.05). The TP receptor component was also demonstrated in experiments when the EP2 
receptor antagonist was omitted. In these experiment the contractions with all other 
antagonists used was totally abolished regardless if BAY u9773 or MK-886 was used to block 
the Cys-LT component (Figure 2B). Yet, when the TP receptor antagonist was excluded a 
marked response was obtained with an Emax of 24.7 ± 3.4% (p < 0.05).  
 
3.3 Inhibition of histamine and cysteinyl-leukotrienes in the presence of COX inhibition 
reduces antigen-induced contraction and unmasks an unknown residual contractile 
component 
COX inhibition in combination with either H1-2 antagonism or FLAP inhibition displayed no 
difference in contraction as compared to COX inhibition alone. However, segments treated 
with a combination consisting of COX inhibition, H1-2 receptor antagonists and FLAP 
inhibitor clearly displayed a reduced maximal OVA-induced contraction, reaching an Emax of 
32.4 ± 3.6% (p < 0.05; Figure 3). When the FLAP inhibitor was exchanged for a CysLT1-2 
receptor antagonist, a similar inhibition was observed, reaching an Emax of 29.6 ± 3.3% 
(p < 0.05). However, when the COX inhibition and antihistamines were used in combination 
with the CysLT1 receptor antagonist montelukast, the reduction was absent, reaching an Emax 
of 79.5 ± 2.4%. 
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The residual response, that was observed regardless if the segments were treated with either 
EP1-2 and TP receptor antagonists or COX enzyme inhibition in combination with H1-2 
receptor antagonists and FLAP inhibition, was further investigated by additional addition of 
antagonists for either the H3 and the H4 receptors (ciproxifan and JNJ 7777120, respectively), 
M1-5 receptors (atropine), 5-HT2A receptor (ketanserin) or B2 receptor (HOE-140). Still, all 
combinations were found to be ineffective in reducing the remaining residual component 
unmasked in the antigen-induced contraction (Table 2). 
 
 
4 Discussion 
Analysis of the antigen-induced contraction in guinea pig trachea is confounded by the 
powerful airway smooth muscle tone maintained by PGE2 acting on contractile EP1 receptors 
and counteracted by relaxant EP2 receptors (Safholm et al., 2013). However, with 
pharmacological interventions using selective receptor antagonists and enzyme inhibitors we 
have shown that the airway smooth muscle contraction induced by antigen is essentially 
mediated by the combined action of histamine, cysteinyl-leukotrienes and prostanoids that act 
on TP receptors. After complete inhibition of these three targets, only a small residual 
constriction component remained. This study shows that the airway smooth muscle antigen-
induced response in guinea pig closely mimics the early allergic reaction (EAR) displayed in 
asthmatic subjects after antigen exposure (Bjorck and Dahlen, 1993; Roquet et al., 1997) and 
to achieve a strong inhibition, several receptors needs to be blocked simultaneously. 
It has previously been reported that removing endogenously produced prostanoids, using non-
steroidal anti-inflammatory drugs (NSAIDs), completely abolishes the basal airway tone of 
the guinea pig trachea (Orehek et al., 1973). This inhibition has been shown to be due to 
reduced levels of endogenous PGE2 resulting in a loss of EP1 receptor-mediated contraction 
(Safholm et al., 2013). In the present study, this inhibitory effect was confirmed by both 
indomethacin and the selective EP1 receptor antagonist ONO-8130, whereas antagonist for 
H1, H2, or TP receptors or the FLAP inhibitor MK-886 had no effect on the basal tone. On the 
other hand, when the EP2 receptor was antagonised, the basal tone was increased, thus 
confirming the balance between EP1 receptor mediated contraction and EP2 receptor mediated 
relaxation in the isolated guinea pig trachea (Safholm et al., 2013). However, zileuton, which 
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generally is considered to be a 5-LOX inhibitor also reduced the basal tone. This may be 
explained by the recent discovery that zileuton in higher concentration also displays COX-
inhibition in mouse peritoneal macrophages and in human whole blood (Rossi et al., 2010). 
Furthermore, the findings that the smooth muscle tone not was reduced by the FLAP enzyme 
inhibitor MK-886, the unselective CysLT receptor antagonist L-648,051 or by BAY-u9773 
(Cuthbert et al., 1991; Linden et al., 1991), supports the hypothesis that zileuton also inhibits 
PGE2 production in the guinea pig trachea. Thus, due to this additional effect, zileuton was 
not used further in the combinations.   
Cumulative OVA exposure of the isolated trachea from sensitised guinea pigs caused a 
reproducible antigen-induced contraction irrespectively of initial smooth muscle tone. 
Addition of the unselective COX inhibitor, indomethacin amplified the maximum contractile 
response to the antigen. This augmented response after COX inhibition or unselective EP 
receptor antagonism AH-6809, seen both in human bronchi (Adams and Lichtenstein, 1985; 
Gorenne et al., 1994) and guinea pig trachea (Burka and Paterson, 1980; Hand and Buckner, 
1979), has been hypothesised to be caused by enhanced release of histamine by removal of 
inhibitory cyclooxygenase products, such as PGE2 (Undem et al., 1987).  Indeed, when the 
EP2 receptor was blocked, the maximum contraction was increased both with and without EP1 
receptor blockade confirming that the increased response was due to inhibition of PGE2. It is 
not possible to conclude from these experiments whether this is caused by reduced release of 
histamine, inhibition of the relaxation, or a combination of the two. However, we have 
demonstrated a role for the contractile EP1 receptor by the reduced maximum effect of the 
antigen when this receptor was blocked.   
To rule out a further prostanoid component in the contraction, experiments were performed 
comparing the effect of general COX-inhibition with selective blockade of PGE2.  The latter 
was assessed by selectively blocking EP1 and EP2 receptors which have been shown to be the 
EP receptors responsible for the contractile and relaxant effect of PGE2 in guinea pig trachea, 
respectively (Safholm et al., 2013) . However, to isolate this component the effect of both 
histamine and Cys-LTs also had to be inhibited.  Thus, in the presence of H1-2 antagonism and 
FLAP inhibition with the tone removed by either an EP1 receptor antagonist or both EP1 and 
EP2 receptor antagonists, a contraction approximately 20% greater was obtained compared to 
when prostanoid synthesis were inhibited. This effect was abolished the by the TP receptor 
antagonist SQ-29,548.  It is established that TXA2 and PGD2 are released during antigen-
induced degranulation (Turner and Dollery, 1988) exerting their main contractile effect in the 
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lung through the TP receptor (Beasley et al., 1989; Larsson et al., 2011). Thus, after removal 
of the tone in combination with antihistamines and FLAP inhibition, the contribution of the 
TP component could be identified. 
As described previously, in both human and guinea pig, the main components of the antigen-
induced contraction are mediated by histamine and Cys-LTs (Bjorck and Dahlen, 1993; Burka 
and Paterson, 1981) and combined inhibition of these mediators are needed to achieve 
substantial inhibition (Sundstrom et al., 2003).  Thus, neither blockade of H1-2 receptors or 
inhibiting the response to Cys-LTs using the selective FLAP inhibitor MK-886 and 
nonselective CysLT1-2 receptor antagonist BAY-u9773 affected the maximum antigen 
response.  One possible reason for this is phenomenon is that the responses to both agonists 
are close to the maximum possible response so that any additive effect cannot be 
distinguished.  Alternatively, the receptors may compete for the same intracellular signalling 
system.  Here we have also shown that combined CysLT1-2 receptor antagonism was required, 
which may be due to the same additive effect.   
Irrespectively of whether the antigen-induced contraction was reduced using antihistamines in 
combination with complete inhibition of COX and 5-LOX metabolites, or by the use of 
antagonists targeting EP1-2, TP or CysLT1-2 receptors, the outcome was the same: an 
approximately 70% reduction of the antigen-induced contraction. Furthermore, atropine, 
ketanserine and HOE-140, all failed to alter this response indicating that muscarinic M1-5 
receptors, serotonin 5-HT2A and bradykinin BK-B2 receptors respectively, do not mediate 
antigen-induced contraction in the guinea pig trachea. 
In conclusion, antigen-induced contractile responses to OVA in the guinea pig central airway 
appears to be due to a major release of histamine and 5-LOX products together with a 
significant effect induced by activation of TP receptors so that inhibition of all three classes of 
receptor is required to substantially reduce the effect. These findings are important for several 
reasons. Firstly, since the specific role of PGE2 has not been established before, both a 
selective and potent EP1 and EP2 receptor antagonist was used revealing PGE2 as a powerful 
modulator of the antigen-induced response. Secondly, by the use of several receptor 
antagonists, the specific contribution of the TP receptor could for the first time be identified. 
Thirdly, since the reduction of the antigen-induced contraction was minimal when the effect 
generated by two mediator classes was inhibited, it was necessary to investigate if inhibition 
by all three mediator classes, histamine, prostaglandins and leukotrienes, had any effect at 
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reducing the airway smooth muscle contraction. This study increases our understanding of the 
mediators released in conjunction with mast cell degranulation and has shown that inhibition 
of three classes of mediator is needed to achieve significant reduction of the antigen-induced 
contraction. As complete COX inhibition induces contractile amplification in both human and 
guinea pig (Adams and Lichtenstein, 1985; Bozkurt et al., 2011), an alternative therapeutic 
approach might be to combine selective receptor antagonists instead of global enzyme 
inhibition, which risks disrupting any potentially protective receptors such as EP2 in guinea 
pig and EP2 and EP4 in human (Buckley et al., 2011; Safholm et al., 2013). From our findings, 
we conclude that PGE2 primarily regulates basal tone whereas prostanoids, such as TXA2 and 
PGD2 contribute as mediators of the antigen-response by activation of the TP receptor.  
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Figure 1(A) Representative trace of concentration-response curves to OVA in guinea pig 
trachea, in the presence or absence of indomethacin (COX). (B) Concentration-response 
curves to OVA in the presence of the COX inhibitor indomethacin (COX; 3 µM), EP1 
receptor antagonist ONO-8130 (EP1; 10 nM) and EP2 receptor antagonist PF-04418948 (EP2; 
10 µM). The contraction of each segment in all experiments was calculated as percentage of 
maximal contraction of 1 mM histamine, 1 mM acetylcholine and 60 mM KCl in relation to 
maximal relaxation, a combination of 0.1 mM papverine and 0.1 mM sodium nitroprusside. 
Data represent mean ± S.E.M (n = 8-23) 
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Figure 2 A-B Concentration-response curves to OVA in the presence of EP1 receptor 
antagonist ONO-8130 (EP1; 10 nM) and EP2 receptor antagonist PF-04418948 (EP2; 10 µM), 
TP receptor antagonist SQ-29,548 (TP; 1 µM), H1 receptor antagonist mepyramine (H1; 1 
µM), H2 receptor antagonist metiamide (H2; 1 µM), FLAP enzyme inhibitor MK-886 (FLAP; 
10 µM) and CysLT1-2 receptor antagonist BAY-u9773 (CysLT1-2; 1 µM).. The contraction of 
each segment in all experiments was calculated as percentage of maximal contraction of 
1 mM histamine, 1 mM acetylcholine and 60 mM KCl in relation to maximal relaxation, a 
combination of 0.1 mM papverine and 0.1 mM sodium nitroprusside. Data represent mean ± 
S.E.M (n = 6-10). 
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Figure 3 Concentration-response curves to OVA in the presence of the COX inhibitor 
indomethacin (COX; 3 µM), H1 receptor antagonist mepyramine (H1; 1 µM), H2 receptor 
antagonist metiamide (H2; 1 µM), CysLT1-2 receptor antagonist BAY-u9773 (CysLT1-2; 
1 µM) and FLAP enzyme inhibitor MK-886 (FLAP; 10 µM). The contraction of each 
segment in all experiments was calculated as percentage of maximal contraction of 1 mM 
histamine, 1 mM acetylcholine and 60 mM KCl in relation to maximal relaxation, a 
combination of 0.1 mM papverine and 0.1 mM sodium nitroprusside. Data represent mean ± 
S.E.M (n = 5-12). 
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Tables 
Table 1 Etone, Emax, pEC50 calculated from a non-linear regression fit based on concentration-
response curve to ovalbumin in isolated guinea pig trachea 
Antagonist/inhibitor target Etone Emax pEC50 n 
Control 33.7 ± 5.5 74.6 ± 2.7 5.0 ± 0.4 23 
TP 41.3 ± 6.0 72.5 ± 3.7 5.1 ± 0.5 5 
TP + H1-2 32.7 ± 6.0 73.8 ± 3.1 5.0 ± 0.5 5 
TP + FLAP 40.9 ± 5.2 72.6 ± 4.6 4.2 ± 0.6 7 
FLAP 45.4 ± 5.0 64.8 ± 2.7 5.3 ± 0.7 8 
FLAP + H1-2 36.1 ± 12.8 66.1 ± 5.9 5.1 ± 2.0 6 
H1-2 46.3 ± 5.1 68.8 ± 3.3 5.1 ± 0.6 5 
5-LO 6.8 ± 3.6 80.6 ± 2.7 4.6 ± 0.2 5 
TP receptor antagonist SQ-29,548 (TP; 1 µM), H1 receptor antagonist mepyramine (H1; 
1 µM), H2 receptor antagonist metiamide (H2; 1 µM), FLAP inhibitor MK-886 (FLAP; 10 
µM), 5-LO inhibitor zileuton (5-LO; 1 µM) and COX inhibitor indomethacin (COX; 3 µM). 
The contraction of each segment in all experiments was calculated as percentage of maximal 
contraction of 1 mM histamine, 1 mM acetylcholine and 60 mM KCl in relation to maximal 
relaxation to a combination of 0.1 mM papverine and 0.1 mM sodium nitroprusside. Data 
represent mean ± S.E.M. 
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Table 2 Etone, Emax, pEC50 calculated from a non-linear regression fit based on concentration-
response curve to ovalbumin in isolated guinea pig trachea 
Antagonist/inhibitor target Etone Emax pEC50 n 
COX + H1-2 + FLAP 1.7 ± 0.8 38.0 ± 2.9 3.6 ± 0.3 14 
COX + H1-4 + FLAP 0.7 ± 0.4 41.2 ± 2.9 3.8 ± 0.2 7 
COX + H1-2 + FLAP + M1-5 0.7 ± 0.5 42.3 ± 8.7 3.3 ± 0.7 6 
COX + H1-2 + FLAP + 5-HT2A 0.1 ± 0.0 37.4 ± 9.0 3.0 ± 0.8 6 
COX + H1-2 + FLAP + B2 0.1 ± 0.0 32.9 ± 5.2 3.9 ± 0.6 6 
COX inhibitor indomethacin (COX; 3 µM), H1 receptor antagonist mepyramine (H1; 1 µM), 
H2 receptor antagonist metiamide (H2; 1 µM), FLAP inhibitor MK-886 (FLAP; 10 µM), 
muscarinic M1-5 receptor antagonist atropine (M1-5; 1 µM), serotonin receptor 2A antagonist 
ketanserine (5-HT2A; 100 nM), bradykinin B2 receptor antagonist HOE-140 (B2; 10 nM) and 
TP receptor antagonist SQ-29,548 (TP; 1 µM). The contraction of each segment in all 
experiments was calculated as percentage of maximal contraction of 1 mM histamine, 1 mM 
acetylcholine and 60 mM KCl in relation to maximal relaxation to a combination of 0.1 mM 
papverine and 0.1 mM sodium nitroprusside. Data represent mean ± S.E.M. 
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Abstract 
Background:  Prostaglandin E2 (PGE2), known to exert its effects through EP1-4 receptors, is 
a potent mediator with the capability to induce both airway smooth muscle contraction and 
relaxation. The majority of studies regarding its role in airways are done in larger conduits, 
however current understanding in asthma spans the whole lung, thus leaving the role of PGE2 
in small airways at large. 
Objective:  The aim of the present study was to investigate the role of PGE2 for basal tone 
and to characterise the receptors mediating responses in human small airways (⌀ < 2 mm). 
Methods:  Isometric force was measured in isolated human bronchial rings after treatment 
with pharmacological agents in the presence or absence of biosynthesis inhibitors and 
receptor antagonists. 
Results:  In segments pre-contracted with histamine, PGE2 induced a concentration-
dependent relaxation (Emin: 48%; pEC50: 6.4±0.4) that was inhibited by EP4 antagonism 
(ONO-AE3-208; 1 µM; Emin: 75%) whereas EP2 antagonism (PF-04418948; 1 µM) had no 
effect. On basal tension, PGE2 or the EP1/E3 agonist 17-phenyl trinor PGE2 caused a 
contraction (Emax: 76%; pEC50: 5.1±0.1 and 58%, respectively) that was inhibited by TP 
antagonism (SQ-29,548; 1 µM; Emax: 9% for both) whereas EP1 antagonism (ONO-8130; 
1 µM) had no effect.  Furthermore, a COX- inhibitor (indomethacin; 3 µM) increased the 
spontaneous tone whereas a FLAP inhibitor (MK-886; 1 µM) decreased it. The tone was most 
effectively increased with a selective COX-2 inhibitor (lumiracoxib; 1 µM). Antagonists for 
TP, IP and EP1-4 had no effect on the basal tension. 
Conclusion:  In human small airways, PGE2 induced a concentration-dependent relaxation 
via the EP4 receptor whereas at higher concentrations it caused a contraction mediated via the 
TP receptor, with no other receptors involved.  
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Introduction 
In human airways, several clinical studies have described prostaglandin E2 (PGE2) as a potent 
smooth muscle relaxant in normal subjects (Kawakami et al., 1973; Walters et al., 1982b) as 
well as in asthmatics (Melillo et al., 1994; Pavord et al., 1993) where it also exerts anti-
inflammatory properties (Gauvreau et al., 1999; Sestini et al., 1996). However, several in 
vitro and in vivo studies in airways have described potent, and sometimes opposing, responses 
after being exposed to PGE2 (Haye-Legrand et al., 1986; Walters et al., 1982a; Walters et al., 
1982c). The reason for this is because PGE2 have the possibility to mediate responses through 
several different receptors (Coleman et al., 1984). Firstly, the primary EP1-4 receptors with the 
capability to induce both contraction and relaxation and secondly, receptors normally 
activated by other prostanoids such as the contractile TP receptor (Armour et al., 1989; 
Coleman et al., 1989).  
Initially it was described that EP2 was the responsible relaxant receptor, based on a study 
using the poorly selective receptor antagonist AH6809 and the receptor agonist misoprostol 
(Abramovitz et al., 2000; Norel et al., 1999). However, recent studies reject the EP2 
hypothesis and implicate EP4 as the responsible receptor (Benyahia et al., 2012; Buckley et 
al., 2011). Despite beneficial relaxing properties by inhaling PGE2, occurrences of upper 
airway irritancy often displayed as cough have been reported (Gauvreau et al., 1999; Pavord 
et al., 1995) which recently was suggested to be mediated via activation of EP3 receptors 
(Maher et al., 2009). 
The majority of studies regarding the role of PGE2 have been performed in large airways 
(approximately 3-5 mm inner airway diameter correlating with 4-6th airway generations. 
Today the current understanding in asthma spans the whole lung, from the central to 
peripheral parts (Tashkin, 2002; van den Berge et al., 2011). Since the role of PGE2 in the 
small bronchi is still uncharacterised, the aim of our study was, using selective receptor 
antagonists, to characterise the PGE2 responses in human small airways (approximately 0.5-1 
mm inner airway diameter correlating with 12-16th airway generations) to ascertain through 
which receptors PGE2 mediates their responses.  
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Methods 
The study was approved by the Swedish ethical review board 2010/181-31/2. 
Isolated tissue preparation 
Macroscopically healthy human lung tissue was obtained from patients (consisting of 17 
males and 19 females with mean age of 64 ± 7 years) undergoing lobectomy (after confirmed 
structural changes within the lobe) and placed immediately in ice-cold Krebs-Ringer PSS 
buffer (NaCl (118.5 mM), KCl (4.7 mM), KH2PO4 (1.2 mM), MgCl2 (1.2 mM), EDTA (0.03 
mM), NaHCO3 (25 mM), glucose (11.1 mM), CaCl2 (2.5 mM) dissolved in demineralised 
water). Within 3 hours, bronchial tissue was, using microscopy, gently dissected clear from 
lung parenchyma under ice-cold Krebs-Ringer PSS buffer condition, cut into intact rings 
(approximately 0.5-1 mm inner airway diameter and 3-5 mm in length) and placed in separate 
wells containing Dulbecco’s modified Eagle medium (DMEM; Gibco, Auckland, NZ) 
supplemented with 1% penicillin (100 IU∙mL-1) and streptomycin (100 μg∙mL-1) (Gibco) 
under sterile conditions. The culture plates were placed in a humidified incubator (37 °C at 
95% O2 and 5% CO2) for 17-24 hours. On the experimental day, the rings were mounted 
horizontally on two metal prongs (200 µm in diameter) for recording of isometric tension 
(ADInstruments Ltd., Hastings, U.K.) using myographs (Organ Bath Model 700MO, DMT 
A/S, Aarhus, Denmark) containing Krebs-Ringer PSS and kept at 37 °C, constantly bubbled 
with carbogen (5% CO2 in O2) to maintain pH at 7.4). Preparations were allowed to 
equilibrate for 30 min with buffer changed every 10 min followed by a step-wise increase in 
tension over 60 min to a resting tension of 1.5 mN (Adner et al., 1996) with buffer changed 
every 15 min. 
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Experimental procedure 
After the equilibration period, as a control of bronchial reactivity and viability, KCl (60 mM) 
was added twice with a wash in-between, which was followed by a second 60 min 
equilibration period including washes. To study the involvement of prostanoids on the basal 
tone, unselective COX inhibitor indomethacin, selective COX-1 inhibitors FR-122047, 
selective COX-2 inhibitor lumiracoxib, selective FLAP inhibitor MK-886, IP receptor 
antagonist CAY10441, TP receptor antagonist SQ-29548, EP1 receptor antagonist ONO-8130, 
EP2 antagonist PF-04418948, EP3 receptor antagonist ONO-AE5-599 or EP4 receptor 
antagonist ONO-AE3-208 were given as a single concentration subsequent to the second 
equilibration period and the force was monitored over 30 minutes. The action of PGE2 was 
investigated by two separate protocols. For the relaxation, segments were treated with 
indomethacin (3 μM) and SQ-29,548 (1 μM) and exposed to histamine (1 μM) to give a stable 
pre-contraction, prior to addition of PGE2. For the contraction two separate concentrations of 
PGE2 were added to segments treated with indomethacin (3 μM) and ONO-AE3-208 (1 μM). 
In both cases, receptor antagonists were added 45 min prior to addition of agonists. To study 
the TP receptor response, U-46619, PGD2, PGE2 and 17-phenyl trinor PGE2 were given as 
two different concentrations in the presence of indomethacin (3 μM; 45 min) and ONO-AE3-
208 (1 μM; 45 min) with or without SQ-29,548 (1 µM; 45 min). Only one response was 
investigated in each preparation. All experiments were ended by adding histamine (1 mM), 
acetylcholine (1 mM) and KCl (60 mM) as a reference for the maximal contraction. 
Drugs and suppliers 
NaCl, KCl, CaCl2, MgSO4, NaHCO3, KH2PO4 and glucose were obtained from VWR (West 
Chester, PA). Histamine dihydrochloride, DMSO, acetylcholine, indomethacin, 
phenylephrine, sodium nitroprusside and papaverine were purchased from Sigma-Aldrich (St. 
Louis, MO). Prostaglandin E2, Prostaglandin D2, SQ-29,548, FR-122047 and 17-phenyl trinor 
PGE2, CAY10441 were obtained from Cayman Chemical (Ann Arbor, MI). Lumiracoxib was 
obtained from SynphaBase AG (Switzerland). MK-886 was purchased from Tocris (Ellisville, 
MO). ONO-8130, ONO-AE5-599, ONO-AE3-208 were kind gifts from ONO 
Pharmaceuticals (Osaka, Japan).  PF-04418948 was a kind gift from Pfizer Central Research 
Division (Groton, CT). Stock solutions of indomethacin, PGE2 (100 mM), PGD2 (100 mM), 
17-phenyl trinor PGE2 (100 mM) and MK-886 (100 mM) were dissolved in 99% ethanol, 
ONO-8130, ONO-AE5-599, ONO-AE3-208, ONO-AE1-259, CAY10441, PF-04418948, FR-
122047, SQ-29,548 and lumiracoxib were dissolved in DMSO.  All stock solutions were 
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stored at -20 °C. The other drugs were dissolved in Krebs-Ringer PSS buffer or deionized 
H2O on the day of the experiment.  Dilutions of drugs were freshly made from stocks prior to 
each experiment. 
Calculations and statistics 
The response generated by agonists is expressed as percentage compared to maximal 
contraction. All data are presented as mean ± SEM. Statistical analysis was performed using 
One-Way ANOVA followed by Bonferroni’s Multiple Comparison Test. For the analysis 
GraphPad Prism 5.01 (GraphPad Software Inc., SanDiego, CA) was used. 
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Results 
PGE2 mediates relaxation through the EP4 receptor in human bronchi 
In segments pre-contracted with histamine (1 μM) in the presence of SQ-29,548 (1 µM), 
PGE2 caused a concentration-dependent relaxation (Emin: 47.7±6.4; pEC50: 6.4±0.4). To 
characterise the receptor responsible for the relaxation, the selective EP2 receptor antagonist 
PF-04418948 and the selective EP4 receptor antagonist ONO-AE3-208 was used. ONO-AE3-
208 (1 µM) caused a rightward shift of the PGE2 induced relaxation (Emin: 75.1±6.0) whereas 
PF-04418948 (1 µM) did not affect the relaxation (Figure 1). 
PGE2 mediates contraction through the TP receptor and not EP1 in human bronchi 
To characterize the contractile receptors involved in the PGE2 response, experiments were 
performed in presence of the EP4 receptor antagonist ONO-AE3-208 (1 µM). PGE2 induced a 
contraction (pEC50: 5.1±0.1), reaching a maximum of 76.1±1.2% (100 µM). The selective TP 
receptor antagonist SQ-29,548 (1 µM) caused a marked inhibition reducing the contraction to 
9.4±1.3% whereas the selective EP1 receptor antagonist ONO-8130 (1 µM) had no effect 
(Figure 2A). Also, the contraction induced by the EP1/EP3 receptor agonist 17-phenyl trinor 
PGE2 (100 µM) was reduced from 58.3±5.7% to 9.4±1.3% by SQ-29,548 whereas ONO-8130 
had no effect (Figure 2B). The contraction caused by PGD2 (100 µM) was reduced from 
74.5±2.6% to 20.8±3.2% by SQ-29,548 (Figure 2C). The potency and selectivity of SQ-
29,548 was shown against the stabile TXA2 mimetic U-46619. Constraining the Schild slope 
and Hill slope to 1 resulted in a pKB value of 7.7 for SQ-29,548 (95% CI: 7.6 to 8.1). 
(Figure 2D). 
Influence of cyclooxygenase inhibitors on the smooth muscle tone 
After the wash and resting period, the unselective COX inhibitor indomethacin (3 µM; 
p<0.05) increased the tone with 23.0±3.6% whereas the FLAP inhibitor MK-886 (1 µM; 
p<0.05) decreased the tone with 15.5±5.1% (Figure 3A).  
To investigate which COX enzyme that is responsible for the increase, selective COX-1 
inhibitor FR-122047 (1 µM) or the selective COX-2 inhibitor lumiracoxib (1 µM) were 
applied for 30 min. Lumiracoxib increased the tone with 66.5±5.1% and FR-122047 increased 
the tone with 24.6±3.7% (p<0.05) of maximal indomethacin response (Figure 3B).  
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To explore which prostanoid receptor might contribute to the increased spontaneous tone 
segments were treated with the TP receptor antagonist SQ-29548 (1 µM), IP receptor 
antagonist CAY10441 (1 µM), EP1 receptor antagonist ONO-8130 (100 nM), EP2 receptor 
antagonist PF-04418948 (1 µM), EP3 receptor antagonist ONO-AE5-599 (1 µM) or EP4 
receptor antagonist ONO-AE3-208 (1 µM) under similar conditions. The contractile effect of 
these antagonists was negligible, 1.1±0.8%, 2.6±0.1%, 1.9±1.1%, 0.8±0.7, 3.0±0 and 4.4±0.5 
respectively, with no difference from the spontaneous decline in untreated segments 
(1.2±1.1%) observed over the same time (Figure 3A). 
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Discussion 
The aim of the present study was to clarify the receptors and responses regarding the action of 
PGE2 in human small airways. These results suggest that PGE2 have the capability to induce 
relaxation through the EP4 receptor and a contraction through the TP receptor. Neither the 
EP1, EP2 nor EP3 receptor seems to play a role regarding force regulation at the level of the 
the airway smooth muscle.  Furthermore, experiments using COX inhibitors increased the 
airway tone whereas a FLAP inhibitor decreased it. Antagonising EP1-4 receptors, as well as 
the TP and IP receptors, did not affect the tone, indicating that PGE2 does not regulate the 
intrinsic tone in human small airways during normal conditions.  
In our study, PGE2 induced a concentration dependent relaxation in small airway segments 
contracted with histamine. The relaxation caused by PGE2 in human primary bronchi and 
small airways was first suggested to be mediated by the EP2 receptor (Norel et al., 1999), 
similar as in the guinea pig trachea (Birrell et al., 2013; Safholm et al., 2013). However, 
recent studies, using potent and selective EP4 antagonists and EP2 and EP4 agonists, have 
proposed that the relaxation in both primary bronchi and small airways is actually mediated 
through the EP4 receptor (Benyahia et al., 2012; Buckley et al., 2011). Antagonising the EP4 
receptor clearly inhibited the relaxation, confirming recent findings with a different EP4 
receptor antagonist. A possible relaxant role for the EP2 receptor was excluded by the use of a 
novel EP2 receptor antagonist, also confirming previously observed lack of effect of a EP2 
receptor agonist on tone (Buckley et al., 2011). Our study confirm recent studies showing that 
PGE2 indeed relax small airways through the EP4 receptor and that the EP2 receptor is not 
involved in human small airway bronchorelaxation. 
In the presence of an EP4 receptor antagonist, higher concentrations of PGE2 and EP1/EP3 
agonist 17-phenyl trinor PGE2 induced a strong contraction that reached 80% and 50%, 
respectively, of maximum tissue response. Antagonising the TP receptor almost completely 
abolished both contractile responses. This is in agreement with previously published results 
regarding the activation of TP receptors by PGE2 and 17-phenyl trinor PGE2 in human larger 
bronchi (Coleman et al., 1989). Furthermore, antagonising the EP1 receptor did not affect the 
contraction. This is different compared to the guinea pig trachea where the main contractile 
receptor to be activated by PGE2 is the EP1 receptor (Coleman et al., 1985; Safholm et al., 
2013). As a verification of the TP antagonist effectiveness, a substantial reduction of the 
contraction of known TP receptor activators PGD2 (Larsson et al., 2011) and the 1000-fold 
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more potent U-46619 (Coleman et al., 1989) was shown. In conclusion, PGE2 induced 
bronchoconstriction in human small airway is mediated by TP receptors, and thus, use of 
selective TP receptor antagonists as anti-bronchoconstrictive therapy in asthma should block 
constrictive effects of TXA2, PGD2 and PGE2. 
Airway preparations of different species possess varying degrees of spontaneous tone (Linden 
et al., 1991; Okazawa et al., 1990; Schmidt et al., 2000). In untreated human bronchial 
segments, a stable airway tone was maintained for at least 30 min. The unselective COX-
inhibitor indomethacin caused a gradual increase over time that stabilised within 25 min. The 
role of cyclooxygenase products is somewhat unclear, with indomethacin previously 
displaying increased (Bjorck et al., 1993; Coleman et al., 1996; Hutas et al., 1981), decreased 
(Ito et al., 1989) or no effect on the tone (Brink et al., 1980). To investigate which of the two 
COX enzymes that was responsible for the increase, selective COX-1 inhibitor FR-122047 
and selective COX-2 inhibitor lumiracoxib were studied. Although neither of the two reached 
the same level of increase in tone as indomethacin alone both increased the tone, with 
lumiracoxib to a greater extent compared to FR-122047. Previously it could be argued that the 
increase is an indomethacin-specific effect, however our observations using selective COX 
inhibitors argue against that explanation. 
In the guinea pig trachea, we have recently showed that the inherent tone is mediated and 
maintained by PGE2, primarily released from the epithelium, by simultaneously activating 
both contractile EP1 and relaxant EP2 receptors (Safholm et al., 2013). Since the increased 
contraction after COX inhibition could be the result of removal of PGE2 responses (Watson et 
al., 1997), selective antagonists for all four EP receptor as well as the TP and IP (Norel et al., 
1999) was used. However, antagonism of a single receptor did neither increase nor decrease 
the basal tone suggesting that the effect is not solely dependent on removal of one relaxant 
component. Furthermore, PGD2 could potentially mediate a relaxant response (al Jarad et al., 
1994) through the DP1 receptor (Boie et al., 1995) that would be concealed by the contractile 
TP receptor (Coleman et al., 1989). However, since no decrease was observed in the presence 
of the TP receptor antagonist we can assume that the DP1 receptor is not involved. 
Another possibility for the indomethacin-induced increase is removal of inhibition of 
leukotriene synthesis (Kuehl et al., 1984), resulting in the greater effect of inherent contractile 
components, such as leukotrienes (Schmidt et al., 2000). Indeed, the FLAP inhibitor MK-886 
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showed a decreased tone clearly displaying an important role for the leukotrienes in 
maintaining the tone.  
Although previous experiments investigating the tone in human airways have been performed 
in large airways (⌀ > 2 mm) our study focused on the small airways. Nevertheless, we 
conclude that there are similarities in regulating the tone when comparing large and small 
airways, where both have the same increase in tone after removal of COX metabolites and 
decreased after removal of 5-LOX metabolites.  
In summary, these data show that EP4 receptor is responsible for the PGE2 induced relaxation 
in human small airways whereas the TP receptor is solely responsible for the contraction 
evoked by PGE2. Furthermore, neither EP1-4, TP nor IP receptors seems to solely play a role 
in regulating the human airway smooth muscle tone during normal condition. Whether or not 
this is the same during inflammatory conditions needs to be further investigated.  The findings 
support selective agonists of the EP4 receptor as a possible novel bronchoprotective 
compounds for the treatment of asthma and other airway constrictive ailments.  
  
12 
 
Figures 
-9 -8 -7 -6 -5
40
60
80
100
ONO-AE3-208 [1 M]
Control
PF-04418948 [1 M]
log [PGE2], M
Fo
rc
e 
(%
 o
f m
ax
im
um
)
 
Figure 1 Concentration-response curves to PGE2 in human small airways. Segments 
contracted with histamine (1 µM) in the presence of COX-inhibitor (indomethacin; 3 µM) and 
TP receptor antagonist (SQ-29,548; 1 µM) subjected to either EP2 receptor antagonist (PF-
04418948; 1 µM) or EP4 receptor antagonist (ONO-AE3-208; 1 µM). Data represent mean ± 
S.E.M. (n = 7). 
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Figure 2 In the presence of COX-inhibitor (indomethacin; 3 µM) and EP4 receptor antagonist 
(ONO-AE3-208; 1 µM) (A) PGE2, (B) 17-phenyl trinor PGE2, (C) PGD2 or (D) U-46619 in 
the presence or absence of TP receptor antagonist (SQ-29,548; SQ; 1 µM). Data represent 
mean ± S.E.M. (n = 3-7) for A-C and a trace from one patient in D. 
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Figure 3 (A) Changes of spontaneous tone in human bronchi subsequent to addition of either 
inhibitor for COX (indomethacin; 3 µM) and FLAP (MK-886; 1 µM) or antagonists for TP 
(SQ-29,548; 1 µM), IP (CAY10441; 1 µM), EP1 (ONO-8130; 1 µM), EP2 (PF-04418948; 1 
µM), EP3 (ONO-AE5-599; 1 µM) or EP4 (ONO-AE3-208; 1 µM) receptors. (B) Increased 
spontaneous tone in human bronchi subsequent addition of COX-1 inhibitor (FR-122047; 1 
µM) or COX-2 inhibitor (lumiracoxib; 1 µM). Data represent mean ± S.E.M. (n = 3-10). 
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